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ABSTRACT 
 
CHARACTERIZATION OF THE COILED-COIL DOMAIN-
CONTAINING PROTEIN 124 (CCDC124) AS A NOVEL 
CENTROSOME AND MIDBODY COMPONENT INVOLVED IN 
CYTOKINESIS 
 
Pelin Telkoparan Akıllılar 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
Co-advisor: Assoc. Prof. Dr. Uygar H. Tazebay 
June 2013, 259 Pages. 
Cytokinetic abscission is the cellular process leading to physical separation of two 
postmitotic sister cells by severing the intercellular bridge. During cell division several 
functional complexes accumulate at the bridge connecting the two sister cells. The most 
noticeable structural component of the intercellular bridge is a transient organelle termed 
as midbody. This novel organelle is localized at a central region, which marks the site of 
cytokinetic abscission. Despite its major role in completion of cell divison, our 
understanding of spatiotemporal regulation of midbody assembly is incomplete. In this 
thesis work, we first characterizated the coiled-coil domain-containing protein-124 
(Ccdc124), a eukaryotic protein conserved from fungi-to-man, at the molecular level. 
We identified that at the sub-cellular level Ccdc124 is localized at centrosomes and the 
midbody depending on stages of the cell cycle. In interphase cells, as well as in mitosis, 
the protein is localized to centrosomes. However at later stages of cytokinesis (late-
anaphase/telophase) Ccdc124 translocates to the midbody. Knockdown of Ccdc124 in 
human HeLa cells leads to accumulation of enlarged and multinucleated cells; however, 
centrosome maturation was not affected. Similarly, in preliminary in vivo assays 
involving down-regulation of Ccdc124-homologue in zebra fish early embryos, we 
observed multinuclear embryonic cells. Furthermore, we have validated a previously 
observed in vitro interaction in our laboratory between Ccdc124 and the Ras guanine 
nucleotide exchange factor 1B (RasGEF1B) by co-immunoprecipitation assays. As 
RasGEF1B is strictly a Rap2 GTP-binding protein specific nucleotide exchange factor, 
this result has suggested a possible involvement of Rap2 in cytokinesis related events. 
Thus, subsequently, we assessed the sub-cellular localization of Rap2 in synchronized 
cells during cytokinesis. We found that even though it does not play a role in cell 
division, Rap2 is localized to the midbody. This result establishes a functional link 
between cytokinesis and activation of localized Rap2 signaling at the midbody. Data 
presented in this thesis work indicate that Ccdc124 is a novel factor operating both for 
proper progression of late cytokinetic stages in eukaryotes, and for establishment of 
Rap2 signaling dependent cellular functions proximal to the abscission site. 
Keywords: Ccdc124, Centrosome, Cytokinesis, Midbody, Rap2 signaling, RasGEF1B
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ÖZET 
 
COILED-COILED DOMAIN-CONTAINING PROTEIN 124 
(CCDC124)’ÜN S!TOK!NEZDE ROL OYNAYAN YEN! B!R 
SENTROZOM VE ORTA-C!S!MC!K (MIDBODY) PROTE!N! 
OLARAK TANIMLANMASI 
 
Pelin Telkoparan Akıllılar 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
E! Danı!man: Assoc. Prof. Dr. Uygar H. Tazebay 
Haziran 2013, 259 Sayfa. 
 
Sitokinetik ayrılma, hücre bölünmesinde iki hücre birbirinden ayrılırken hücreler 
arası köprünün fiziksel olarak kopmasını sa"layan hücresel süreçtir. Hücre 
bölünmesi sırasında pekçok i!levsel yapı hücreler arası köprüde bir araya gelerek 
bölünmeyi düzenlerler. Hücreler arası köprünün en belirgin parçası, köprünün orta 
bölgesinde lokalize olan ve kopu! noktasını belirleyen orta-cisimcik (midbody) 
adındaki geçici organeldir. Hücrelerin düzgün !ekilde bölünmesi esnasındaki önemli 
rolüne ra"men, orta-cisimci"i olu!turan proteinlerin tamamı ve bunların nasıl 
düzenledi"i tam olarak bilinmemektedir. Bu tez çalı!masında, insandan mayaya 
kadar korunmu! yeni bir ökaryotik protein olan coiled-coil domain-containing 
protein-124 hücresel, moleküler, ve i!levsel olarak tanımlanmı!tır. Çalı!mada 
sunulan sonuçlar, Ccdc124’ün hücre döngüsünün evrelerine ba"lı olarak sentrozom 
ve orta-cisimcikte konumlanan yeni bir protein oldu"unu göstermektedir. Ccdc124 
interfaz evresi ve mitozun erken safhalarında sentrozoma lokalize olurken, 
sitokinezin geç evrelerinde (geç-anafaz/telofaz) sentrozomdan ayrılarak orta-
cisimci"e konumlanmaktadır. #nsan HeLa hücre modelinde yaptı"ımız çalı!malarda, 
Ccdc124 ifadesinin dü!ürülmesi sonucunda sentrozom sayısı ve olu!umu 
etkilenmezken, büyük ve çoklu sayıda çekirde"e sahip (bi/multinuclear) hücrelerin 
sayısının arttı"ını belirledik. Aynı !ekilde, zebra balı"ı erken embriyolarında yapılan 
öncü çalı!malarda, Ccdc124 gen ifadesinin baskılanması benzer !ekilde çok-
çekirdekli embriyonik hücre olu!umlarına sebep olmu!tur. Bunlara ek olarak, bu tez 
çalı!masında, daha önce laboratuvarımızda in vitro olarak gösterilmi! olan 
Ccdc124’ün Ras-guanin nükleotid de"i!im faktörü proteini-1B (Ras-guanine 
nucleotide exchange factor-1B, RasGEF1B) etkile!imi birlikte çökeltme deneyleri ile 
valide edilmi!tir. RasGEF1B sadece Rap2 GTP-ba"layan proteine özgü bir aktivatör 
de"i!im faktörü oldu"u için, bu sonuç Rap2 proteininin de hücre bölünmesi sırasında 
veya sonrasında rolü olabilece"ini dü!ündürmü!tür. Bu nedenle, senkronize edilmi! 
hücrelerde sitokinez sırasında Rap2 G-proteinin hücresel konumunu ara!tırdık. 
Bunun sonucunda, Rap2’nin hücre bölünmesi sırasında rol oynamamasına ra"men, 
bölünme sırasında orta-cisimcikte konumlandı"ını bulguladık. Bu tez çalı!ması, aynı 
zamanda bir sentrozom proteini olan Ccdc124 proteininin orta-cisimcikte 
konumlanarak sitokinez ile, sitokinez sonrası hücresel i!levleri düzenleyen yeni bir 
moleküler faktör olarak i!lev gördü"ünü gostermektedir.  
 
Anahtar kelimeler: Ccdc124, orta-cisimcik (Midbody), Rap2 sinyal yolu, 
RasGEF1B, sentrozom, sitokinez
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CHAPTER 1. INTRODUCTION 
 
1.1 The Cell Cycle 
All living organisms starting from primitive unicellular bacteria to the most 
developed multicellular ones are generated by a repeated cycle mechanism, known as 
the cell cycle. The cell cycle is both a complex and a highly ordered process. During 
the process one cell duplicates its genome accurately, and it is divided into new but 
genetically identical two daughter cells.  In addition to genomic duplication, cells 
also duplicate their other organelles and mass of proteins to maintain their size. 
Conversely, to maintain the nucleo-cytoplasmic ratio, duplication of DNA content 
and cytoplasmic content is viably bound to each other.  
The eukaryotic cell cycle is divided into four sequential different phases: the first gap 
interval (G1), DNA synthesis phase (S), the second gap interval (G2), and the mitosis 
phase (M; see below). G1, S, and G2 phases are together known as the interphase, 
which altogether takes close to 23 hours in higher eukaryotes followed by 1 hour of 
M phase [1]. In the synthesis or S phase, DNA replicates itself, which nearly takes 
half of the cell cycle time. Following the S phase, generation of bipolar mitotic 
spindles, segregation of sister chromatids, and separation of cells occur during the M 
phase. Cytokinesis, or separation of two daughter cells can either be considered as 
the final part of the M phase, or it is also called as the cytokinesis phase (C phase) 
distinct from the M phase [2]. The G1 and G2 phases, which stand for “gaps” in the 
cell cycle, are intervals between DNA synthesis (S phase) and mitosis (M phase). 
These two gaps allow cell growth, and provide time to ensure cellular conditions 
suitable for progression of S and M phases. The cell is preparing for DNA synthesis 
during the G1 phase, and its length is determined by external conditions. If external 
conditions are not suitable for cell cycle progression, then cells may enter resting G-
zero (G0) state. G0 cells do not actively go through the cell cycle (quiescent) until 
conditions are suitable for the growth [3]. Similarly, cells prepare for the M phase 
during G2, which is the second gap interval in the cell cycle.  
The progression of the cell cycle depends on the external signals such as mitogens 
and growth factors. The cell responds to these extracellular signals via pathways 
regulated by cyclins through their associations with cyclin-dependent-kinase proteins 
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(CDKs), [4]. CDKs are serine/threonine kinases that are activated at specific times in 
the cell cycle (Fig. 1.1), [5]. 
 
 
 
 
 
 
Figure 1.1. The Cell Cycle. Schematic drawing of cell cycle dependent activation of 
cyclins and CDKs. Modified from, Israels and Israels, 2000, The Cell Cycle, The 
Oncologist 5, 510-513, ©AlphaMed Press. 
 
The constant activity of the CDKs during cell cycle progression is critical, because 
inhibition of their activities may cause disruption of mitosis [1]. CDKs are primarily 
regulated by interactions of specific cyclin molecules that are continuously 
synthesized or degraded in a stage dependent manner throughout the cell cycle. 
Typically, cyclins bind to CDKs, and via nuclear localization signals on cyclins, 
CDKs are targeted to the nucleus where they phosphorylate a variety of cell cycle 
regulatory substrates (see below). There are four main classes of cyclins: G1-cyclin 
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(cyclin D), G1/S-cyclin (cyclin E), S-cyclin (cyclin A) and M-cyclin (cyclin B). 
During G1 phase, cyclin D associates with Cdk4 and Cdk6 and formation of the 
cyclin/CDKs complexes results activation of CDKs by their phosphorylation [6]. 
Moreover, they phosphorylate a key protein, Retinoblastoma (Rb) protein that 
regulates G1 phase of the cell cycle by controlling the critical restriction point (R-
point) of the G1. In fact, hypo-phosphorylated Rb forms complex with E2F, which is 
a transcription factor, and inhibits transcription of the target genes. After 
phosphorylation of Rb by the cyclinD/CDK4-6 complexes, Rb dissociates from E2F 
and allows transcription of target genes [5]. One of them is cyclin E, which 
complexes with Cdk2, and it is required for passage of restriction point. In the 
meantime, Rb stays in phosphorylated form until completion of mitosis. The 
cyclinE/CDK2 complexes are required for transition from G1 to S phase of the cell 
cycle. During G1/S transition the expression of cyclin A increases and stays stable 
through the S phase [4]. In the early S phase, cyclin A complexes with Cdk2 and 
then, in the late S phase, form complex with cdk1. Cyclin A/CDK2 complex initiates 
DNA synthesis and their activity remains high during G2 until that prevents excess 
DNA replication by binding site of replication site. Following to the completion of 
DNA replication, cell division occurs during M phase, and the activation of mitotic 
events is triggered by formation of cyclin B/CDK1 complexes [1]. When cells are 
ready to divide, cdc25 activates cdk1 by dephosphorylating this key kinase molecule. 
Cyclin B/CDK1 triggers chromosomal condensation, nuclear envelope breakdown, 
cytoskeleton rearrangement, and reorganization of Golgi and endoplasmic reticulum 
[1].  
 
1.1.1. Cellular Aspects of Different Stages of Mitosis and Cytokinesis 
M phase could be considered as the most complicated and highly regulated phase of 
the cell cycle, which is divided into six major stages: the first five stages involves 
nuclear division (mitosis) and the last one is known as the cytokinetic abscission 
(Fig. 1.2), [7]. Once the size of the cell increases, and chromosomes replicated 
concomitant to centrosome duplication, mitosis (M) begins with the prophase. At this 
initial stage, replicated chromosomes condense by recruiting specialized proteins 
called condensins [7] forming two identical sister chromatids. In the meantime the 
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mitotic spindles begin to be formed by the centrosomes translocating to two opposite 
cellular poles (see below). Prometaphase begins with the breakdown of the envelop 
into vesicles, which is an important step for spindle assembly, as it facilitates 
attachment of chromosome kinetochores to centrosomes (or spindle pole bodies in 
lower eukaryotes) that are located at two opposite poles of the cell. During 
metaphase, chromosomes are in their most compact form and can be easily 
visualized at this stage. Chromosomes are aligned at the center of the cell on the 
metaphase plate and sister chromatids are attached to spindles poles via microtubules 
of kinetochores. 
 
Figure 1.2. Comparison of the phases of mitosis in terms of their chromosome 
condensation and alignment status. Modified from Pines and Rieder, 2001, Re-
staging mitosis: a contemporary view of mitotic progression. Nature Cell Biology 3, 
E3-E6, ©2001 Macmillan Magazines Ltd. 
 
At anaphase microtubules of kinetochores start shortening and spindle poles move to 
outward. As a result, sister chromatids partition to dividing daughter cells. The last 
step of the mitosis is telophase, during which sister chromatids arrive to the spindle 
poles, and chromosomes start to decondensate. The nuclear membrane reassembles 
around each chromosome, and finally contractile ring begins to form to prepare the 
cell to cytokinesis; the process of separation of daughter cells from each other. The 
molecular requirements for cytokinesis are highly conserved among all major animal 
model systems (Fig. 1.3), [8]. Cytokinesis is initiated with assembly of antiparallel 
microtubules at the center of spindle midzone, which is called central spindle during 
anaphase [9]. At final stages of cytokinesis, separation of sister cells are completed 
by a process called abscission, which leads to irreversible fission of plasma 
membranes at the intercellular bridge between dividing cells. 
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Figure 1.3. Schematic diagram of the different stages of cytokinesis. 
Microtubules, green; chromatin, blue; contractile actin ring, red; centrosomes, black 
dots. Modified from Guizetti and Gerlich, 2010, Cytokinetic abscission in animal 
cells. Seminars in Cell and Developmental Biology, 21, 909-916, ©2010 Elsevier 
Ltd. 
 
1.1.2. Molecular Regulation of Cytokinetic Abscission 
In dividing animal cells, cytokinesis initiates with the assembly and constriction, 
organized by signaling from the anaphase spindle of an equatorial contractile ring. 
Two main components of the cytoskeleton, actin and tubulin are essential structural 
proteins for successful cytokinesis in eukaryotes. Together with spindle asters, the 
central spindle determines the position of the cleavage plane by directing localization 
and activation of the key G protein, Ras-homologue A (RhoA), at the cell cortex  
[10]. RhoA GTP-binding proteins are lipid-modified molecules, and this 
modification allows association with the plasma membrane at the ingressed cleavage 
furrow close to the midzone. Like all Ras-superfamily of GTP-binding proteins, 
RhoA bound to guanosine triphosphate (GTP) is in its active form, while when it is 
bound to guanosine diphosphate (GDP) it is inactive [10]. GDP/GTP re-exchange, 
and thus activation of RhoA is carried-out by the translocation of a RhoA-specific 
guanine nucleotide exchange factor (GEF) named as Ect2 to the midzone. Then, 
RhoA directly activates formins, and active formin proteins elongate the linear actin 
filaments for formation of contractile ring. Also, RhoA indirectly activates myosin II 
motor activity by phosphorylation of myosine light chain with the help of ROCK and 
citron kinases [11]. Subsequently, activated myosin II binds to actin filaments, and 
triggers constriction of the contractile ring. In fact, Ect2 is itself recruited to the 
central spindle by binding to Centralspindlin complex component CYK-4 [10]. 
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Centralspindlin is mostly important for animal central spindle assembly, which is a 
hetero-tetrameric complex consisting of homodimers of both CYK-4 (RhoGAP) and 
MKLP1 (mitotic kinesin-like protein) proteins. Importantly, the interaction between 
CYK-4 and Ect2 is regulated by Plk1 (polo-kinase-1), and Plk1 is recruited to central 
spindle through microtubule-associated protein PRC1 [8]. On the other hands, Cdk1 
negatively regulates these interactions, and it inactivates Ect2, MKLP1, and PRC1 by 
phosphorylating these effectors in early stages of mitosis, and thus it prevents 
premature cytokinesis. During anaphase after segregation of chromosomes, the 
activity of Cdk1 begins to decline and inhibitory sites of multiple spindle 
components are dephosphorylated [12] and cytokinesis is triggered (cytokinetic 
furrow formed). Aurora B is another key mitotic regulator kinase, which is involved 
in establishment of the timing of cytokinetic abscission [13]. Aurora B targets a 
number of proteins that localize to the cleavage furrow. Therefore, it has been 
proposed that phosphorylation of intermediate filaments at the cleavage furrow 
destabilizes the filaments in preparation for cytokinesis [14, 15]. Aurora B also 
phosphorylates myosin II regulatory light chain at the cleavage furrow. Inhibition of 
Aurora B activity prevents proper myosin II localization to the cleavage furrow and 
disrupts spindle midzone organization [16]. Mutation of Aurora B target sites in 
intermediate filament proteins leads to defects in filament deformation and prevents 
the final stage of cytokinesis  [15]. 
After completion of cleavage furrow formation, two daughter cells remain connected 
to each other with a thin intracellular bridge, which contains dense antiparallel 
microtubule bundles that overlap at a central region called midbody. The cytoplasmic 
bridge between two daughter cells must be cleaved to form genetically identical two 
cells. This terminal stage of cytokinesis is known as the abscission stage [17]. 
Abscission occurs by removal of cytoskeletal structures from intracellular bridge, 
followed by constriction of cell cortex and plasma membrane fission. Following the 
ingression of the intracellular bridge until actomyosin ring reaches to 1-2 µm 
diameter, Golgi and recycling endosome-derived vesicles accumulate at the midbody 
region during late-telophase (see below). Vesicles in intracellular bridge fuse with 
plasma membrane, and they increases surface of the membrane before abscission. In 
addition, midbody accumulation of many different vesicle targeting and tethering 
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factors, including centriolin and exocyst complex, Rab35, Rab11-FIP3, v- and t-
SNARES and BRUCE are required for efficient abscission [18].  
 
1.2 The Role of Centrosome in Cell Division 
Microtubules (MT) are highly dynamic tubular polymers and they are essential 
component of cytoskeleton proteins in all eukaryotic organisms. MTs have critical 
roles in many cellular processes such as intracellular transport of proteins and 
organelles, motility of motor proteins, establishment of cell polarity and cell division  
[19, 20]. MTs are hollow tubes with fast growing plus ends and slowly growing 
minus ends, and they are composed of !- and "-tubulin proteins. These proteins form 
heterodimers when bound to GTP and come together with lateral and longitudinal 
contacts [20]. The structure of MTs is not stable, and in dividing cells MT dimers 
reorganize to form bipolar mitotic spindles in a cell cycle dependent manner [19]. 
The organizations of all these properties of MTs are arranged by microtubule 
organizing centers (MTOCs). Major MTOCs in eukaryotes are centrosomes in 
animal cells, and spindle pole bodies in fungi [19]. The centrosome is a subcellular 
non-membrane bound organelle that regulates the MT spatial organization and 
nucleation [21]. Thus it influences many cellular activities including maintenance of 
cell shape, motility, cell polarity, spindle formation, chromosomal segregation, and 
cell division [22]. 
The centrosome consists two cylindrical centrioles and pericentriolar material (PCM) 
that surrounds the centrioles (Fig. 1.4). Centrioles are cylinders made of nine MT 
triplets found in many eukaryotes and organize two important organelles; cilia and 
centrosome. The older centriole is known the mother or mature centriole, and the 
younger one is known as the daughter centriole [23]. They are polarized through 
proximal- and distal-axis, and while both of them recruits MTs in their vicinity, only 
mother centriole can bind MTs at the subdistal apandages [24]. Centrioles are 
surrounded by electron dense material, pericentriolar matrix (PCM) that contains 
many coiled-coil domain containing centrosomal proteins and #-tubulin together with 
#-TuRC. PCM associated with centriols and regulate their assembly [22]. 
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Figure 1.4. The centrosome is composed of two centrioles, connected by 
interconnecting fibers and surrounded by the pericentriolar material (PCM). 
Microtubules are nucleated from the pericentriolar matrix and the appendages of the 
maternal centriole. Figure adapted from Nature Rev. Mol. Cell Biol. 2, 688-698. © 
2001 Macmillan Magazines Ltd. 
 
Centrosomes are duplicated once per cell cycle, and there are four main phases of 
centrosome duplication: centriole disengagement, nucleation of daughter centriols, 
elongation of procentrioles and separation of centrosomes [21]. Disengagement of 
centrioles occurs during G1/S and it is important for limiting duplication of 
centrioles once per cell cycle. The disengagement of centrioles is catalysed by 
proteolytic activity of separase proteins [25]. Under cell cycle regulation by the 
kinase Plk1, separase enzyme cleaves cohesin that bind two centrioles to each other  
[22]. During S phase, centriole assembly factors accumulate and the newly 
synthesized daughter centrioles remain tightly bound to mother centriole, which 
elongate throughout S and G2 phases. At the last step of the centriole cycle at the 
G2/M transition, centrioles accumulate more PCM and duplicated centrosomes are 
separated and form the bipolar mitotic spindlepoles [25]. 
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In early studies, one of the components of centrioles was thought to be microtubule-
organizing structures for assembling the mitotic spindles. However, many eukaryotes 
such as fungi and higher plants do not contain centrioles, yet they could still organize 
bipolar mitotic spindles. Interestingly, when centrioles were removed by laser 
ablation, mitotic spindles still formed [26, 27]. Furthermore, to obtain direct 
experimental support, Renata et al. [28] inhibited centrioles formation in flies and 
mutant flies were developed normally, but they were suffered from defects in their 
sensory organelle cilia. These studies clearly indicated that centrioles are not 
essential for microtubule organization, and the components that promote the 
formation and organization of microtubules were mostly found in the surrounding 
dynamic proteinaceous material, PCM [19]. The exact composition of PCM is still 
not known, even though several high throughput proteomics studies have addressed 
this issue [29,30]. Among proteins associated with PCM, #-tubulin is found as an 
essential factor for microtubule nucleation, and microtubule organization in all 
eukaryotic organisms. It was firstly found in the filamentous fungus Aspergillus 
nidulans, and it was identified as an essential factor for formation of microtubules 
from the spindle pole body [31, 32]. #-tubulin nucleates polymerization of the 
microtubules form !- and "-tubulin monomers. Early studies on biochemistry of #-
tubulin show that it forms complex with members of gamma complex proteins  
(GCPs), which coming together with #-tubulin, they form the #-TuRC complex [19]. 
In addition to nucleation and organization features of #-TuRC, it also stabilizes 
microtubules by capping minus ends and prevents depolimerization of the 
microtubules [19].  
 
1.3 The Midbody Composition and Formation at the Cytokinetic Abscission 
The midbody is an electron dense transient organelle formed at the mid-space 
between dividing cells, first described by German biologist Walther Flemming in 
1891. The mammalian midbody is formed after furrow ingression from tightly 
packed antiparallel microtubules at the spindle midzone during cytokinesis  [33, 34]. 
In order to understand its exact composition during cytokinesis, Skop et al. [33] 
isolated midbodies from Chinese hamster ovary (CHO) cells, and they studied its 
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composition by LC-MS associated multidimensional protein identification methods. 
They identified 160 novel candidate proteins, 57 of them (36%) was previously 
shown to play roles in cytokinesis [33]. Also, by using immunofluorescence methods 
in HeLa cells, clear midbody localization of these 10 novel proteins (RACK1, 
IQGAP1, Keap1, Endplasmin/GRP4, RAB GDI, KIF4, AnnexinII, BIP, Glut1, 
Novel/CGI-49, and GM130) during cytokinetic abscission were validated [33]. 
Despite having a list of midbody proteins, knowledge about the organization and 
localization of these proteins to the midbody region is still limited. The midbody 
proteins could be categorized into three major groups, as bulge proteins, dark zone 
proteins, and flanking proteins [34]. The bulge (stem body) at the center of the 
midbody (Fig. 1.5) accumulates centralspindlin proteins and its interacting partners, 
such as CEP55, ARF6 and the Rho-GEF protein Ect2  [35, 36]. A narrow region onto 
microtubule bundle in the center of the midbody, where #-tubulin staining is blocked, 
accumulates the known interacting pairs PRC1 and KIF4 [34]. In reference to 
antibody-excluding characteristics, this localization is described as the  
 
 
 
Fig. 1.5. Midbody is formed of various zones with different molecular 
compositions. The upper and lower ‘bulge regions’ are indicated by white arrows, 
and flanking zones were marked with multiple white arrow-heads. Dark zone area, 
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and flanking zones were also indicated on top of the electron-micrograph. Bar 
represents 1 µm. Figure modified from Guizetti and Gerlich, 2010, Cytokinetic 
abscission in animal cells. Seminars in Cell and Developmental Biology, 21, 909-
916, ©2010 Elsevier Ltd. 
 
“dark zone”. Two broader bands on microtubules outside the dark zone (known as 
the “flanking zone”) accumulates midbody forming factors such as CENPE, MKLP2 
and Aurora B [34], whose relocalizations to the midbody is concomitant with the 
midbody maturation. The dark zone protein PRC1 localizes microtubule overlaps and 
stabilizes these overlapping regions [34]. The other dark zone protein, KIF4, binds to 
plus end of microtubules and it inhibits elongation of microtubules. Midbody 
assembly and function are regulated by three different kinases: Cdk1, Aurora B and 
Plk1 [34]. During initiation of cytokinesis at telophase, cyclin B is degraded by 
anaphase promoting complex (APC) and inhibits activation of Cdk1. This inhibition 
of Cdk1 on its turn activates Plk1. Active Plk1 phosphorylates centralspindlin 
complex and recruits Ect2, and initiates cleavage furrow formation and cell 
contractility [37]. During metaphase/anaphase transition Plk1 also inhibits abscission 
factor CEP55 by phosphorylating it and thus preventing its untimely recruitment to 
the anaphase spindle [38]. In anaphase, degradation of Plk1 by APC activates 
CEP55, a protein with a coiled-coil domain (CCD) motif, leading to the initiation of 
cytokinetic abscission  [39, 38]. On the other hand, the flanking zone kinase, Aurora 
B, functions as the factor determining the precise site of abscission by negatively 
regulating RhoA and annilin proteins [34]. Previous studies have also indicated the 
presence of microtubule nucleation-related proteins that are shared between the 
centrosome and the midbody, which is characterized by anti-parallel microtubule 
bundles emanating from the central spindle [9]. These include for instance #-tubulin, 
and because of this the midbody is also considered as a secondary MTOC associated 
with the contractile ring forming at the site of cleavage furrow ingression  [40].  
Importantly, membrane traffic is now established to have the central role in 
successful completion of cytokinetic abscission. During abscission, the midbody ring 
serves as the recruitment site for secretory vesicules [41], which are essential in 
formation of multivesicular bodies forming the site of abscission (Fig. 1.6). In 
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addition to secretory membrane trafficking, it is clear that endosomal traffic also 
contributes remarkably to cytokinesis  [10].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Abscission in animal cell cytokinesis. A, intracellular bridge and the 
midbody structure showing microtubules entering the dense midbody matrix 
containing the kinesin-like factor, Mklp1. B, a model for membrane trafficking 
during cytokinesis in animal cells. (i), Late in telophase, membrane vesicles are 
delivered along microtubules down the intracellular bridge. These vesicles may be 
delivered from the Golgi or endocytic compartments in the cell body (open arrows) 
or may arise directly by endocytosis adjacent to the midbody (filled arrows), or from 
both sources. Initial tethering of these vesicles is expected to be dependent on both a 
Rab GTPase and the exocyst-tethering complex. Abscission is an asymmetric 
process, preferentially occurring on one side of the midbody, perhaps controlled by 
the centrosomes and a subset of centrosomal proteins such as centriolin  [40, 88]. (ii) 
Retraction of microtubules from the midbody allows these membranes to fuse both 
with one another and with the plasma membrane. (iii) Abscission occurs once this 
membrane network completely fills this space and creates a new section of plasma 
membrane. Recent evidence suggests that this involves the ESCRT complex [42]. 
Microtubules, green; midbody, dark blue. Figure and legends modified from Barr 
and Gruneberg, 2007, Cytokinesis: Making and Placing the Final Cut. Cell, 131: 
847-860. © 2007 Cell Press. 
 
The key factor for completion of membrane fission events is Endosomal Sorting 
Complex Required for Transport III (ESCRT-III) [42]. ESCRT-III is an important 
abscission factor, which mediates membrane deformation in various important 
biological processes (e.g. virus budding, autophagy). A centrosome protein CEP55 
interacts with ESCRT proteins Tsg101 and ALIX and recruits ESCRT-III to the 
midbody while it translocates there at late telophase (Figs. 1.6 and 1.7),  [39, 42, 10]. 
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The final step of the abscission is membrane cleavage for which first actin-myosin 
ring should be disassembled on one side of the midbody narrow [10]. Disassembly of 
midbody microtubules is mediated by recruitement of an ESCRT interacting partner 
protein, spastin [43, 44]. Subsequently, spastin depolymerizes microtubules 
introducing the final cut in cytokinetic abscission  [44]. 
 
   
 
1.4 Involvement of Ccdc Proteins in Centrosome and Midbody Functions 
The centrosome is a dynamic non-membranous organelle with PCM assembled 
around centrioles, as mentioned above. It organizes microtubules that regulate cell 
shape, polarity, adhesion and mobility [45, 46]. In addition, it also facilitates 
intracellular transport and positioning of the organelles. To understand dynamic 
composition and localization of centrosome proteome, recently Jakobsen et al. have 
characterized the human centrosome by using a mass spectrometry-based proteomics 
approach combined with an antibody based subcellular screen of candidate proteins. 
In this work, 116 known and 40 novel candidate centrosome proteins were identified, 
of which 22 were validated as entirely novel centrosome components, and 5 turned 
out to associate preferentially either with mother or daughter centrioles [30]. 
Interestingly, these analyses also indicated that the majority (%60) of centrosomal 
proteins contain CCD (coiled-coil domain) type oligomerization motifs as their 
predominant structural features, which seem to be important for proper centrosome 
Figure 1.7. Organization of the 
intracellular bridge and the 
midbody. Schematics show (a) 
central plane and (b) surface 
views of the intracellular bridge. 
Major protein complexes were 
indicated. Figure taken from 
Green et al., [10] Cytokinesis in 
Animal Cells. Annual Rev. Cell. 
Dev. Biol. 28, 29-58. © 2012 by 
Annual Reviews. 
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assembly. In addition they compared localization of these candidate proteins between 
interphase and mitotic stages by stainings methods. Most of the CCD containing 
(CCDC) proteins localized differentially to centrosomes, spindles, and midbody 
during cell cycle, in a way similar to CEP55 and #-tubulin, which are also coiled coil 
domain containing proteins  [39], (Pelin Telkoparan and Uygar Tazebay, 
unpublished observations). When the expression levels of these candidate proteins 
were downregulated using RNAi methods, multiple types of cell division defects 
were observed [30]. Similarly, previous studies of Skop et al. [33] also indicated the 
predominant roles of CCDC proteins in midbody establishment and cytokinesis. Two 
major proteins involved in formation of the midbody and establishment of the 
abscission site, PRC1 and MKLP1, are CCDC type proteins, and absence of their 
CCD motifs perturbs subcellular localizations, and thus, functions of these factors  
[34]. Therefore, it must be clearly stated that CCDC proteins form the backbone of 
PCM and the midbody, possibly forming a docking platform for several factors (such 
as, SNARE complexes, ESCRT machinery proteins, G-protein activator GEFs, and 
Rab family docking regulators, etc.) involved in completion of cytokinetic 
abscission.  
 
1.4 RasGEF1 Family of Guanine Nucleotide Exchange Factors (GEFs) 
During their functional cycle, Ras-superfamily of G proteins cycle between an active 
GTP-bound conformation and an inactive GDP-bound form. This cycle of G proteins 
is regulated by guanine nucleotide exchange factors (GEFs) and GTPase activating 
proteins (GAPs). GEFs activate G-proteins by stimulating the binding of GTP, and in 
reverse, GAPs lead to their inactivation due to the catalysis of GTP hydrolysis to 
GDP [47]. Briefly, GEFs catalyze the dissociation of the GDP nucleotide from the G 
protein by affecting the nucleotide-binding residues so that the nucleotide affinity is 
diminished and, therefore, the nucleotide is released and subsequently replaced by 
GTP. In fact, mostly the affinity of the G proteins for GTP and GDP is similar, and 
the GEF does not directly favor binding of GTP over GDP. Thus the resulting 
increase in GTP-bound over GDP-bound forms is due to remarkably higher cellular 
concentration of GTP as compared to GDP [47].  
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Active small G proteins control diverse signaling networks important for the 
regulation of cell proliferation, survival, differentiation, vesicular trafficking, and 
gene expression [48]. Best-studied examples of small G-proteins belong to the Ras-
family, which comprises H-Ras, N-Ras, K-Ras. These small G proteins are also 
known to be oncogenic proteins, and they have functions in many signaling events 
that control processes like proliferation, differentiation, morphogenesis and apoptosis  
[49]. Remarkably, each small G proteins family has its own non-homologous GEFs 
and GAPs proteins. RasGEFs have CDC25 homology domain (CDC25 HD), which 
is essential for the activity of these proteins. CDC25 HD is an ancient domain and its 
origins date back to the last eukaryotic common ancestor [50]. GEFs that have 
CDC25 HD regulate Ras, Rap and Ral family of G proteins, which are altogether 
named as Ras proteins. The smart database platform (http://smart.embl-
heidelberg.de/smart) lists 28 RasGEF-CDC25 domains, most of which, occur in 
tandem with an N-terminal extension of Ras-Exchange Motif (REM) domain, which 
are in close contact with each other [51].  
RasGEF1 genes encode a subgroup of highly conserved Ras guanine nucleotide 
exchange factors [51]. The combined data generated from EST projects and genome-
scanning gene-prediction programs suggest that vertebrates have three distinct 
RasGEF1 (1A, 1B, and 1C) genes. Phylogenetic analysis of the predicted RasGEF 
proteins show that the fish and mammalian proteins have only slightly diverged 
during evolution [50].  
Previous in vitro studies carried-out by Elif Yaman have clearly indicated that 
RasGEF1 family of GEFs are specific activators of Rap2, while they do not affect 
exchange of nucleotides on Rap1 [51]. Same authors have also found residues on 
Rap2 contributing to the recognition of this G protein by RasGEF1 family, and 
proposed that Phe-39 is the key residue in establishing the specificity of interaction 
between RasGEF1 and Rap2 [51]. 
 
1.5 The Significance of Rap Signaling in Cell Biology 
Ras-Proximal (Rap) family proteins are Ras-like small G-proteins, which act as 
molecular switches, typically cycling between a GDP-bound inactive and a GTP-
bound active state, as mentioned above. In fact, Rap1 was originally identified as a 
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suppressor of Ras-induced transformation, on the basis of similarity in effector-
binding regions, which were proposed to compete with Ras in effector recognition  
[52]. It is now widely accepted that Rap could also function independently of Ras, 
and it could signal via its own set of effectors [53]. Functions attributed to Rap1 
comprise the control of establishment of cell polarity [54, 55], activation of integrin-
mediated cell adhesion [56, 57, 58, 59] and the regulation of cell–cell contacts  [60, 
61]. Additionally, Rap1 has been implicated in cell proliferation [62] and secretion  
[63, 64]. There are five known mammalian Rap proteins; Rap1A, Rap1B, Rap2A, 
Rap2B, Rap2C. There is about 95% sequence identity between Rap1A and Rap1B, 
and about 90% identity between Rap2A, Rap2B, and Rap2C. In addition Rap2 
proteins share %60 similarities between Rap1 [51, 53]. Effectors of Rap GTP-
binding proteins consist of Ras/Rap-binding domain (RBD) or Ras/Rap-association 
(RA) domain to interact with active Rap protein. In addition it was shown that citron 
homology domain (CNH) bind only active Rap2, and not Rap1 proteins, and 
therefore it is a discriminative domain between these two groups of related G 
proteins [65]. Following the interaction of active Rap proteins, effectors play role in 
different biological processes, such as integrin mediated cell adhesion, cell-to-cell 
junctions, cell polarity, exocytocis and cell proliferation [53]. In addition, 
endogenous Rap proteins were visualized by fluorescence protein-tagging methods, 
and they are found to localize many subcellular membrane compartments of the 
mammalian cells including the perinuclear Golgi apparatus, endoplasmic reticulum, 
endocytic vesicles, secretory vesicles and the nuclear envelope [53]. It is now 
revealed that in different membrane compartments, there exists different Rap 
interacting effector proteins that could induce different downstream pathways [53, 
66]. 
 
1.6 Aim of This Study 
Intrigued by its strict conservation in all eukaryotic species, we decided to functionally 
characterize the human counterpart of the coiled-coil domain-containing protein 124 
(Ccdc124). We propose that it is a novel component of the centrosome during interphase 
and at the G2/M transition. We then decided to study the subcellular localization of 
Ccdc124 during cell division. We found that Ccdc124 relocated to the midbody at 
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telophase, and acted as an essential molecular component in cytokinetic abscission. It 
was previously proposed by members of our group that Ccdc124 is an interaction partner 
of the Ras-guanine nucleotide exchange factor 1B (RasGEF1B; Elif Yaman, PhD. 
Thesis, 2009). We aimed to further validate this interaction, and identified that these two 
proteins interact at the midbody where this GEF could activate the small G protein Rap2  
[51] at pre-abscission stages. We then decided to knock-down Ccdc124 in embryos of 
the vertebrate model organism Danio rerio (zebrafish) by using specific morpholino 
oligonucleotides, and observed enlarged cells with compromised genetic stability in 
various tissues, thereby validating our observations on the role of Ccdc124 in cellular 
abscission. We propose that the coiled-coil protein Ccdc124 on one hand contribute to 
the regulation of cytokinetic abscission at the midbody, and on the other hand it recruits 
RasGEF1B to the midbody where this exchange factor activates the small G protein 
Rap2. Data presented in this thesis work propose a mechanistic link between cytokinetic 
abscission and Rap signaling that is mainly linked to the formation of cell-cell junctions, 
regulation of cell-extracellular matrix adhesion, and establishment of cell polarity [53], 
i.e., molecular processes that must follow cell division while tissues are formed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
18 
CHAPTER 2. MATERIALS AND METHODS 
 
 
2.1 MATERIALS 
 
2.1. 1. Bioinformatics Tools 
Amino acid sequence of the Ccdc124 and its homologue gene sequences were 
downloaded from NCBI homologene. The conservation pattern of the novel gene 
among all eukaryotic species was analysed using ClustalW2 (version 2.1) multiple 
alignment program and sequence similarities between the species were investigated 
via FASTA. Phylogenetic tree of Ccdc124 was done using neighbor joining (NJ) 
method in MEGA4 bioinformatic tool. Coiled coild domain of Ccdc124 was 
analyzed in COILS (www.ch.embnet.org/software/COILS_form.html) 
bioinformatics platforms. Canditate functional sites of the Ccdc124 protein was 
searched in ELM bioinformatics tool (http://elm.eu.org/about.html) .  
 
2.1.2. Agarose gel solutions 
 
Ethidium bromide: 10 mg Etidium bromide was dissolved in 1 ml deionized      
water (ddH2O) and diluted into 1mg/ml. 
 
Agarose gel, 1%: 1g agarose was dissolved in 100 ml TAE.  
 
TAE, 50X: Tris base, 242 g; Tritiplex III (EDTA), 37.2 g; glacial acetic 
acid, 57.1 ml were mixed and completed volume to 1 L with 
ddH2O. Dilute 1X for working solution and store at room 
temperature. 
 
6X Loading dye: 0.05 g bromophenol blue were dissolve in 10 ml ddH2O water, 
              and added into 30% glycerol solution. 
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2.1.3. Microbiology Strains  
 
Escherichia coli (E. coli) DH5! and BL21 bacterial strains were used in this study. 
 
2.1.4 Microbiology Solutions 
 
LB medium: 10 g tryptone, 5g yeast extract and 5g NaCl were prepared in 1 
ddH2O and autoclaved immediately after preparation. 
 
Agar medium: Bacto agar was added 1.5 % into LB buffer then autoclaved 
and poured onto plates, waited at room temperature overnight 
for solidification of agar plates. 
 
Glycerol stock solution: 25 ml %100 (sterile) glycerol were mixed with 25ml 
autoclaved LB near fire. 
SOB Liquid medium: 2% tryptone, 0.5% yeast extract, 10mM NaCl 2.5mM KCl           
were prepared in ddH2O. Then 10mM MgCl2 and 10mM          
MgSO4 were added into solution. 
 
SOC Liquid medium: SOB with 20mM Glucose.  
 
Transformation Buffer (TB): 10mM PIPES, 15mM CaCl2 and 250mM KCl  
were added, pH is adjusted to 6.7 with KOH then 55mM 
MnCl2 was put into solution and sterilized with 0.45 mm filter. 
 
Miniprep Solution I: 50mM Glucose, 25mM Tris-HCl (pH 8.0), 10mM EDTA  
(pH 8) are dissolved in ddH2O. 
 
Miniprep Solution II: 0.2N NaOH, 1% SDS were used freshly. 
 
Miniprep Solution III: 5M Potassium acetate and 11.5 ml Glacial acetic acid were    
   completed to 100ml with ddH2O. 
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RNase (20mg/ml): 1M Tris pH 8.0 and 5M NaCl were combined with 20 mg     
RNase, then solution was boiled for 15 minutes and store at -
200C. 
 
Ampicillin: 100mg/ml stock solution were prepared in ddH2O then 
sterilized by filtration and stored at -200C. Working solution is 
100$g/ml.  
 
Kanamycin: 40mg/ml kanamycin stock solution prepared in ddH2O then 
sterilized by filtration and stored at -20°C. Working solution is 
40$g/ml.  
  
2.1.5 Western Blot Solutions 
 
Protein lysis buffer: 50mM Tris-HCl (pH 8.0), 250mM NaCl, 1% NP-40, 1x  
Protease Inhibitor Cocktail were dissolved in ddH2O. 
 
IP buffer: 50mM Tris-HCl (pH 7.5), 5mM MgCl2, 150mM NaCl,  
                        1 tabl/50ml Complete Protease Inhibitor Cocktail 
 (Roche 1460500), 0.5 ml/50ml Phosphotase Inhibitor 
 Cocktail 1 (SIGMA P2850-5ml), 0.5 ml/50ml Phosphotase 
Inhibitor Cocktail 2 (SIGMA P5726-5ml) were mixed in 
ddH2O. 
 
Ral Buffer: % 10 glycerol, 200mM NaCl, 50mM Tris 7.5 pH,  %1 NP40 
5mM MgCl2 were prepared in ddH2O and 50ul          
Apoprotinin, 50ul Leupeptin, 50ul Na3VO4, pipette point NaF 
inhibitors were added for 50ml final volume. 
   
Semi-dry Transfer Buffer, 1X: 39mM Glycine, 48mM Trizma base, 0.037% SDS 
and 200ml Methanol were mixed. Then volume was completed to 1L with ddH2O. 
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Running Buffer, 5X: 15.1 g Trizma base, 95 g Glycine, 50 ml 
                                    10% SDS were completed to 1L with ddH2O. 
 
Wet transfer buffer, 10X: 30.3 g Tris base and 144 g Glycine were dissolved in 1L         
ddH2O. Dilute 1X for working solution with ddH2O and add 
20% Methanol store at 4C° (use freshly).  
 
TBS, 10X:                  12.1 g Trizma base and 87.6 g NaCl were dissolved in 1 L      
                                    ddH2O and pH was adjusted to 8.0. Tween-20 was added into          
                                   1X TBS to a final 0.1%.   
 
Gel staining solution: Coomassie brilliant blue G.250, 100 mg; absolute ethanol, 
50 ml; phosphoric acid (85%), 100 ml were prepared in ddH2O 
volume was completed to 1 L with and solution was filtered.  
 
Gel de-stain solution: 20% methanol and 7% acetic acid were mixed in ddH2O. 
40% acrylamide was purchased from Millipore. (Cat no. 800804) 
 
Gel formulations (10 ml): Mix tris buffer, SDS and 40% acrylamide in ddH2O  
according to the gel percentage as described in the Table 2.1. Immediately prior to 
pouring the gels, add 10% APS and TEMED shake gently to initiate polymerization 
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Table 2.1: SDS-PAGE Gel Formulations 
 
Running Gel 7.5%  10%  12%  15%  
 1 2 1 2 1 2 1 2 
1.5 Tris HCl 
pH 8.8 
2500 5000 2500 5000 2500 5000 2500 5000 
ddH2O 5415 10830 4790 9580 4290 8580 3540 7080 
40% Acryl/bis 
37.5:1 
1875 3750 2500 5000 3000 6000 3750 7500 
10% SDS 100 200 100 200 100 200 100 200 
10% APS 100 200 100 200 100 200 100 200 
TEMED 10 20 10 20 10 20 10 20 
 
 
 
 
 
 
 
Stacking Gel 4% 
 1 2 3 4 
0.5 Tris HCl pH 6.8 1250 2500 3750 5000 
ddH2O 3145 6290 9435 12580 
40% Acryl/bis 
37.5:1 
500 1000 1500 2000 
10% SDS 50 100 150 200 
10% APS 50 100 150 200 
TEMED 5 10 15 20 
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APS, 10% (w/v): 0.1 g ammonium persulfate was dissolved in 1 ml ddH2O,  
                                   filtered and stored at -20°C. 
 
Gel loading buffer, 5X (20ml) was purchased from Fermentas (#R0891).  
Protein ladders were purchased from Fermentas (#26616) and BIO-RAD (#161-
0373). As well as gel loading buffer was prepared manually; 50 mM Tris-HCl pH 
6.8, 1% SDS, 0.02% bromophenol blue, 10% Glycerol and 5% 2-mercaptoethanol. 
 
1.5 M Tris-HCl, pH 8.8: 121.1 g Trisma base were prepared in 200ml ddH2O and 
                                     pH was adjusted 8.8 with HCl. 
 
0.5 M Tris-HCl, pH 6.8: 121.1 g Trisma base were prepared in 200ml ddH2O and 
                                     pH was adjusted 6.8 with HCl. 
 
Blocking solution (w/v): 2.5 g milk powder was prepared in 1x TBS-Tween. 
 
Stripping solution was used commercially. (Milipore, Lot: PS01795976) 
 
2.1.6 IP reagents 
 
GFP beads were used from Chromotek (lot :120420001A). Flag beads(A2220-5ml) 
and HA beads (E6779-1ml) were acquired from SIGMA. Protein G Sepharose 4 
(10054549) and Protein A Sepharose (10043746) beads were purchased from GE 
Healthcare. 
 
2.1.7 Polymerase chain reaction (PCR) and reagents and cDNA synthesis 
reagents 
 
RevertAid First Strand cDNA synthesis Kit was used from Fermentas (#K1622). Pfu 
polymerase (#EP0502), 10mM dNTP Mix (#R0192) and taq polymerase (#EP0402) 
were also from Fermentas. 
 
  
24 
2.1.8 Vectors 
 
DNA ladder were from Fermentas (1kb #SM0313, 100BP #SM0313). pEGFP-N2 
(Clonetech), pEGFP-C3 (Clonetech), pmCherry-C1 (Clonetech), pEYFP-
C1(Clonetech),  pcDNA4/TO/Myc/his A,B,C (Invitrogen), p3xFlag-
CMV10/14(Sigma) were obtained commercially. 
pRFP-Rab11, pRFP-Rab5, pYFPTNIK, GFP-RalGDS constructs were provided from 
Hans Bos laboratory (UMC, Utrecht, Netherlands). The Ccdc124 esiRNAs and 
control esiRNAs were from SIGMA. 
 
2.1.9 Oligonucleotides 
 
Oligonucleotides in the table 2.2 were synthesized by IONTEK (Istanbul, Turkey). 
 
Table 2.2: List of primers used in this thesis work. 
 
Primer ID Sequence (5’-3’) 
LocSeq-F TGGCCACGTCCAGCAAGGTC 
LocSeq-R TCCGCCACGCTGAGCACTGCA 
HlocF0 GAGACGGACTCTTGCTATGTTG (Tm62) 
HllocR0 AGCCTTGCCGCCACCTTTATTGG (Tm66) 
RAP2A_RT_F TCTACCGCAAGGAGATCG AG 
RAP2A_RT_R TCTGCCTTCGCTGGACGATA 
RAP2AF GGATCCAAGCTTATGCGCGAGTACAAAGTGGTG 
RAP2Arev GAATTCGATATCCTATTGTATGTTACATGCAG 
RAP2A6HisR GAATTCGATATCCTAATGGTGATGGTGATGATG 
TTGTATGTTACATGCAGAACAGC 
RASGEF1B-F1 AAGCTTGCGGCCGCATGGAACAAAAACTCATCTCAGAAGA
GGATCTGATGCCTCAGACTCCTCCCTTTTCAT 
RASGEF1B-F2 AAGCTTGCGGCCGCATGCCTCAGACTCCTCCCTTTTCAG 
RASGEF1B-R1 GGATCCTCTAGAAACTCTGCCTAAGAGGCTCGACCTT 
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RASGEF1B-R2 GGATCCTCTAGATATCCCTTTGAAGTGGGATGGTATA 
RASGEF1B-RT-
F 
GAGCACCAGAGACTAAGTGA 
RASGEF1B-RT-
R1 
CCCTTTGTATAGACTGTGGC 
RASGEF1B-RT-
R2 
AACAGAGAGGAAGCAGTGGA 
RASGEF1B 1. 
Iso pmCherry-
C1-F 
AGATCTCGAGTGATGCCTCAGACTCCTCCCTTTTCAG 
RASGEF1B 1. 
Iso pmCherry-
C1, pEGFP-C3 R 
GTCGACGAATTCTTAAACTCTGCCTAAGAGGCTCGACC 
RASGEF1B 1. 
Iso pEGFP-C3 F 
TCAGATCTCGAGATGCCTCAGACTCCTCCCTTTTCAG 
RAP2A pEYFP-
N1-F and 
pmCherryC1-F 
GAGCTCAAGCTTATGCGCGAGTACAAAGTGGTG 
RAP2A 
pmCherryC1R 
GGTACCGTCGACCTATTGTATGTTACATGCAG 
RAP2A pEYFP 
-N1 R 
GGTACCGTCGACTGTTGTATGTTACATGCAGAA 
CAGCA 
L-HA-R GGATCCTCTAGATCAAGCGTAATCTGGAACATCGTATGGGT
ACTTGGGGGC 
HALNG-F1 GAATTCAAGCTTATGCCCAAGAAGTTCCAG 
T103A-F GCCCAGATCGAGGACGCGCTGCGCGCGAGACCATCAG  
T103A-R CTGATGGTCTCGGCGCAGCGCGTCCTCGATCTG GGC 
T103D-F  
 
GCCCAGATCGAGGACGACCTGCGCCGAGACCATCAG 
 
T103D-R  CTGATGGTCTCGGCGCAGGTCGTCCTCGATCTGGGC 
T103E-F  GCCCAGATCGAGGACGAGCTGCGCCGAGACCAT CAG 
T103E-R  CTGATGGTCTCGGCGCAGCTCGTCCTCGATCTGGGC 
S141A-F  GTGCTGGAGGAGGGCGCCGTGGAGGCGCGCGACC 
S141A-R  GGTGCGCGCCTCCACGGCGCCCTCCTCCAGCAC 
S141D-F  GTGCTGGAGGAGGGCGACGTGGAGGCGCGC ACC 
S141D-R  GGTGCGCGCCTCCACGTCGCCCTCCTCCAGCAC 
S141E-F  GTGCTGGAGGAGGGCGAGGTGGAGGCGCGC ACC 
S141E-R  GGTGCGCGCCTCCACCTCGCCCTCCTCCAGCAC 
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S122A –F  GCCGAGAAAGCCAAGGCCCATCTGGAGGTGCCG 
S122A –R  CGGCACCTCCAGATGGGCCTTGGCTTTCTCGGC 
S122D –F  GCCGAGAAAGCCAAGGACCATCTGGAGGTGCCG 
S122D –R  CGGCACCTCCAGATGGTCCTTGGCTTTCTCGGC 
S122E –F  GCCGAGAAAGCCAAGAGCATCTGGAGGTGCCG 
S122E –R  CGGCACCTCCAGATGCTCCTTGGCTTTCTCGGC 
Ccdc124GFP-
Full_F 
AAGCTTGAATTCATGCCCAAGAAGTTCCAGGGTGAG  
 
Ccdc124_L64M_
GFP_F 
AAGCTTGAATTCATGGAACGTAAGAAGGAGACG 
Ccdc124V142M
_GFP_F 
AAGCTTGAATTCATGGAGGCGCGCACCATCGAG 
Ccdc124GFP_N
2_REV 
GGTACCGGATCCTCTTGGGGGCATTGAAGGGCAC 
Ccdc124_M1L-F CCCTGCTGAGGGCTGCCCAAGAAGTTCCAGGGTG  
Ccdc124_M1L-R CACCCTGGAACTTCTTGGGCAGCCCTCAGCAGGG 
Ccdc124_M47L-
F 
CAAACACGTCCTGAGGAAGGAGCAGCGCAAGGAG 
 
Ccdc124_M47L-
R 
CTCCTTGCGCTGCTCCTTCCTCAGGACGTGTTTC 
GAPDH–F  GGCTGAGAACGGGAAGCTTGTCAT  
GAPDH–R  CAGCCTTCTCCATGGTGGTGAAGA 
 
 
 
2.1.10 Cell culture reagents 
 
100X non-essential amino acids was acquired from GIBCO (#11140), 
penicillin/streptomycin was purchased from Biochrom AG (A2213) and 100X 
(200mM) L-glutamine was purchased from GIBCO (#25030). 
 
PBS 10x: NaCl, 80 g; KCl, 2 g; KH2PO4, 2.4 g, Na2HPO4, 14.4 g; were 
dissolved   in 1 L of ddH2O and adjust to volume pH 7.2–7.4. 
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                        Geneticin-G418:  It was purchased from GIBCO (#10131) and 500 mg/ml 
solution was prepared in ddH2O after filtration it was stored at 
-20°C (stock solution). 200-800 µg/ml  (working solution). 
 
Puromycin:     2 mg/ml solution was prepared in ddH2O in then was sterilized 
by filtration and was stored at -20°C (stock solution). 2µg/ml 
(working solution). 
 
Polyethylenimine (PEI#23966) transfection reagent: 200mg PEI was dissolved in 
pure etanol. 
 
DMEM and DMEM/F12 was purchased from GIBCO and prepared by adding 10% 
FBS, 1% L-glutamine, 1% penicillin/streptomycin and 1 % non-essential amino 
acids.   
 
2.1.11. Immunofluorescence reagents 
 
Blocking solution:   2% BSA, 0.1% Triton-X in 1x PBS. 
 
Washing Solution:   0.1% Trition-X in 1x PBS 
 
DAPI (4’, 6-diamino-2-phenylindole): 0.1-1 µg/mL working solution in double-
distilled water. 
Mounting medium was purchased from DAKO (#10053437). 
 
2.1.12. Antibodies 
 
All of the antibodies were purchased from different companies. Name of the 
companies and dilutions are depicted in table 2.3. 
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Table 2.3 List of antibodies used in this thesis work. 
 
 
Antibody 
ID 
Origin 
species 
Company Lot WB IF 
CCDC124-
Cter 
Rabbit(100-
150) 
BETHYL A301-834 1/1000 1/100 
CCDC124-
Middle 
 
Rabbit(173-
223) 
BETHYL A301-835 1/1000 1/200 
Anti-Nter 
CCDC124 
Rabbit Cambrige 
Research 
Biochemicals 
 1/5000  
Anti-Rap2 Rabbit Genetax GTX108831 1/2500 1/250 
Anti-Rap2 Mouse BD-
biosciences 
610215 1/1000 1/100 
Anti-
RasGEF1B 
Rabbit Cambrige 
Research 
Biochemicals 
 1/1000 1/100 
Anti-Plk1 Rabbit Nurhan Ozlu  1/100.000 
(IP) 
1/10.000 
Anti-Plk1 Rabbit Abcam 109777 1/1000 1/200 
Anti-Flag Mouse Sigma F3165 1/5000 
(IP) 
 
Anti-alpha 
tubulin 
Mouse Santa Cruz 
Biotec. 
 Sc-5286 1/5000 1/500 
Anti-beta 
tubulin 
Rabbit Santa Cruz 
Biotec. 
Sc-9104  1/100 
Anti-gama 
tubulin 
Mouse Abcam 11316 1/1000 1/200 
HA ab. Mouse Santa Cruz 
Biotec. 
Sc-7392 1/1000 1/200 
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HA-HRP Mouse Cell signaling 29993 1/5000 
 
 
Anti-mouse  Goat Sigma A2304 1/5000  
Anti-Rabbit Goat Sigma A9169 1/5000  
Anti-
FlagHRP 
Mouse Sigma A8592 1/240.000 
(IP) 
 
Alexa 488 Mouse Invitrogene 898236  1/500 
Alexa 488 Rabbit Invitrogene A11034  1/500 
Alexa 568 Mouse Invitrogene A11031  1/500 
Alexa 568 Rabbit Invitrogene 898234  1/500 
Anti-GFP Rabbit Sigma G1544 1/1000  
Anti-
RACK1 
Rabbit Sigma R1915 1/5000 1/200 
 
 
 
2.1.13 Cell Syncronization Reagents 
 
Nocodazole (Sigma #M1404):  10mg/ml stock solution was prepared in DMSO. 
200ng/$l were used as working dilution. 
 
                    Thymidine (Sigma #T1895): 100mM stock solution was prepared in ddH20. 
Working solution was 2.5uM.  
 
2.1.14 Mass spectrometry reagents 
 
Stable N-ter Flag Ccdc124, C-ter Flag Ccdc124, YFP-RasGEF1B and EV (3Xflag-
CMV-14 and EYFP-N1 plasmids) expressing HEK293 cell lines were generated and 
used in experiments (see below). DMEM cell culture medium (Gibco) was routinely 
used in experiments. Cell culture medium lacked arginine, lysine or methionine. 
Dialyzed fetal bovine serum (Gibco) without essential amino acids for SILAC 
labeling were commercially obtained and used in all experiments. Antibiotics 
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(penicillin and streptomycin, 100X Invitrogen), and Glutamine (100X, Invitrogen) 
were supplied when necessary. For immunoprecipitations GFP antibody bound 
commercial beads (Chromotek, #120420001A) and Flag antibody bound commercial 
beads (Flag beads, A2220-5ml) were used. L-Arginine monohydrochloride (Sigma, 
#A6969), L-Lysine (Sigma #L9037), L-Methionine (Sigma #M5308) were used in 
light SILAC media. 
SILAC amino acids L-arginine-13C6 monohydrochloride (Cambridge Isotope 
Laboratories, CLM-2265); L-arginine-13C615N4 hydrochloride (Sigma-Isotec, 
#608033); L-lysine-13C615N2 hydrochloride (Sigma-Isotec, #60804); L-methionine-
13C,2H3 (methyl-13C,2H3) (Sigma-Isotec, # 299154) were used in heavy SILAC media 
preparation. 
8 M urea (Sigma, U5128) in 0.1 M Tris/HCl pH 8.5 (UA) was prepared as 1 ml per 1 
sample. 0.5M NaCl was in ddH2O (Prepare 0.25 ml per 1 sample). Trypsin was used 
from 0.4 µg/µl stock. 0.05M Iodoacetamide (IAA) was prepared in UA. 0.05M 
Ammonium bicarbonate was dissolved in ddH2O (ABC).  
Trifluoroacetic acid (TFA), Formic acid (FA) and Complete protease inhibitor tablets 
(Roche Diagnostics) were also used in these assays.  
 
2.1.15 Mass-spectrometry Equipment used in Analysis 
 
LTQ-Orbitrap Mass spectrometer (Thermo Fisher Scientific) was used in analysis. 
Agilent 1200 series Nano-flow HPLC system was attached to apparatus. Protein and 
peptide identification software tools were used a served in analysis (Mascot-version 
2.2.03, Matrix Science). Scaffold (version 2.05.02, proteome Software Inc.) was used 
for peptide validation. Raw mass spectrometric data were analyzed by MSQuant 
software package (version 1.0.13.12). Thermo-mixer set to 20ºC. Micrococon YM-30 
filter  (Milipore, Cat no. 42410). 
 
2.1.16 Zebrafish injection reagents 
Ccdc124 morpholino (5’- CTGGGACTTTCCTTTTCCTGAGCCA-3’), RasGEF1B 
morpholino (5’-GGGTGGCGTCTGAGGCATTTTGTC), chordin positive control 
(5’-ATCCACAGCAGCCCCTCCATCATCC-3’) , and standard control morpholino 
  
31 
(5’-CCTCTTACCTCAGTTACAATTTATA-3’) were purchased from GeneTools, 
Philomath, OR, USA). 1x Danieau solution; 58 mM NaCl, 0.7 mM KCl, 0.4 mM 
MgSO4, 0.6 mM Ca (NO3)2 , 5.0 mM HEPES pH 7.6. 
 
2.2 METHODS 
2.2.1. General methods 
2.2.1.1 Bacterial strains storage 
Bacterial strains were stored by “Glycerol-Stock” method. A single colony was picked 
from agar plate then it was inoculated into 3 ml LB in 15 ml cononical tube. Falcons 
were incubated O/N at 37ºC and at 225 rpm. For glycerol stock, 500µl bacterial culture 
was added into 500 µl of sterile 50% glycerol-50%LB mix. This mix was frozen at -
80ºC. 
 
2.2.1.2 Competent cell preparation 
 
DH5% (or another suitable strain) strains were grown in SOB medium at 20ºC for 5-7 
hours until to reach from OD600 of 0.2 to OD600 of 0.5-0.6 (logarithmic growth range) 
by shaking at 225 rpm. When the optical density was reached, the flask was cooled 
down on ice for 10 minutes. Then cells poured into sterile 50 ml tubes. Cells were 
harvested by centrifugation at 2500xg for 10 minutes. (rotor must be prechilled). 
Supernatants were discarded and pellets were resuspended in ice-cold transformation 
buffer and kept on ice for 10 minutes. The suspension was then centrifuged at 
2500xg for 10 minutes. The pellet was gently resuspended in ice-cold TB containing 
7% DMSO and left on ice for 10 minutes. 0.2 ml aliquots were pipetted into cold 
microcentrifuge tubes. 
Tubes were immediately put into liquid nitrogen to freeze rapidly and stored at –
80ºC. 
2.2.1.3 Transformation of E.coli 
Competent cells were taken from –80ºC stock thawed on ice. 200 µl of cells were put 
into 15ml polypropylene tubes and placed on ice. Appropriate amount of plasmid 
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was added onto competent cells. Then cells were incubated with plasmid on ice for 
30 minutes. Then heat-shocked for 30 seconds at 42ºC, then the tubes were 
transferred to an ice bath for 2 minutes and 800 µl SOC was added. Following 
incubation for 1 hour at 37ºC with vigorous shaking, 50-100 µl cells were plated out 
on LB-agar with selective antibiotics and incubated at 37ºC O/N. 
2.2.1.4. Plasmid DNA purification 
2.2.1.4.1. Small Scale Plasmid DNA preparation by Alkaline Lysis Method 
Transformed bacterial cells were grown in 3 ml selective antibiotics contaning LB 
medium O/N at 37ºC by shaking at 225 rpm. 1.5 ml bacterial culture was taken and 
centrifuged for 1 minute at 13,000 rpm in a micro centrifuge. Then the supernatant 
was discarded, and  the pellet was resuspended in 100 µl Solution I. Freshly prepared 
200 µl of Solution II was added and inverted 2-3 times. Bacterial chromosomal DNA 
and proteins (cell debris) were precipitated by addition of 150 µl of Solution III. This 
mixture was left on bench for 2-3 minutes, and then centrifuged for 15 minutes at 
13,000 rpm. The supernatant was transferred to another 1.5 ml tube. The plasmid 
DNA was mixed with two-volume ice-cold absolute ethanol. The plasmid was 
precipitated by centrifugation at 13,000 rpm, at room temparature for 15 minutes. 
The supernatant was discarded and the pellet was washed 1-2 times with 500 µl of 
70% ethanol and centrifuged at 13,000 rpm for 15 minutes. Then supernatant was 
discarded and the pellet was left at room temperature for 15 minutes to air dry and 
resuspended in 20-50 µl of sterile ddH2O containing 20 µg/ml RNaseA. Samples 
were stored at 4ºC for short term or at –20ºC for long term. The quality of the 
miniprep was checked by agarose gel electrophoresis and the amount of plasmid was 
measured by using spectrophotometer (Nanodrop ND-100, ND100.V3.1.1 software). 
2.2.1.4.2 Purification of plasmid with Fermentas GeneJET Plasmid Miniprep 
Kit 
This plasmid isolation method was used for cloning and sequencing procedures. To 
isolate plasmid DNA by using Fermentas GeneJET Plasmid Miniprep Kit (#K0503) 
1.5 ml bacterial culture was used following manufacturer’s instructions. 
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2.2.1.4.3 Large Scale Plasmid DNA preparation 
This plasmid isolation method was preferred because it facilated the use of plasmids 
in cloning and mammalian cell transfection assays by using “Promega Pureyield 
Plasmid Midiprep kit (#A2495)” following manufacture’s instructions. 
2.2.1.5. Quantification of Nucleic Acids 
Nucleic acid concentrations and purities were determined by using ND-1000 V3.7.1 
software in the Nanodro model  from Thermoscientific Company. 
2.2.1.6. Restriction enzyme digestion of plasmid DNA  
1-10 µg plasmid DNA was routinely used during restriction enzyme digestion and 
performed in 20-100 µl reaction volume. Reaction was done in appreciate conditions 
by following suggestion of manufacturers. Restriction enzymes were used from 
Fermentas Company. 
2.2.1.7 Vector construction  
The C-ter HA epitope tagged Ccdc124 (L-HA) was cloned into XbaI/HindIII sites of 
pcDNA4/TO/MYC/HIS-B plasmid vector by PCR method. LHA-forward and LHA-
reverse primers (Sequences was shown in table 2.1) were used. The S122A, S122D, 
T103A, T103D, S141A, S141D, T96A, T96D Ccdc124 phospho sites mutation 
containing plasmids were prepared on L-HA plasmid by site directed mutagenesis as 
mentioned in methods. 
The RAP2Awt construct was cloned into HindIII/EcorV sites of 
pcDNA4/TO/MYC/HIS-B by PCR method with RAP2A-F and RAP2A-R primers. 
The RAP2A-His plasmid was cloned into HindIII/EcorV sites of 
pcDNA4/TO/MYC/HIS-B plasmid by PCR cloning using RAP2A-F and 
RAP2AHis-R primers. 
For identification of an alternative translation start site in Ccdc124 ORF methionine 
residue (Met-47) in Ccdc124 ORF was mutated to Leu amino acids in Ccdc124-HA 
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vector construct using Ccdc124_M47L-F and Ccdc124_M47L-R primers by site 
directed mutagenesis method (see below).  
To prepare Full-Cter-GFP-Ccdc124 and Truncated-Cter-GFP-Ccdc124 plasmid 
constructs, Ccdc124-GFP-Full-F, Ccdc124-L64M-GFP-F, Ccdc124V142M-GFP-F 
and GFP-N2-R primers were used and Ccdc124 constructs were cloned into 
EcorI/BamHI sites of pEGFP-N2 plasmid via PCR cloning method. 
The RasGEF1B constructs were cloned into XhoI/EcorI sites of pmCherryC1, 
pECFP-C1, pEGFP-C3, pEYFP-N1 plasmids (cloning primers were shown in the 
Table 2.1). 
The RAP2A was cloned into HindIII/SalI sites of pmCherryC1, pEYFP-N1 plasmids 
(Primers were shown in the Table 2.1). 
2.2.1.8 Site directed mutagenesis 
Ccdc-124 Ser, Thr, Tyr putative phosphorylation site mutants were generated on the 
plasmid vector containing C-ter HA-linked version of Ccdc124 (L-HA) using the 
sense and antisense primers were shown in the table 2.2. 
40 ng template DNA and 10 pmol of sense (S) and anti-sense (AS) primers were 
used in mutagenesis PCR reactions which involved 5 min. initial denaturation at 95ºC 
followed by 18 cycles of 1 min 60ºC, 6 min 68ºC, 1 min 95ºC, and the final extension 
step of 10 min 68ºC. Then, samples were subjected to DpnI digestion and 
transformed into E.coli DH5a competent cells. The plasmids were isolated and their 
sequences were verified by sequencing.  
2.2.1.9. Agarose gel electrophoresis of DNA 
Agarose was dissolved in 1X TAE buffer (DNA samples < 1kb were separated in 1-
2% agarose gel, > 1kb were loaded 0.8% agarose gel.) in microwave and ethidium 
bromide was added to a final concentration of 10 µg/ml. The DNA samples were 
prepared with 1x loading dye and were loaded onto gels. The gel was run in 1x TAE 
at different voltage and time depending on the size of the DNA fragments. 
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2.2.2. Cell culture methods 
2.2.2.1. Cell lines and Stable clones 
Human embryonic kidney (HEK293), Human cervical cancer cell line (HeLa), 
Human osteosarcoma (U2OS) cell line, Huh7, MCF7N, HepG2, Snu449, Retinal 
Pigment Epithelial-1 (RPE-1) cell line, and RPE1-GFP-Centrin, RPE1-GFP-Plk1 cell 
lines were used in this study. Cell lines having Trex in their names are similar to 
those explained above, except that they contain a constitutively expressed bacterial 
tetracycline repressor (TetR) gene. 
To obtain stably N-ter-Flag-Ccdc124, C-ter-Flag-Ccdc124, and N-ter-GFP –Ccdc124 
expressing HEK293 cell lines, a cytotoxicity curve was performed with Geneticin-
G418. 600 µg/ml G418 was chosen for selection. HEK293 cells were transfected 
with Flag-Ccdc124, Ccdc124-Flag, GFP-Ccdc124 plasmid constructs and their 
controls by using Fugene6 transfection reagent as mentioned table 2.4. 1-2 day later, 
transfected cells were seeded onto 150mm plates. After 24 hours growth medium 
were changed with selection antibiotic containing medium. We waited 7-14 days for 
formation of colonies. Then colonies were transferred into 6 well plates and cell 
pellet of the colonies were used to perform immunoblotting. Positive colonies were 
selected and preserved by freezing for future experiments. 
2.2.2.2 Growth conditions of cell lines 
HEK293, Trex-293, Huh7, HepG2, Trex-HepG2 U2OS cells, and HeLa cells were 
maintained in high glucose DMEM, MCF7N, Trex-MCF7, Snu449, Trex-Snu449 
cell lines were grown in RPMI, C2C12 in %20 FBS containing DMEM, 
differentiated C2C12 was grown in DMEM (high glucose + glutamine, no Sodium 
Pyruvate) Donor equine serum, insulin and Retinal Pigment Epithelial-1 (RPE1) cells 
were grown in DMEM/F12 (1:1) supplemented with 10% FBS, 1% 
penicillin/streptomycin (P/S) and 1% L-glutamine and kept at 37 ºC in a humidified 
5% CO2 atmosphere. RPE1 cells were obtained from Nurhan Özlü (Koç University, 
Istanbul), and RPE1 lines stably expressing GFP-Centrin, and GFP-Plk1 were gifts 
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from Greenfield Sluder (U. Mass. Medical School, MA), and Prasad Jallepalli 
(Memorial Sloan-Kettering, NY), respectively. 
2.2.2.3 Cell cycle synchronization  
Cells were synchronized by a first thymidine block (2,5 mM) for 16 hours, released 
for 8 hours, and then blocked a second time with thymidine for 16 hours, followed by 
200 nM nocodazole treatment/12 hours. Mitotic arrested cells were collected by 
“mitotic shake-off”, and either analyzed directly (0 min.), or recultured for 15, 30, 
45, 60, 120, 150, and 180 mins. At the beginning of the experiments cell cycle status 
of samples were established by FACS analysis as described in Fabbro et al. [39] and 
at each time point cells were processed for Immunofluorescence. 
2.2.2.4 FACS analysis of the cells 
1x106 unsynchronized or synchronized cells were collected as samples, and 
resuspended in 0.3 ml of PBS buffer. Cells were fixed by addition of 0.7 ml cold 
ethanol (70%), left on ice for 1hr, and then washed and resuspended in 0.25 ml of 
PBS in which they were treated with 0.5mg/ml RNAse-A for 1 hr at 37ºC. Cellular 
DNA is then stained with 10 µg/ml propidium iodide (PI) solution, and cytometric 
analysis was performed by FACS at 488 nm. Data was analyzed by using Accuri C6 
C flow plus software. 
2.2.2.5. Cryopreservation of stock cells 
Exponentially growing cells in 100mm cell culture plate were harvested by 
trypsinization and collected in 5 ml growth medium. Then, cells were precipitated at 
1500 rpm for 3 min. The pellet was suspended in a freezing medium (10% DMSO, 
10% FCS and 80% DMEM). Pellets were resuspended in 1ml freezing medium in 
cryotubes and they were left at -20ºC O/N. The next day cells were stored-80ºC for 1 
day to 1 month. Finally, the tubes were transferred into the liquid nitrogen storage 
tank for future experiments. 
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2.2.2.6. Thawing of frozen cells 
The frozen cell line was taken from the liquid nitrogen tank and immediately put on 
ice and then placed into a 37ºC water bath for 1-2 minutes. The cells were transferred 
into 15ml tubes and resuspended in 5ml growth medium. The cells were centrifuged 
at 1500 rpm for 3 minutes. Supernatant was discarded and the pellet was resuspended 
in 10 ml culture medium to be plated into 100 mm dish. After overnight incubation 
culture mediums were replenished. 
2.2.2.7. Transient transfection of eukaryotic cell lines 
2.2.2.7.1. Transfection of cell lines using FuGene-6 and PEI  
Cell lines were transfected with plasmid DNAs using FuGENE-6 reagent (Roche) 
and PEI. FuGENE:DNA and PEI:DNA ratios were determined experimentally to be 
3:1 for, HeLa and U2OS, 1:2,5 for HEK293 cells. In general, appropriate amount of 
cells were seeded onto tissue culture dishes the day before the transfection, so that 
they reached 80-90% confluency on the day of transfection. Before the transfection, 
growth medium was aspirated and replaced with growth medium without antibiotics. 
Serum and antibiotic free medium were mixed with plasmid DNA in 1.5 ml tubes 
and appreciate transfection reagent were added on the mix, incubated at RT 30 
minutes for Fugene and 20 minutes for PEI. Transfection reagent/DNA mix was 
added dropwise to the plate of cells. Transfected cells were incubated for 24 hr at 
37°C in an incubator with an atmosphere of 5% CO2 in air. 1 day after transfection 
medium was refreshed with growth medium and placed back to incubator for a 
further 24 hours. The transfection reagents and appropriate amounts of DNA used for 
transfection in different cell lines and different culture plates were given in Table 2.4. 
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Table 2.4. The amounts of reagents and media that were used in Fugene and PEI 
transfection methods. 
      Type of plate 
Reagents 
150mm plate 100mm plate 6 well plate 12 well plate 
H
EK
29
3 
 
90 $l 15$l 2.5$l 1.5$l 
H
eL
a 108 $l 18$l 3$l 1.5$l 
FU
G
E
N
E
 
 
U
2O
S 108 $l 18$l 3$l 1.5$l 
PEI 
(HEK293) 
37.5$l 15$l 2.5$l - 
DMEM W/O 1ml 0.5ml 0.1ml 0.1ml 
DNA 18$g 6 $g 1$g 0.5$g 
Culture 
medium 
20 ml 10ml 2ml 1ml 
 
2.2.2.7.2. Transfection of cell lines using Lipofectamine RNAiMax 
50 nM of Mission® esiRNA from Sigma-Aldrich (cat. EHU004061) was used for 
silencing Ccdc124 in HeLa cells by using Lipofectamine RNAiMax (Invitrogen) as 
transfection reagent.  
500 µl of optiMEM was added in 6 well plates, 50ng siRNA was added on top of 
optiMEM, and mixed gently. 5µl Lipofectamine RNAiMax was added to each well 
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containing diluted RNAi molocule, mixed and they incubated at RT for 10-20 min. 
Cells were diluted in 2.5 ml complete medium without antibiotics, added onto RNAi-
lipofectamine mix and mixed gently by rocking the plate back and forth. Cells were 
analysed 48-72 hours later by WB, IF. 
2.2.3 RNA extraction 
The expression level of Ccdc124 and GAPDH in different cell lines was monitored 
by semiquantitative RT-PCR. RNA was prepared from cell pellets using the 
NucleospinRNA II kit (Macherey-Nagel #740955) as recommended by the 
manufacturer. The RNA preparation protocol included on-column Dnase treatment 
step, minimizing the presence of genomic DNA in the RNA samples. RNA 
concentrations were determined by spectrophotometry. 
2.2.4 cDNA synthesis and RT-PCR assay 
Revert-Aid first Strand cDNA Synthesis Kit (MBI Fermantas #K1622, Germany) 
was used for preparation of first strand cDNA from 2ug of total RNA. Semi-
quantitative RT-PCR primers amplified two or more exonic sequences. –RT control 
was prepared to ensure the amplification from cDNA only. 
PCR amplification was done in 25 µl reaction volumes containing 1X PCR buffer, 
1.5 mM MgCl2, 200 µM dNTP, 10 pmoles of each primer, and 1 unit of Taq DNA 
polymerase (Fermentas). Thermal cycler conditions consisted of an initial 
denaturation step at 95°C for 5 min; a loop cycle of 95°C, 20sec / 60°C, 20sec / 
72°C, 30sec; and a final extension at 72°C for 5 minutes. The cycle number varied 
for each transcript amplified, for Cdc124 and RAP2A 30 it was 30 cycles, for 
RasGEF1B (1.iso) it was 35 cycles, and cycle number for GAPDH was 21 cycles. 
PCR products were run on 2% agarose gel. 
2.2.5 Western blotting 
Cells collected from 6 well culture plates were lysed in 50 $l lysis buffer. Protein 
concentrations were determined by Bradford assay. 40 $
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denatured in gel loading buffer at 95°C for 5 min, resolved by SDS-PAGE using a 
12% gel, and electrotransferred onto PVDF membranes (Millipore). 
2.2.6 Immunoprecipitation (IP) 
For RasGEF1B/Ccdc124 co-immunoprecipitation experiments, HEK293 cells were 
transfected with Flag-Ccdc124 and YFP-RasGEF1B vectors. 48 hours later, cells 
were lysed in NP-40 lysis buffer, flag-tagged agarose beads (A2220, Sigma-Aldrich) 
were used to precipitate proteins for two hours, followed by a centrifugation for 30 
sec. at 8800 rpm, then beads were washed three times with NP-40 lysis buffer. 50$l 
sample buffers were added to lysates and incubated at 95°C for 5 min, fractionated 
by SDS-PAGE for immunoblot analysis and transferred onto PVDF membranes 
(Millipore). Anti-GFP (G1544, Sigma-Aldrich) and anti-Flag-HRP M2 (A8592, 
Sigma-Aldrich) were used in Western blot analysis. Blotted proteins were visualized 
using the ECL detection system (Amersham). 
2.2.7 Immunofluorescence (IF) 
HeLa cells on cover slips were fixed by ice cold 100% Metanol for 10 min at -20, 
washed three times with PBS-T; blocked in 2% BSA for 1 hour and incubated 1 hour 
with primary, washed again three times with PBS-T and incubated for 1 hour with 
suitable secondary antibodies. Fluorescent images were taken by Zeiss Imager-A1 
microscope with a Zeiss Acroplan 40X objective. Images were captured on the Zeiss 
Axia Cam MRc 5- CCD camera for fixed samples. Microscope control and image 
processing were done through Axiovision version 4.6 software program (Universal 
Imaging).  
2.2.7 In vitro CKII Kinase Assay 
CKII kinase was purchased from NEB Biosciences (New Jersey, USA). In CKII 
phosphorylation analysis of Ccdc124, in each experimental set-up 1.5 µg nickel 
column purified his-tagged Ccdc124 (kindly provided by Elif Yaman) was used. For 
detection of phosphorylation, ATP (100 µM) was replaced by ATP-#-S (100 µM; 
Epitomics, #3701-1), and thiophosphorylate its substrate. Then thiophosphorylation 
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site on the substrate is alkylated with p-nitrobenzyl mesylate (PNMB, Epitomics, 
#3700-1) and following tagged kinase substrate was detected by a specific antibody 
(Thiophosphate Ester RabMAb, Epitomics, #2686-1). In control experiments, CKII 
activity was inhibited by addition of 10 µM of 4,5,6,7-Tetrabromo-2-
azabenzimiddazole (TBB; Calbiochem # 218697) to in vitro assay reactions. In vitro 
kinase reaction was carried-out for 30 min. at 30°C using CKII protein (100 U) 
incubated with pure 1.5 µg his-tagged Ccdc124 protein as substrate using ATP-#-S 
followed by alkylation 2 hours with PNBM at RT.  
2.2.8 Mass spectrometry 
Stable N-terminal (N-ter) and C-ter-Flag tagged Ccdc124, YFP-RasGEF1B, Empty 
Vector control (3xFlagCMV14), and YFP (control) expressing monoclonal HEK293 
cell lines were prepared by Fugene transfection method. Then, these stable clones 
were selected, and they were maintained in DMEM containing 1% penicillin/ 
streptomycin, 10% FBS, and 0.6mg/ml Geneticin. Stable isotope labeling by amino 
acids in cell culture (SILAC) was performed for six doublings in SILAC medium 
containing light or heavy lysine and arginine aminoacids, 1% penicillin/ 
streptomycin, 10% FBS and 0.6mg/ml Geneticin. Following the collection of the 
cells by scraping, the cells lysed in NP-40 buffer and cleared by centrifugation. The 
supernatants were transferred to new eppendorf tubes and protein concentrations of 
were calculated using Bradford assay. The light amino acids and heavy amino acid 
containing lysates were mixed in 1:1 ratio. After that, lysates were bound to Flag 
beads or GFP beads for two hours to allow precipitation. There are two methods to 
convert them into peptides with suitable sizes for MS analysis. The first one is based 
on the solubilization of proteins in SDS gel, whereas the second one is the detergent 
free digestion of proteins in solution using filter-aided sample preparation (FASP) 
methods. We performed both of the methods for Ccdc124 and only FASP method for 
RasGEF1B analysis. For the first method, we added 2x sample buffer onto washed 
beads following IP and we loaded proteins into commercial Nu-Page gel 
(Invitrogen). Then, bands were cut and isolated from the gel. Following this step, 
these gel slices were digested with trypsin at 37°C, and supernatants were put into 
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new eppendorf tubes. Subsequently, we acidified the digestion mixture with TFA 
(1%) to stop digestion reaction, and we added 2-gel volumes of 1% TFA/30% ACN 
for extraction of peptides. Finally the extraction solution and digestion mixture were 
combined and the organic component was evaporated in a vacuum centrifuge. 
MS samples were also prepared with FASP method in some experiments. Bound 
proteins were eluted from beads with a low-pH buffer. Eluted lysates were mixed 
with 200µl of UA (see Materials) in the filter and centrifuged. Supernatant was 
discarded and 100 µl IAA (see Materials) was added and mixed at 600 rpm in a 
thermo-mixer for 1 min. and samples were incubated without mixing for 20 mins. 
Then, samples were centrifuged twice at 13000 rpm for 10 min. Subsequently, filters 
were washed two times 100 µl UA, and again two times with 100 µl ABC (see 
Materials) buffer. Following the addition of 40 µl trypsin, samples were incubated at 
37°C for O/N. After that filter units were transferred into new collection tubes, and 
centrifuged at 13000 rpm for 10 min. Finally, peptides were eluted using 0.5 M NaCl 
and desalted. Before to LC-MS/MS analysis, peptides dried in vacuum centrifuge 
and reconstituted in 5% formic acid (FA). 
After preparation of samples with in-gel digestion, or in solution digestion method 
(FASP), peptides were loaded to a reversed phase nano-LC-MS/MS analysis 
consisting of an Agilent 1200 series HPLC system connected to an LTQ-Orbitrap 
mass-spectrometer (Thermo Fischer Scientific).  
Raw spectrometric data from the SILAC experiments were analyzed by using 
MaxQuant software package (version 1.0.13.12).  MS/MS spectra were searched 
against IPI human database (version 3.52) using Mascot (Version 2.2.04). 
2.2.9 In vivo studies 
2.2.9.1 Morpholino injections of Zebrafish embryos  
For knockdown of Ccdc124 function in zebrafish embryos a specific morpholino was 
designed to block translation of Ccdc124 by complementary binding to Ccdc124 
transcripts three nucleotides upstream of the AUG site. Ccdc124 and control 
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morpholinos were diluted at 2.5 ng/$l in 1x Danieau solution supplemented with 
0.05% phenol red (Sigma). A total of 4 nl of diluted morpholino was injected into 1 
cell stage zebrafish embryos and embryos were analyzed at 2 hpf, 5 hpf, and 3 dpf. 
Western blot quantification using a zebrafish sequence-specific anti Ccdc124 
antibody in 3 dpf larvae revealed a 35 % decrease of Ccdc124 protein in morphants 
when compared to uninjected or control morpholino-injected embryos. For early 
embryo analysis and quantification of DNA content, embryos were incubated with 
the vital stain BODIPY 505/515 (Molecular Probes) and subjected to confocal 
microscopy imaging. Embryos were co-labeled with DAPI to visualize nuclear DNA 
contents. Confocal images were thresholded and binarized and the number of 
positive pixels was counted as a measure of DNA content per cell. 
 
 CHAPTER 3. RESULTS 
 
3.1 Molecular characterization of Ccdc124 as a protein 
CCDC124 was previously found in our group as an expressed eukaryotic conserved 
gene when putative down-stream cis-acting transcriptional regulatory elements of the 
Na+/I- Symporter (NIS) gene were studied (unpublished results). In those past studies, 
in an attempt to find novel transcriptional regulatory sites of NIS, we had started 
computational analyses to identify conserved non-coding regions of NIS gene (Hani 
Alotaibi, Serap Erkek, Pelin Telkoparan, and Uygar H. Tazebay, unpublished results). 
Different putative conserved regions were identified in human, rat and mouse 
genomes by using VISTA bioinformatics tools  [67]. These regions were then 
analyzed by luciferase assays, and the most 3$ fragment displayed a very high 
transcriptional activity (Hani Alotaibi and Uygar H. Tazebay, unpublished). It was 
then realized that this did not contain a 3$ regulatory element of the NIS gene, but 
rather it was a region that control the expression of a novel gene called CCDC124. 
In the present thesis work, we carried-out functional analysis of CCDC124 which 
encodes an mRNA that is transcribed from chromosome 19p13.11, consisting of five 
exons, of which exon 1 is non-coding. Ccdc124 protein sequence was aligned with 
other species via BLAST analysis it was indicated that the protein encoded from this 
genetic locus shares, 70% identity/89.1% similarity with its orthologue NP_956859 in 
the vertebrate model Danio rerio (zebrafish), or 50.4% identity/72.6% similarity with 
Y73E7A.1 in the invertebrate Caenorhabditis elegans. CCDC124 has also other  
orthologs in lower eukaryotes, such as the filamentous fungus Aspergillus nidulans 
(AN0879.2; 35.1% identity/58.2% similarity), or the fission yeast 
Schizosaccharomyces pombe (SPBC29A10.12; 33% identity/57.8% similarity), while 
it is not found in the budding yeast Saccharomyces cerevisiae.  
Protein sequences of Ccdc124 from different species were compared by Clustal W2 
alignment program (Fig. 3.1). 
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Figure 3.1 Protein sequence alignment of known and predicted amino-acid sequences 
of Ccdc124 orthologs from different species (see the text). The alignment was 
performed by using ClustalW (2.1 version) alignment program 
(http://www.ebi.ac.uk/clustalw/). Asterisks (*) indicate positions of fully conserved 
residues; column (: shows conservation within a strong group of amino acids; and 
dots (.) indicate conservation within weaker groups of amino acids. Residue coloring 
is according to standard physiochemical criteria (red: small hydrophobic; blue: acidic; 
magenta: basic; green: hydroxyl, amine and basic). 
 
This analysis showed that Ccdc124 is highly conserved especially through residues 
25-80 and 160-210 among all investigating eukaryotic species including lower 
eukaryotic species, except the budding yeast Saccharomyces cerevisiae. This strong 
evolutionary conservation suggests a very basic biological function for Ccdc124. 
Subsequently, we constructed phylogenetic trees from alignments shown in Fig. 3.1 
using neighbor joining (Fig.3.2). Amino acid sequences derived from the full-length 
cDNA sequences encoding Ccdc124 from 17 species were indicated in the alignment 
presented in Fig. 3.1. The following sequences were used to construct alignments: 
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(NP_001129675.1) Ccdc124 [Homo sapiens], (XP_001173732.1) Ccdc124 isoform 2 
[Pantroglodytes], (XP_001115097.1) Ccdc124-like [Macaca 
mulatta],(XP_003432943.1) Ccdc124-isoform 1, (NP_001033612.1) Ccdc124 [Bos 
aurus], (NP_081240.1) Ccdc124 [Mus musculus], (NP_001099541.1) Ccdc124 
[Rattus norvegicus], (XP_424681.1) Ccdc124 [Gallus gallus], (NP_956859.1) 
Ccdc124 [Danio rerio], (NP_650777.1) CG6013 [Drosophila melanogaster], 
(XP_312989.3) AGAP004110-PA [Anopheles gambiae str. PEST], 
(NP_001040712.2) Protein Y73E7A.1, isoform a [Caenorhabditis elegans], 
(NP_596057.1) HMG-box variant [Schizosaccharomyces pombe 972h-
],(XP_363558.1) hypothetical protein MGG_01484 [Magnaporthe oryzae 70-
15],(XP_962308.1) hypothetical protein NCU07666 [Neurospora crassa OR74A], 
(NP_563993.1) uncharacterized protein [Arabidopsis thaliana] (NP_001053553.1) 
Os04g0561600  [Oryza sativa Japonica Group]. As expected, Ccdc124 is conserved 
from Human to lower eukaryotes. Vertebrate Ccdc124s were clustered together 
reflecting taxonomic relationship among these organisms. Similarly invertebrate, 
plant and lower eukaryote members formed separate but related clusters (Fig.3.2). 
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Figure 3.2 Phylogenetic trees of Ccdc124.The tree was generated using the program 
MEGA version 4. The tree was calculated using Neighbour Joining method. Numbers 
at the branches indicate bootstrap values. The bar shows number of substitutions per 
mutation site. 
 
 
 
CCDC124 gene encodes a 223 amino acids protein and have two conserved coiled 
coil domains (CCD) in the N-terminus of the protein between  residues  18-82 via 
ELM (http://elm.eu.org)  search. An analysis of coiled-coil domains using COILS 
(www.ch.embnet.org/software/COILS_form.html) bioinformatics platforms indicated 
that the protein has two independent coiled motifs located at the N-terminus between 
residues 18-82 (Fig. 3.3), and therefore it is considered as a CCD containing protein. 
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Figure 3.3 Schematic representation of the coiled-coil prediction of Ccdc124 
obtained by the COILS (www.ch.embnet.org/software/COILS_form.html) 
bioinformatics analysis platform. Ccdc124 contains two main coiled-coil domains at 
its N-terminal part. 
 
CCD is an interaction domain and it typically consists of two !-helices that are 
twisted around each other to form a supercoil. Most coiled coil proteins are in their 
left-handed forms. Sequences of left-handed parallel coiled coils are characterized by 
heptad repeats  [68]. The first and fourth of the residues of heptads are formed by 
apolar (leucine, valine, isoleucine) residues and these residues stabilize helix by 
hydrophobic interactions. The residues fifth and seventh are usually charged 
(glutamate or lysine) to form ionic inter-helical interactions. The other three residues 
are hydrophilic, and they form helical surfaces [68]. As indicated in Fig. 3.3, our 
bioinformatics analysis has revealed that human Ccdc124 fulfills these sequence 
requirements of CCD-containing (CCDC) proteins (see Fig. 3.3).  
CCDC proteins have many roles in different biological functions, such as signal 
transduction, molecular recognition, establishment of mechanical stability to cells, 
and it is also involved in kinesin-linked movement processes [69]. Previous 
biochemical studies and mass-spectrometry analyses on purified centrosomes have 
shown that proteins with CCD motifs are abundant in Pericentriolar matrix (PCM) 
[30, 70]. Close to 150 different proteins were identified in the PCM at different 
cellular stages, about 60% of which contain predicted CCD type oligomerization 
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motifs [30]. This gave us initial hints about a possible centrosome localization of 
Ccdc124, a hypothesis that we followed closely in coming sections, below. 
 
3.2 Expression profiling of CCDC124 in mammalian tissues and cell lines 
Previous work in our laboratory involving Northern blot analysis of CCDC124 gene 
revealed that this gene is ubiquitously expressed in all human tissues, and relatively 
high levels of expression were detected in brain, liver, spleen, skeletal muscle, testis, 
and ovaries (Serap Erkek, M.Sc. thesis, 2008 and [71] ). In these analyses, a transcript 
of ~1061 nucleotides was detectable in all human organs tested, in agreement with the 
predicted size of CCDC124 mRNA in the NCBI databases (http://genome.ucsc.edu), 
except the placenta where we observed a second shorter mRNA species (~950) 
indicative of a transcript variant [71].  
We established the expression profile of CCDC124 by RT-PCR in various cell lines 
of different tissue origins. In this study, we have not observed a significant 
expresssion variation among those cell lines compared to GAPDH (Fig. 3.4). This 
study also indicated that CCDC124 was ubiquitously expressed in all cell lines tested. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Expression analysis of CCDC124 in different human cell lines. cDNA 
from cell lines were amplified with CCDC124 RT primers. PCR products were 
loaded agarose gel and analyzed by electrophoresis. Human embryonic kidney 
(HEK293), Human cervical cancer cell line (HeLa), Human osteosarcoma U2OS cell 
line, Huh7, MCF7N, HepG2, Snu449 cell lines were used in this study. Cell lines 
having Trex in their names are similar to those explained above, except that they 
contain a constitutively expressed bacterial tetracycline repressor (TetR) gene. (-) 
control, indicates the negative control reaction sample without the RT enzyme. 
 
To characterized CCDC124, we first decided to characterize the recognition 
specificity of Ccdc124 in Western blots by different specific antibodies that are 
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available to us. This is because there are three rabbit polyclonal antibodies that 
recognize different epitopes in Ccdc124: two commercially available ones (Bethyl 
labs. A301-834, and A301-835), and one self-generated antibody through Cambridge 
Biological Research (CRB) laboratory. Note that Ccdc124 is a 223 residue protein, 
and Bethyl-A301-834 recognize an internal epitope located between residues 100 to 
150 of Ccdc124. Therefore, we will refer to this antibody in this thesis as the “anti-
mid-Ccdc124” antibody. Bethyl-A301-835 recognize a C-terminus epitope (residues 
173-223), thus it is referred as “anti-C-ter-Ccdc124” antibody in the text. The third 
reagent, the antibody that was produced by our laboratory on order to CRB, recognize 
the very N-terminus 24 amino acids of Ccdc124, and therefore it is referred as the 
“anti-N-ter-Ccdc124” ab (Serap Erkek, M.Sc. thesis, 2008; [71]).  
We have carried out Western blots either by using lysates from untransfected 
HEK293 cells, or lysates from CMV-promoter expressed Ccdc124, from N-terminus 
Flag-epitope tagged Ccdc124, from C-terminus Flag-epitope tagged Ccdc124, C-
terminus HA-tagged Ccdc124, N-terminus GFP-tagged Ccdc124, and as a control 
empty vector transfected cells (Fig. 3.5 A-D). We first incubated the blot membrane 
with the N-ter-Ccdc124 specific antibody, and clearly validated that this Ab 
recognized the 32 kDa Ccdc124 band, as the band intensity was increased in CMV-
Ccdc124 transfected cell lysates (Fig. 3.5 B). As expected, the N-terminus flag-tagged 
Ccdc124 had an increased size (~35 kDa) due to flag-epitope insertion (Fig. 3.5 B). 
Again, expectedly, this antibody detected GFP-Ccdc124 as a band of ~55 kDa (Fig. 
3.5 B). Also, HA-tagged Ccdc124 was correctly detected as a ~34 kDa protein (Fig. 
3.5 B). In addition to those, we noticed that the N-ter-Ccdc124-specific antibody also 
detected an unspecific band of around 70 kDa (upper band). We did not pay further 
attention to this unspecific band in coming experiments, because the intensity of this 
band did not increase when cells were transfected with CMV-Ccdc124 vectors (Fig. 
3.5B) 
Interestingly, flag-tag insertion to Ccdc124 also had some unexpected consequences 
such as destabilization of the protein: in this blot we have not detected a size increase 
in Ccdc124 when flag-tag was inserted to C-terminus, and the N-terminus flag-tag 
containing protein was very much destabilized. (Fig. 3.5 B).  When a similar blot 
membrane was incubated with mid-Ccdc124 ab, we observed similar bands, but we 
also noticed an extra band of ~26 kDa (indicated with asterisk) in cells transfected 
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with CMV-Ccdc124, N-terminus flag-tagged, or C-ter HA-tagged Ccdc124 plasmid 
constructs (Fig. 3.5 C). The same 26 kDa band was also detected by C-ter-Ccdc124 
recognizing ab (Fig. 3.5 A) in CMV-Ccdc124 or N-ter Flag-Ccdc124 transfected cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Characterization of Ccdc124 protein in immunoblots by using three 
different antibodies recognizing different epitopes. HEK293 cells were transfected 
with Empty Vector, CMV-Ccdc124, N-ter/C-ter-Flag tagged-Ccdc124, C-Ter-HA-
Ccdc124 and N-ter-GFP tagged-Ccdc124 plasmid constructs. Proteins extracted from 
transfected HEK293 cells and 40µg of proteins were loaded into %12 SDS gel and 
stained with A) anti-Cter-Ccdc124 antibody, B) anti-Nter-Ccdc124 antibody, C) anti-
Mid-Ccdc124 antibody, D) N-ter-Ccdc124 antibody incubated membrane was 
stripped then incubated with anti-HA antibody. Asterisks (*) indicate an alternative 
smaller band that was undetectable with the N-ter-Ccdc124 specific Ab. Calnexin 
expressions were indicated as gel-loading controls. 
 
But interestingly not in C-ter HA-epitope carrying lysates (Fig. 3.5 C). We wondered 
whether the non-recognition of the 26 kDa band in C-ter HA-tagged Ccdc124 could 
be due to a possible masking of the C-ter epitope by HA, and therefore we incubated 
the blot membrane shown in Fig. 3.5 B this time with an HA-tag specific Ab (Fig. 3.5 
D), which revealed the 26 kDa band once again. This indicated that the C-ter epitope 
in C-ter HA-tagged Ccdc124 protein was masked possibly by steric hindrance 
between epitopes. Because this 26 kDa protein was recognized both by anti-mid- 
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Ccdc124 Ab, by anti-C-ter-Ccdc124 Ab, and by anti-HA antibody in cells having 
suitable constructs, we were sure that it was a part of Ccdc124 and not a non-specific 
protein detected by those Abs.  
We wondered the origin of this 26 kDa band, and hypothesized that this smaller 
Ccdc124 could be generated by the usage of a possible alternative start codon in the 
protein. When a bioinformatics analysis was carried out on ATG codons of Ccdc124, 
we detected codon of the Met-47 residue as such an alternative putative start site. 
Subsequently, when we mutated this ATG codon to CTG (Leu), this 26 kDa Ccdc124 
have now disappeared, clearly indicating that it was resulting from this second 
alternative start (ATG) codon (Fig. 3.6). After we established the possibility of an 
alternative start codon in Ccdc124, it was shown that the ATG that we found truly 
provides an alternative Kozak sequence, forming a second ribosome recognition site 
in CCDC124 [72]. 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Identification of an alternative translation start site in Ccdc124 ORF. An 
internal methionine residue (Met-47) in Ccdc124 ORF was mutated to Leu amino 
acids in a Ccdc124-HA vector construct. Ccdc124-M47L-HA, and Ccdc124-HA (wt) 
plasmids were transfected into HEK293 cells. Whole-cell lysates were 
immunoblotted using anti-N-ter-Ccdc124 (A), anti-Mid-Ccdc124 (B), anti-HA (C) 
antibodies. Asterisks (*) indicate the alternative smaller protein generated from the 
Ccdc124 ORF. 
 
We then addressed the instability problem of Flag-tagged Ccdc124 (see Fig. 3.5 A-
D), by further analyzing these Flag-tagged versions of Ccdc124 in Western blots 
using an anti-Flag Ab (Fig. 3.7). We observed that when Flag-tag is inserted to C-
terminus of the protein, the size of Ccdc124 did not increase to previously detected 
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~35 kDa level, but the intensity of the ~32 kDa band increased (Fig. 3.7). Whereas, 
when the flag-tag was inserted to N-terminus, size of Flag-Ccdc124 was detected as 
~35 kDa (Fig. 3.7). This suggested the possibility that when flag-epitope was inserted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
to C-terminus, the protein was cleaved either from the N-terminus or from an internal 
position. In collaboration with the laboratory of Johannes L. Bos at the Utrecht 
University Medical Center (the Netherlands), we thus decided to carry-out a mass-
spectrometry peptide analysis on major bands obtained in experiments with N- and C-
ter flag-tagged versions of Ccdc124, in order to fully characterize this observation. 
For this work, we first established stable HEK293 cell lines that either carried Flag-
Ccdc124, Ccdc124-Flag, or empty vector as negative control (Fig. 3.8; empty vector 
not shown). N-ter and C-ter Flag tagged-Ccdc124 vectors were transfected into 
HEK293 cells and were left in antibiotic selection for 15 days. 
 
 
 
 
 
 
 
Figure 3.7 Position of flag-tag 
insertion affects the stability of 
Ccdc124. C-ter or N-ter-Flag 
tagged Ccdc124 plasmids were 
transfected into HEK293 cells. 
Whole cell lysates were extracted, 
and analyzed by immunoblots 
using anti-Flag antibody. 
Calnexin expression was 
displayed as loading control. 
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We then selected colonies with high expression levels of Flag-Ccdc124 (colony 9) or 
Ccdc124-Flag (colony 8) constructs, and flag-tagged Ccdc124 proteins were immuno-
precipitated by using sephadex beads covered with anti-flag-Abs (see Materials and 
Methods). We then run these purified proteins in nuPAGE commercial SDS gel 
(Invitrogen), followed by cutting relevant bands from the gel, and subjected these 
bands to mass-spectrometry analysis (Fig. 3.9 A-B). This analysis have indicated that 
the Ccdc124-Flag protein band labeled as the “band 3” in Fig. 3.9 had lost an N-
terminal peptide, and thus it was converted to a protein of 30 kDa. A similar change 
in size was not observed in N-ter Flag-tag inserted Ccdc124, indicating that the N-ter 
proteolytic cleavage in C-ter Flag-tagged Ccdc124 was due to the positioning of the 
flag-tag. Briefly, when Flag-tag was inserted to C-ter of Ccdc124, the stability of N-
ter of Ccdc124 was compromised, leading to a proteolytic cleavage of the protein 
(Fig. 3.9). 
 
 
 
 
 
 
Figure 3.8. Analysis of Ccdc124 
expression in stable colonies. N-
ter or C-ter-Flag-tagged Ccdc124 
vectors were stably transfected to 
HEK293 cell line, and colonies 
were selected in geneticin 
containing selection medium. 
Encircled colonies bearing Flag-
Ccdc124 (colony 9), and 
Ccdc124-Flag (colony 8) vectors 
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Figure 3.9. Mass-spectrometric peptide analysis of N-ter and C-ter Flag epitop tagged 
Ccdc124 proteins. A) Gel photo: Flag-tagged proteins were immunoprecipitated by 
anti-flag antibodies and they were separated by SDS-PAGE. Bands around 30-35 kDa 
that were differentially expressed in flag-tagged Ccdc124 expressing cells (numbered 
as 1, 2, and 3) as compared to empty vector controls were cut from the gel, and 
subjected to mass-spectrometry analysis. B) Peptides obtained in those molecular 
analysis were indicated as red in sequences presented below. Band 3 was missing the 
very N-terminus peptide (QKEL…) as compared to bands 1 and 2. 
 
 
(Band 3) 
(Band 1) 
(Band 2) 
A 
B 
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Figure 3.10. Expression analysis of Ccdc124 in different cell lines by Western 
blotting method. A) Proteins extracted from indicated cell lines and 40µg of proteins 
were loaded into %12 SDS gel and blotted using anti-Ccdc124 antibodies.  B) 
HEK293 or HeLa cells were transfected with Ccdc124 specific siRNAs (+) or control 
(scrambled) siRNAs, and similar immunoblots were carried-out to identify the 
Ccdc124 band. When two bands were detected in a cell line, the lower band turned 
out to be the specific Ccdc124 band. Calnexin was monitored as loading control. 
 
 
 
Endogenous expression level of Ccdc124 was also checked in different cell lines 
protein extracts by western blotting method. In order to detect Ccdc124, a 
commercially purchased antibody, which recognizes between residues 100-150 of 
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Ccdc124 was used. This antibody gave the expected 32 kDa band belonging to 
Ccdc124. We also proved the Ab specificity of this 32 kDa band after transfecting 
selected cell lines (HeLa and HEK293) by CCDC124 specific siRNAs and 
monitoring the protein band that was lost (Fig. 3.10). We did not observe any 
difference at the expression levels of CCDC124 among the tested cell lines.  
 
3.3 Subcellular Localization of Ccdc124 
In order to understand the biological function of Ccdc124, we assessed the subcellular 
localization of endogenous Ccdc124 in HeLa (human cervix cancer origin) cells in 
culture. We fixed HeLa cells with %100 cold methanol and blocked them firstly with 
%2 BSA, then we incubated fixed cells with anti-N-ter, anti-mid, and anti-C-ter 
specific Ccdc124 antibodies, followed by anti-Alexa 488 rabbit secondary antibody to 
determine localization of the protein. Stainings of the HeLa cells with Ccdc124-
specific antibodies revealed a dot-like staining pattern, independent of the Ccdc124 
antibody selected (Fig. 3.11A, and Fig. 3.12). However, we have detected Ccdc124-
HA or N-ter-GFP-labeled-Ccdc124 as diffused cytoplasmic proteins, whereas C-ter-
GFP-tagged Ccdc124 had a dot like subcellular localizational appearance (Fig 3.11 
D) reminiscent of stainings with anti-mid-Ccdc124 and anti-C-ter-Ccdc124 antibodies 
(see below, compare Fig. 3.11B with C and D), even though there were some 
cytoplasmic backgrounds as well. One explanation of these discrepancies could rely 
on the strong promoters (CMV) of vectors expressing tagged-versions of Ccdc124, 
which was resulting in high background signals hiding precise localization of 
complexes including Ccdc124. 
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Figure 3.11 Cell stainings of endogenous or overexpressed Ccdc124. (A) HeLa cells 
were stained by using anti-C-ter Ccdc124 antibody, and a dot-like (puncta) 
subcellular localization pattern of Ccdc124 was observed. HeLa cells were transfected 
with N-ter-GFP-Ccdc124 (B), C-ter-HA Ccdc124 (C), or C-ter-GFP-Ccdc124 vector 
constructs, and transfected cells were either stained with mid-Ccdc124 ab (C), or the 
GFP-signal is used to assess subcellular localization of Ccdc124 (B and D). 
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Stainings of the HeLa cells with anti-C-ter and anti-mid Ccdc124 antibodies reveal a 
dot-like pattern, which made us think that Ccdc124 could be localized in the 
centrosome (Fig.3.11-B). Furthermore, it was previously shown that coiled-coil 
domain containing proteins are abundant in centrosomes  [30]. To analyse whether 
Ccdc124 was localized to centrosome or not, we syncronized cells at G2/M stage of 
the cell cycle by by sequential double thymidine and nocodazole treatments (see 
Materials and Methods) and followed cell cycle stage-dependent subcellular 
localization of endogenous Ccdc124 by immunofluorescence assays using mid-
region, or C-terminal epitope (residues 173 to 223)-specific antibodies together with 
the centrosome marker protein, #-tubulin (Fig. 3.12). These experiments indicated 
centrosome colocalization of Ccdc124 with #-tubulin at interphase, metaphase, and 
anaphase stages, albeit it was relatively diffused to the pericentrosomal region at 
anaphase (please see Fig. 3.13 for growth synchronized cells). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Endogenous Ccdc124 is localized at the centrosome in asynchronous 
growing cells. HeLa cells was fixed with % methanol, then costained with anti-mid 
Ccdc124 and anti-#-tubulin antibodies. During different stages of the cell cycle 
Ccdc124 is clearly localized at the centrosome together with centrosome marker #-
tubulin protein. Bars represent 10 µm. 
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Figure 3.13. Endogenous Ccdc124 is present at the centrosome and it concentrates at 
the center of the midbody in cytokinesis. (A) HeLa cells were arrested at G2/M phase 
by sequential double thymidine and nocodazole treatments, then the drug was 
washed-off, cells were analyzed by Immunofluorescence at time points with intervals 
of 15 minutes, and they were classified according to phases of mitosis, and 
cytokinesis. Samples of cells were then costained with anti-Ccdc124 and anti-#-
tubulin antibodies, and in interphase and prophase, Ccdc124 was observed as puncta 
in cells, and it is located in the MTOC area. In metaphase and anaphase cells, 
Ccdc124 appeared at the spindle poles. Ccdc124 was present at the cleavage furrow 
and at the spindle poles in late anaphase, and concentrated in the midbody during 
cytokinesis. (B) HeLa cells were transfected with the N-ter flag-Ccdc124 vector 
construct and 48 hours later samples of cells were subjected to immunofluorescence 
costainings using anti-flag and anti-#-tubulin Abs together. Representative 
micrographs of cells at different stages of cell cycle are given. (C) Ccdc124 was also 
colocalized with GFP-centrin on centrosomes in RPE1 cells. (D-E) At telophase and 
cytokinesis Ccdc124 is observed as puncta typically associated with the midbody 
positioned at the middle of intercellular bridge separating daughter cells, as detected 
with !-tubulin staining. (F) Peptide competition assays were done by pre-incubating 
anti-N-ter-Ccdc124 antibody with the corresponding epitope peptide in 200-fold 
molar excess amounts. Signals generated by Ccdc124 localized at the midbody 
(shown with arrowhead) were lost in immunoflurescence assays where peptide pre-
treated antibodies were used. Bars represent 10 µm. 
 
 
 
Centrosome localization of endogenous Ccdc124 was further confirmed in cells 
containing another centrosomal marker, GFP-Centrin  (Fig. 3.13-C) , [73]. Centrin is 
localized in centrioles and it is required for centriole duplication and segregation.  
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Very interestingly, we found that at telophase and in cytokinesis Ccdc124 dissociates 
from centrosomes and relocalizes first to the midzone, subsequently accumulating at 
the midbody at cytokinesis, as assessed by its colocalization with the midzone-
specific #-tubulin (Figure 3.13-A, or B for the colocalization of flag-Ccdc124 with #-
tubulin), or by its positioning at the midbody marked by the empty mid-space in !-
tubulin stainings (Figure 3.13-E). Immunofluorescence signals generated by Ccdc124 
localized at the midbody (shown with arrow-head) were lost in when peptide pre-
treated antibodies were used in peptide competition assays. In these studies we used 
anti-N-ter-Ccdc124 antibodies pre-incubated with the corresponding epitope peptide 
(200-fold molar excess amounts). This result indicated that Ccdc124 signals coming 
from the midbody were specific. Polo-like-kinase-1 (Plk1) is involved in regulation of 
cytokinesis by translocating to the midbody, and therby contributing to its assembly  
[39, 34]. We decided to use Plk1 as a second midzone/midbody marker, and we 
assessed once again the midbody localization of Ccdc124 in two separate cell lines, 
the stable GFP-Plk1 expressing Retinal Pigment Epithelia-1 (RPE1-Plk1(WT), a gift 
from Prasad Jallepalli at Memorial Sloan kettering Institute, NY, USA) and HeLa 
(Figure 3.14A and B). In these analysis, we detected that at the midbody Plk1 in fact 
surrounds the puncta where Ccdc124 is localized, rather than being fully 
superimposed with it (Figure 3.14, inset). 
 
These results indicated that Ccdc124 is a component of centrosomes at interphase, 
and mitosis, and moreover it translocates to the midbody during the last stages of cell 
division and separation of post-mitotic sister cells; a stage termed as cytokinetic 
abscission. 
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Figure 3.14 Ccdc124 colocalized with Plk1 on midbody in HeLa and RPE1 cells at 
cytokinesis. Cell divisions were synchronized as described in the legend of Figure 2, 
above. (A) Subcellular localization of Ccdc124 was detected with anti-Ccdc124 
antibodies recognizing the mid-region of protein in RPE1 cells stably expressing 
GFP-Plk1, indicating a colocalization of Ccdc124 and Plk1 at the midbody during 
cytokinetic abscission. (B) Representative immunofluorescence microscopy images 
of HeLa cells costained with anti-Ccdc124 (mid-region specific) and anti-Plk1 
antibodies illustrating midbody colocalization of both proteins. Inset; 25x digital 
magnification of the midbody region. Bars represent 10 µm 
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3.4 Ccdc124 knockdown in human cell lines and in Zebrafish embryos 
Subcellular localization of Ccdc124 dynamically changes during mitosis. Endogenous 
Ccdc124 is present at the centrosome in interphase, prophase and metaphase (Fig. 
3.13). Subsequently, it concentrates at the midzone and at the pericentriolar space in 
late-anaphase, and localized in the midbody during cytokinesis (Fig. 3.13 and 3.14). 
Essential roles of centrosomes on cytokinesis were described in previous studies  [74, 
26, 75]. 
Additionally, a number of midbody localized proteins were previously shown to be 
involved in cytokinetic abscission  [34]. Therefore, we investigated whether down-
regulation of Ccdc124 by RNAi methods would cause cyctokinetic failure as well, or 
not. Thus, in order to investigate a possible function of Ccdc124 in separation of 
dividing sister cells, we initially knocked-down CCDC124 in HeLa cells by 
separately transfecting them with siRNAs specifically targeting this gene, and control 
scrambled siRNAs. 48 hours after transfection of siRNA, we firstly monitored the 
knock-down efficiency by immunoblots that we carried-out using lysates obtained 
from Ccdc124-specific siRNA transfected or scrambled siRNA transfected controls, 
and observed approximately 75-80% decrease in Ccdc124 levels in cells that received 
gene specific siRNAs as compared to scrambled siRNA transfected controls (Figure 
3.15).  
We then analyzed cellular phenotypes, centrosome localizations, and midbody 
functions in Ccdc124 depleted cells using above mentioned siRNA species. 
Immunofluorescence microscopy analysis reveled that cytokinetic abscission was 
remarkably blocked as assessed by the increased percentage of multinucleated cells 
(Figure 3.15-B) from less than ~3% in scrambled control siRNA transfected cases to 
~15% in Ccdc124-specific siRNA received asynchronous cultures 48 hours after 
Ccdc124 siRNA transfections (Figure 3.15-C). However, in those Ccdc124 depleted 
cells centrosomes still form, although in aberrant numbers as asessed by 
immunostainings that mark #-tubulin complexes (Fig. 3.15 D). It should be noted, 
however, that Ccdc124 was not completely depleted at the protein level by siRNA 
mediated knock-downs, and was still present at lower levels in siRNA treated cells 
(Figure 3.15-C).  
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Figure 3.15 siRNA mediated depletion of Ccdc124 in HeLa cells leads to cytokinesis 
failure. A) Immunoblot of Ccdc124 in scrambled siRNA and Ccdc124 esiRNA or 
shRNAs (1, 2, 3) transfected HeLa cells at 48 hrs post-transfection. Calnexin 
expression was monitored as loading control. B) Graph of immunofluorescence 
microscopy data shows the percentage of scrambled (Scrmbl) or Ccdc124 esiRNA 
transfected cells (n=1814 and n=2029, respectively; counts obtained in at least 3 
independent experiments) that proceeded through mitosis but repetitively failed to 
cleave, leading to multinucleation. C) Representative images of Ccdc124 depleted 
multinuclear cells described in B). !-tubulin is shown in red, green 
immunofluorescence stainings that indicate centrosome and midbody localizations of 
Ccdc124 were shown by white arrowheads. Such strong dot-like Ccdc124 stainings 
were missing in Ccdc124-depleted multinuclear cells.  D) In Ccdc124 depleted 
multinuclear cells MTOCs still form as detected by #-tubulin and Plk1 costainings. 
Two different sets of representative cells are shown. One normally dividing 
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cytokinetic cell was also present in each representative picture set as internal control. 
Bars represent 10 µm. 
 
 
Thus, we established that Ccdc124 had an important role in cytokinesis of cells 
growing in culture, as down-regulation of this gene leads to an aberrant accumulation 
of multinuclear cells. We then decided to test whether the same effect will be 
observed in vivo when the expression of Ccdc124 homologue in zebrafish embryos 
are down-regulated by using morpholino (MO) mediated knock-down methods (see 
below). MOs are typically 25 bases antisense oligonucleotides and they have altered 
nonionic backbone when compared to DNA and RNA  [76]. MOs trigger formation 
of RNA-MO hybrids, and the altered backbone of morpholinos make them resistant to 
digestion by RNAse-H. Therefore, MO antisense oligonucleotides block translation 
directly by binding complementary mRNA sequences within 5’ untranslated region 
(UTR), usually close to translation start site. Because MO-mRNA hybrids are not 
degraded (as in siRNA mediated knock-down mechanisms), RT-PCR is not an 
effective method of analysis to detect MO dependent changes on the expression levels 
of targeted genes. Typically, in zebrafish MOs are introduced into the yolks of 1-8 
cell-staged embryos  [77] One of the most important advantages of MO treatments are 
fast identification of morphological changes (phenotypes) within the first 3 days of 
zebrafish embryo development. To investigate the function of Ccdc124 in an in vivo 
system, we studied the effect of Ccdc124 depletion in zebrafish embryos by using 
MO injections. A translation-blocking MO was designed to bind immediately 
upstream of the translation start codon of Ccdc124, and it was injected into fertilized 
zebrafish embryos at one-cell stage. Morphants were then compared to control MO 
injected embryos, and uninjected embryos (Fig. 3.16). We first observed that a high 
number of morphant embryos exhibited mortality. A total of 41.4 ± 5.3% of Ccdc124 
morphant embryos terminated development before 3 dpf, in contrast to 9.28 ± 3.94% 
and 5.35 ± 1.97% in control morpholino-injected and uninjected embryos, 
respectively (Figure 3.16-A). 
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Figure 3.16. Effects of Ccdc124 knock-down in zebrafish embryos. (A) 
Quantification of embryo mortality (open circles) and developmental malformations 
(filled circles) for control morpholino-injected (ctrl, 254 embryos, 4 independent 
experiments), Ccdc124 morphants (ccdc, 661 embryos, 7 experiments) and wild type 
(wt, 374 embryos, 7 experiments) control embryos. The incidence of embryos 
displaying irregular cleavage patterns at 2 hpf (filled circles) parallels embryo 
mortality. (B) zCcdc124 depleted embryos show developmental defects characterized 
by a shortened body and spinal cord malformations. Control morpholino injected 
embryos have clear developmental retardations, but they do not display drastic 
morphological aberrations. Developments of uninjected embryos were normal. (C) 
Protein was extracted 36 h after injection, and 80 µg of proteins were immunoblotted 
for analysis of zCcdc124 and zebrafish #-tubulin. A densitometric analysis of band 
intensities corresponding to this blot was also shown. zCcdc124 expression level was 
reduced in MO injected samples. #-tubulin was used a loading control and it was not 
affected by zCcdc124 depletion. (D) Wild type (left panel), scrambled MO injected 
(middle panel), and Ccdc124 morphant (right panel) embryos stained with the nuclear 
stain DAPI (pink) and BODIPY-505/515 (green) to visualize cell boundaries. 
Ccdc124 morphants show developmental defects with irregular numbers of unusually 
large cells containing large amounts of nuclear DNA. Bars represent 100 µm. 
 
 
The surviving zebrafish larvae displayed severe developmental defects, such as small 
head, reduced eye, and spinal cord malformation phenotypes. No such phenotypes 
were observed in wild type and control morpholino-injected embryos, but injection of 
control morpholino caused a slight growth retardation (3.16-B), without major 
developmental defects. We also checked expression levels of zCcdc124 proteins in 
MO injected, scrambled control MO injected, and MO-uninjected 36h embryos, and 
we confirmed that zCcdc124 was down-regulated in morphologically defective 
morphants, as compared to controls. Interestingly, zCcdc124 expression levels were 
not affected by Ccdc124-specific MO injections in morphants without major 
morphological defects (see unaffected phenotypes, Fig. 3.16 B-C). Densitometric 
quantification of band intensities have indicated an approximately 42% decrease in 
Ccdc124 levels in morphants, as compared to scrambled MO received embryos (3.16 
C). 
The failure of Ccdc124 morphants to develop normally, and the high incidence of 
mortality suggest a crucial function of Ccdc124 during early zebrafish development. 
We therefore analyzed Ccdc124 morphants for developmental abnormalities at early 
 74 
stages (2 hpf and 5 hpf) wondering whether they would parallel the results of 
Ccdc124 knock-downs by specific siRNA transfections to HeLa cells in our in vitro 
experiments. Indeed, a high percentage of early embryos showed an abnormally 
reduced number of cells at 2 hpf. At this time point wild type littermates developed to 
the 64-cell stage, but Ccdc124 morphants displayed perturbed cleavage patterns with 
far less than 64 cells at the same time point. Moreover, a high number of embryos 
showed unusually large cells and abnormal patterns and localization of nuclear DNA, 
suggesting that cytokinesis might be affected when Ccdc124 is knocked-down 
(Figure 3.16-D). Only slight developmental delays were observed in scrambled 
control-MO received early embryos, but other than this, developmental defects and 
genomic instabilities were not observed at levels comparable to Ccdc124-morphants 
(Fig 3.16 B and D). Co-injections have not done together with p53 morpholino 
injections, therefore this experiment will be provided when Zebrafish injections are 
repeated in future experiments. Again, unlike WT embryos or scrambled MO 
received controls, nuclear DNA in morphant embryos was less compact and widely 
distributed within affected cells lacking clear nuclear organization. Strikingly, the 
incidence of embryos that underwent abnormal development closely resembled the 
percentage of dying embryos when compared across morphant and control embryos 
(Figure 3.16-D).  
The disrupted cleavage pattern of early Ccdc124 morphant zebrafish embryos with 
large cells that contained an abnormally large quantity of DNA strongly suggests that 
developing blastomeres were able to replicate their DNA but might have failed to 
undergo proper cytokinesis, which is similar to the results that we observed in our cell 
culture assay (see above, Figure 3.16-C). This clearly reconfirms the crucial role of 
Ccdc124 during cell division. 
 
3.5 Ccdc124 interaction with RasGEF1B 
A yeast-two-hybrid analysis previously carried-out in our laboratory identified 
RasGEF1B as an interaction partner of Ccdc124. A direct interaction between 
Ccdc124 and RasGEF1B was also detected by in vitro GST-pull down assays  [51]. 
We decided to study and validate this interaction by co-IP experiments. We 
transfected HEK293 cells together with Flag-Ccdc124 and GFP-RasGEF1B 
containing expression vectors. Flag-tagged Ccdc124 proteins were immuno-
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precipitated by using G-agarose beads covered with anti-flag-Abs (see Materials and 
Methods) and western blot analysis was done with anti-GFP antibody (to detect 
RasGEF1B) and Flag antibodies. We observed a very clear interaction between 
Ccdc124 and RasGEF1B in these assays (Fig. 3.17). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 RasGEF1B is an interaction partner of Ccdc124. HEK293 cells were 
either transfected with Flag-Ccdc124 or GFP-RasGEF1B expression vectors alone, or 
they were co-transfected with Flag-Ccdc124 and GFP-RasGEF1B together, then 
immunoprecipitations (IP) were carried-out on cell lysates using protein-G beads with 
anti-Flag antibodies, and subsequently immunoblots were done using anti-GFP 
(monitoring GFP-RasGEF1B) or anti-Flag-HRP (to assess Flag-Ccdc124) antibodies. 
Lysates from HEK293 cells that did not receive any expression vectors (NoTr) were 
used as controls. Presence of GFP-RasGEF1B in transfected cells was confirmed by 
immunoblots done using anti-GFP Abs and lysates of cells that received GFP-
RasGEF1B expression vectors.  
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Figure 3.18 Validation of RasGEF1B antibody. (A) Alignment of C-ter Human and 
Zebrafish protein sequences. The alignment was performed as mentioned before. 
(B) HEK293 cells were transfected with mCherry-labeled human RasGEF1B or YFP-
labeled humanRasGEF1B expression vectors (mCherry-RasGEF1B and YFP-
RasGEF1B, respectively), after 48 hours cells were lysed, proteins were separated by 
SDS-PAGE, and immunoblot was performed with anti-RasGEF1B antibody alone (1 
µg at 1:1000 dilution), and then the membrane was stripped and sequentially reprobed 
first with the same antibody pre-incubated with 100 ng of competing 20mer peptide 
epitope [C]- NNMEKDR-W-KSLRSSLLNRT corresponding to C-terminus of ZF-
RasGEF1B, and then with anti-GFP antibody recognizing YFP as its epitope in YFP-
RasGEF1B. Calnexin expression was monitored as loading control. 
 
We wondered whether interactions between YFP-RasGEF1B and Flag-Ccdc124 as 
detected in co-IP experiments could indicate a functional interaction between these 
two proteins. In order to analyze possible cellular functions of endogeneous 
RasGEF1B protein in human cells lines, and to be used in in vivo Zebrafish studies 
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we generated a rabbit polyclonal antibody recognizing the conserved C-terminal 19 
amino acids epitope of both Human the Zebrafish orthologue of RasGEF1B 
(Fig.3.18-A). Those antibodies were ordered by our team to an antibody production 
company called Cambridge Reserach Biochemicals (CRB, UK) which generated the 
antibodies and delivered to our laboratory. We performed immunoblot assay to 
investigate specificities of these antibodies. For this, we overexpressed RasGEF1B in 
HEK293 cells by using RFP-RasGEF1B and YFP-RasGEF1B plasmid constructs. 48 
hours after transfections, immunoblots were performed with anti-RasGEF1B 
antibody, and then the membrane was stripped and sequentially reprobed first with 
the same antibody pre-incubated with 100 ng of competing 20mer peptide, and then 
with anti-GFP antibody recognizing YFP-RasGEF1B (Fig.3.18-B). We observed that 
the new antibody specifically recognizes human RasGEF1B protein. 
 
 
 
 
 
 
 
 
 
Figure 3.19. Representative Western blotting results of endogenous RasGEF1B 
protein expression in various selected human cell lines. 60 µg protein was loaded on 
the SDS gel. Calnexin was used as a loading control. 
 
We also analyzed endogenous expression level of RasGEF1B in 8 different human 
cell lines by western blotting method. RasGEF1B is ubiquitously expressed in all cell 
lines that we used. However, the most expression of RasGEF1B was observed in 
HEK293 cell lines and the lowest expression was observed in Hep3B. 
 
By using the new RasGEF1B antibody we wanted to determine whether the 
subcellular localizations of RasGEF1B and Ccdc124 were comparable throughout the 
cell cycle. In fact, in a previous study, RasGEF1B was shown to localize in 
endosomal vesicles when fluorescent protein-fused versions (YFP-RasGEF1B or 
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mRFP-RasGEF1B) were ectopically expressed in asynchronous CHO cells  [78]. We 
validated localization of RasGEF1B in asynchronous U2OS cell line. We observed 
similar results as above, as RasGEF1B was co-localized together with the early 
endosomal marker Rab-5 in U2OS cell line (Fig. 3.20).  
 
 
 
 
Figure 3.20 RasGEF1B is colocalized with early endosomal marker protein Rab-5 in 
U2OS cells. U2OS cells were transfected with both YFP-RasGEF1B and RFP-Rab5 
plasmid constructs, and then images were taken by using a time-lapse confocal 
microscope in collaboration with Johannes L. Bos laboratory at the University 
Medical Center (UMC), Utrecht, the Netherlands. 
 
However, the subcellular localization of RasGEF1B was not previously addressed in 
cell cycle-synchronized cells. Identification of an endosomal vesicle factor such as 
RasGEF1B as an interaction partner of centrosomal and/or midbody localized 
Ccdc124 is particularly interesting, because critical roles of endosomes in formation 
of multi-vesicular bodies required for physical separation of cells during cytokinetic 
abscission are very well established in recent studies  [79].  
Subsequently we analysed localization of RasGEF1B and we observed that even 
though in HeLa cells at interphase and prophase it displays characteristics of 
previously suggested cytoplasmic/early endosome localization  [78], in metaphase 
cells, RasGEF1B was located at a pericentrosomal/centrosomal position, as assessed 
by its co-localization with #-tubulin; a subcellular localization identical to that of 
Ccdc124 (Figure 3.21, compare with Figure 3.13-A). Again similar to Ccdc124, at 
telophase and during cytokinesis RasGEF1B was detected at the midzone and in the 
midbody (Figure 3.13), implying a possible role of Ccdc124 in linking RasGEF1B 
dependent signaling at the midbody to cellular abscission. 
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Figure 3.21 RasGEF1B is an interaction partner of Ccdc124, and it is localized at 
peri-centrosomal space and midbody. Subcellular localizations of RasGEF1B proteins 
in synchronously dividing HeLa cells were detected with specific anti-RasGEF1B 
antibodies. Cell division was synchronized as described in the legend of Figure 3.13, 
above. (A) Representative immunofluorescence microscopy images of HeLa cells 
costained with anti-RasGEF1B and anti-#-tubulin antibodies, the latter illustrating the 
position of MTOCs and the midbody at cytokinesis. (B) HeLa cells costained with 
anti-RasGEF1B and anti-!-tubulin antibodies. RasGEF1B detected at the midzone 
and at the midbody were shown by white arrows. (C) HeLa cells transiently 
transfected with GFP-RasGEF1B were fixed and stained using anti-Ccdc124 Abs. 
Arrowheads indicate midbody positions of GFP-RasGEF1B, Ccdc124, and their 
colocalizations at the midbody. Bars represent 10 µm. 
 
3.6 RasGEF1B knock-down in human cell lines and Zebrafish embryos. 
Subcellular localization of RasGEF1B changes dynamically similar Ccdc124 during 
cell cycle. It is also localized to the midbody during cytokinesis like Ccdc124, so we 
wondered whether down-regulation of RasGEF1B by RNAi methods would cause 
any cyctokinetic failure. We tried to down regulate RasGEF1B in HeLa and HEK293 
cell lines. However, our target siRNAs did not downregulate the expression of 
RasGEF1B in both cell lines, we could not investigate the effect of the RasGEF1B 
ablation on cytokinesis in human cell line.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. Transfection of RasGEF1B siRNA into HeLa and HEK293 cells. Cells 
transfected with target RasGEF1B siRNA or Scrambled control siRNA. 48 after 
transfection proteins were extracted from the cells, and loaded into SDS-gel. 
Corresponding PVDF membrane was covered with anti-RasGEF1B antibodies, then 
visulized by ECL plus detection reagent. Calnexin was used as loading control. 
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In addition we made efforts to observe the effect of RasGEF1B depletion in in vivo 
Zebrafish system. We designed morpholino oligos against the 5’ UTR region of the 
RasGEF1B gene, and we have started injections in parellel to Ccdc124 studies on 
zebrafish embryos. We observed similar morphant phenotypes on RasGEF1B MO 
injected embryos in our preliminary results (data not shown). Our studies on the 
effect of RasGEF1B ablation in Zebrafish embryo models are ongoing. 
 
3.7 Functional interactions between RasGEF1B and Rap2 small G proteins.  
Activation of small G proteins is regulated by guanine nucleotide exchange 
factors (GEFs, please see the Introduction part). Previous functional studies in our 
laboratory have shown that RasGEF1 family of GEFs specifically activates Rap2 in 
vitro by stimulating guanine nucleotide exchange of this small G protein, while they 
do not activate other members of the Ras family. We therefore wondered whether 
Rap2A will also localize in centrosomes and midbody during different stages of cell 
cycle, and at cytokinetic abscission similar to Ccdc124 and/or RasGEF1B. First, we 
checked endogenous expression profiles of RAP2A by RT-PCR in various different 
cell lines. In these studies, we did not observe a significant expression variation 
among different cell lines (Fig. 3.23). Also, this study showed that RAP2A was 
ubiquitously expressed in all cell lines that we tested. 
 
 
Figure 3.23 Expression analysis of Rap2A in various human cell lines. cDNA from 
cell lines were amplified with Rap2A RT primers. PCR products were loaded agarose 
gel and analyzed by electrophoresis. Human embryonic kidney (HEK293), Human 
cervical cancer cell line (HeLa), Human osteosarcoma U2-OS cell line, Huh7, 
MCF7N, HepG2, Snu449, Retinal Pigment Epithelial-1 (RPE-1) cell line, and RPE1-
GFP-Centrin, RPE1-GFP-Plk1 cell lines were used in this study. Cell lines having 
Trex in their names are similar to those explained above, except that they contain a 
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constitutively expressed bacterial tetracycline repressor (TetR) gene. –Control, 
indicate the negative control reaction sample without the RT enzyme. 
 
 
 
Subsequently, we performed immunofluorescence assays by using anti-Rap2A 
antibody in HeLa cells and we did not observed Rap2A in centrosomes of 
asynchronous cells, or at any stage during cell cycle. However, Rap2 localized peri-
centrosomal region in metaphase cells, and migrates to the midzone during 
anaphase/telophase (Figure 3.24-A). This result was in contrast to its homologue 
Rap1 that is non-responsive to RasGEF1B (Figure 3.24-B), [51]. We also observed 
that in synchronously dividing cells, 90 mins after they were released from 
nocodazole, at initial stages of cytokinesis Rap2 associates with microtubules 
originating at the midzone, and it migrates to the very center of intercellular bridge 
(boundaries marked with %-tubulin), relocating itself to midbody during cytokinetic 
abscission (Figure 3.24-C). Expectedly, at midbody the position of Rap2 overlapped 
both with RasGEF1B and with Ccdc124 in binary comparisons (Figure 3.24-D and 
3.24-E). 
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Figure 3.24 Endogenous Rap2 relocates to the midzone at anaphase, and to the 
midbody during late-telophase/cytokinetic abscission. (A) HeLa cells were arrested 
atG2/M phase by sequential double thymidine and nocodazole treatments as 
described in the legend of Figure 2, and they were classified according to phases of 
mitosis, and cytokinesis. Samples of cells were then stained with anti-Rap2 antibody, 
and with DAPI to visualize DNA. At anaphase Rap2 was detected at the midzone 
with staining characteristics reminiscent of endosomes, and at telophase/cytokinesis 
Rap2 wasobserved as puncta at the middle of the intercellular bridge, a position 
typically occupied by midbody associated factors. (B) Endogenous Rap1 does not 
relocate to the midzone/midbody during anaphase to cytokinetic abscission. HeLa 
cells were arrested at G2/M phase by sequential double thymidine and nocodazole 
treatments as described in the legend of Figure 2, and they were classified according 
to phases of mitosis, and cytokinesis. Samples of cells were then costained with anti-
Rap1 and anti-%-tubulin antibodies, which were used to monitor intercellular bridge 
and the space containing midbody complexes. DAPI staining was used to visualize 
DNA. (C) Following synchronization of cells as above, 80 mins. After nocodazole 
was washed-off samples were taken with four consecutive intervals of 10 minutes (I, 
II, III, and IV), the last one (IV) corresponding to ~120 minutes after the drug was 
removed, and dynamic positioning of Rap2 at the intercellular bridge in respect to %-
tubulin was monitored. A time-dependent relocalization of Rap2 from peripheral 
flanking regions to the midbody was detected. 
Intercellular bridge localizations of Rap2 were concluded with observations from a 
sample of ~50 cells in which over 75% showed similar positioning patterns. Two 
representative pictures were displayed. (D) At anaphase, Rap2 was clearly localized 
at the midzone, and RasGEF1B was flanking Rap2, while during cytokinetic 
abscission both proteins were colocalized at the puncta characterizing the midbody.  
(E). Rap2 and Ccdc124 colocalize to the midzone/midbody at telophase, and to the 
midbody during late-telophase/cytokinetic abscission. HeLa cells were arrested at 
G2/M phase by sequential double thymidine and nocodazole treatments as described 
in the legend of Figure 2, and they were classified according to phases of mitosis, and 
cytokinesis. Samples of cells were then stained with anti-Rap2 and anti-Ccdc124 Abs, 
and with DAPI to visualize DNA. At anaphase Rap2 was detected at the midzone, but 
did not colocalize with Ccdc124. At telophase, however, the two proteins were 
observed at the midzone/midbody, and they fully overlapped at midbody during 
cytokinetic abscission. Bars represent 10 µm. 
 
3.8. Rap2 effectors in cytokinesis (RBD-RalGDS and YFP-TNIK). 
We inquired whether midbody localized Rap2A was functionally active during 
cytokinesis. In order to assess this, we transfected cells with GFP tagged Rap Binding 
Domain of RalGDS (GFP-RBD/RalGDS) that acts as an artificial effector of GTP-
bound (active) Rap2, and it serves as a subcellular Rap2 activity reporter  [80]. 24 
hours after transfection of the GFP-tagged RBD, we immuno-stained HeLa cells 
using Rap2A specific antibodies and Alexa-568-labeled secondary antibodies (red). 
We detected subcellular localization of both Rap2A and GFP-RBD in diffusely 
cytoplasm with partial co-localization at interphase (Figure 3.25-A).  
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Figure 3.25 Active form of Rap2 (Rap2.GTP) is localized at the midbody (A) HeLa 
cells were transfected with the vector containing GFP-labeled Rap Binding Domain 
of RalGDS [GFP-RBD (RalGDS)] which interacts only with the GTP-bound active 
form of Rap2, and cells were monitored at interphase and at cytokinetic abscission 
following immunostainings involving anti-Rap2 monoclonal Abs and Alexa568-red 
labeled anti-mouse secondary Abs. Colocalization of GFP-RBD (RalGDS) with Rap2 
indicated that at the midbody Rap2 is in its active (Rap2.GTP) form (B) GFP-RBD 
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(RalGDS) transfected HeLa cells immuno-stained with anti-RasGEF1B and anti-!-
tubulin and anti-!-tubulin antibodies. GFP-RBD (RalGDS) detected at the midbody 
was shown by white arrow heads. Bars represent 10 µm. 
 
However, during cytokinetic abscission, GFP-RBD (RalGDS) very clearly 
colocalized with Rap2 at the midbody, indicating that Rap2 protein identified at the 
spindle midzone/midbody is in its GTP-bound active form (Figures 3.25-A), and that 
it may potentially act on its specific effectors at this location. Additionally, we have 
also shown midbody localization of GFP-RBD (RalGDS) by immunostaining cells 
together with !-tubulin or #% tubulin antibodies (Figure 3.25-B).  
The dominant negative (Rap2-S17N) and constitutively active mutant (Rap2-G12V) 
forms of Rap2 also localized to midbody, suggesting that Rap2 protein activity was 
not essential for its own localization to midzone/midbody (Figure 3.26-A). 
However, midbody localization of GFP-labeled RBD (RalGDS) depended on the 
presence of an active Rap2, as in cells co-transfected with dominant negative version 
of Rap2 (Rap2-S17N) the reporter protein GFP-RBD (RalGDS) did not relocate with 
the same efficiency to the midbody during cytokinesis as compared to cells 
transfected with wild-type Rap2 (Figure 3.26-). No aberrations in cytokinetic 
processes in cells expressing neither dominant negative (S17N) nor constitutively 
activated mutant (G12V) Rap2 proteins were observed. 
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Figure 3.26 Midbody localization of Rap2 is independent of its signal transduction 
activity. (A) HeLa cells were transfected either with WT Rap2 tagged containing HA 
epitope (Rap2-WT), with HA-Rap2 having an activating mutation (Rap2-G12V), or 
with the dominant negative form of HA-tagged Rap2 (Rap2-S17N) and midbody 
localizations of Rap2 proteins were monitored by using monoclonal HA-antibodies 
followed by Alexa488-labeled (green) secondary anti-mouse IgG Abs. Samples were 
co-stained with !-tubulin (polyclonal) antibodies followed by Alexa568-red labeled 
anti-rabbit IgG secondary antibody treatments. At least 50 cells were monitored after 
each transfections, with ~95% of cells displaying similar HA-Rap2 localizations. 
Localization of Rap2 to the midbody was independent of its cellular G protein 
activity. (B) HeLa cells were cotransfected with GFP-RBD (RalGDS) either together 
with HA-Rap2-WT, or with HA-Rap2-S17N (inactive dominant negative form) and 
positioning of GFP-RBD (RalGDS) were assessed by monitoring GFP-signal 
observed at the midbody. Localization of the GFP-RBD (RalGDS) depended on the 
presence of active Rap2 in cells. As in (A), at least 50 cells were monitored in each 
experiment, and representative pictures display Rap2 and GFP-RBD (RalGDS) 
localizations observed at least ~90% of cells cotransfected with indicated vectors. 
Bars represent 10 µm. 
 
In addition, we tested whether a known effector of Rap2,! Traf2- and Nck-
interacting kinase (TNIK)  [65], accumulated at the cytokinetic abscission site. 
When we monitored subcellular localization of a YFP labeled version of TNIK after 
transfection of HeLa cells with vectors carrying this recombinant Rap2 effector 
protein, we identified YFP-TNIK at midbody during cytokinesis (Figure 3.27-A). 
Interestingly, in experiments where we have transfected HeLa cells with YFP-TNIK 
expression vector alone, we observed that nearly 41.6% of transfected cells remained 
joint to each other at time points corresponding to immediate post-cytokinetic stages, 
as compared to ~4.9% joint cells observed among population of cells transfected with 
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GFP-RBD-RalGDS, or to ~7.9% joint cells found in the population of cells 
transfected with Rap2-WT alone (Figure 3.27, B and C), with a clear YFP-TNIK 
accumulation at the borders of these joint (unseparated) cells. 
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Figure. 3.27 Rap2 effector TNIK relocates to midbody during cytokinesis, and it 
triggers accumulation of joint post-cytokinetic sister cells when overexpressed. (A) 
HeLa cells were transfected YFP-labeled Rap2 effector protein TNIK (YFP-TNIK), 
they were synchronized as described at the legend for Figure 2, samples were then 
fixed for immunofluorescence and subcellular localizations of YFP-TNIK and Rap2 
were established. The small G protein Rap2 and its effector YFP-TNIK colocalizes at 
the midbody in cells at cytokinesis. (B) Graph presenting results of HeLa cell 
transfections with vectors expressing GFP-RBD (RalGDS), wild-type Rap2, or YFP-
TNIK. Black bars, average numbers of cells count per frames at 200x magnification; 
grey bars, average numbers of joint cells (as in panel B) count at each frame. GFP-
RBD transfectants: average cell counts/frame 121.6 ± 6.62, average number of joint 
cells/frame: 6.0 ± 0.63 (approx. 4.9%); Rap2-WT transfectants: average cell 
counts/frame 122.1 ± 3.48, average number of joint cells/frame: 9.6 ± 3.38 (approx. 
7.9%); YFP-TNIK transfectants: average cell counts/frame 123.5 ± 3.15, average 
number of joint cells/frame: 52.5 ± 4.61 (approx. 41.6%). Arbitrarily, about 120 cells 
were count per frame, and 7 frames were analyzed per transfections (n=3, data are 
mean ± s.d). (C) HeLa cells that were transfected with YFP-TNIK were synchronized 
as above, released from nocodazole treatment for 150 min. in order to enrich at the 
post-cytokinetic stage, and then sub-cellular localizations of YFP-TNIK and Rap2 
were established. Two representatives of joint cells marked with YFP-TNIK 
localization at borders of post-mitotic daughters were shown. Bars represent 10 µm. 
 
The endogenous activation of local Rap2 signaling at midbody did not require 
pretreatment of cells with secondary messengers such as cAMP, diacylglycerol 
(DAG), or calcium that were previously shown to stimulate Rap signaling through 
activation of various GEFs  [81, 82]. This indicate that recruitement of RasGEF1B to 
the midbody could be sufficient for regulation of Rap2 activity, as well as for 
translocation of Rap2 effectors YFP-TNIK or GFP-RBD-RalGDS to this subcellular 
location. 
 
3.9 Mass-spectrometric analysis of Ccdc124 and RasGEF1B 
A large number of peptides from a variety of complex mixtures can be sequenced and 
characterized by mass spectrometry approaches. We performed mass spectrometry 
analysis using liquid chromatography-mass spectrometry (LC-MS/MS) to assess 
possible additional interacting partners of Ccdc124 and RasGEF1B proteins. This 
would help us to better characterize cellular complexes in which these proteins were 
involved. For this purpose we first generated stable HEK293 N-ter/C-ter-flag tagged 
Ccdc124, HEK293-Empty-Flag cell lines (see section 3.2) and HEK293-YFP-
RasGEF1B, HEK293-YFP cell lines to be used in affinity purification of Ccdc124 or 
RasGEF1B. 
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Initially, stable C-ter/N-ter-Flag-Ccdc124 and EV-HEK293 cells were pulled down 
using Flag-Ab covered sephadex beads (see Materials and Methods). Then, proteins 
were eluted from beads and elutions were fractionated by SDS-gel (Fig.3.28). 
Subsequently, we sliced-out bands corresponding to both the N-ter/C-ter-Flag-
Ccdc124, as well as bands obtained in Ccdc124 pull-downs as compared to samples 
coming from EV-transfected controls (14 different bands, as indicated in Fig. 3.27). 
We then performed trypsin digestion on all those gel slices. Following the trypsin 
digestion, we purified peptides and analyzed them by using a high resolution and high 
accuracy LC-MS/MS platform (see Materials and Methods). Table 3.1 includes a list 
of proteins pulled down together with Ccdc124 proteins that were flag-tagged at both 
ends. Proteins indicated by bold letters in Table 3.1 were at least 1.5-fold higher in 
Ccdc124 pulled-down samples, as compared to control EV pull-downs. Moreover, 
this analysis validated once again that Ccdc124 encodes an approximately 32 kDa 
protein, as we previously explained (see Figure 3.9 above). We have also observed 
that the C-ter-flag leads to a proteolytic cleavage of the Ccdc124 protein unlike the N-
ter-positioning of the flag-tag in Ccdc124, as we had observed and presented 
previously in Results section 3.2 (see Fig. 3.9). 
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Figure 3.28. Gel purification of N-ter/C-ter flag-tagged Ccdc124 and its interaction 
partners. Numbers indicate purified bands that were subjected to LC-MS/MS 
analysis. 
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 Table 3.1 List of Ccdc124 putative interacting proteins identified using LC-MS/MS method from gel digestion. 
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For the quantitative analysis of Ccdc124 or RasGEF1B interaction partners by MS, 
we performed stable isotope labeling by amino acids (SILAC) metabolic labeling 
methods [83]. It involves growing of two cell populations (control and target sample) 
in the presence of light amino acids and heavy amino acids separately. After five cell 
doublings, SILAC labels amino acids in proteomes of cells through normal metabolic 
ways. SILAC method distinguishes two proteomes by molecular weight of light and 
heavy amino acids, facilitating the removal of false positives, and therefore it 
provides a reliable quantitative proteomics analysis [84].  
 
Following the above mentioned methodologies, HEK293-Flag-Ccdc124 cells, 
HEK293-YFP-RasGEF1B cells and HEK293-EV containing cells (CMV-Flag, or 
YFP) were grown in appropriate (light and heavy) SILAC media. In forward 
experiments, heavy amino acids (Lys8, Arg10) labeled specifically HEK293-Flag-
Ccdc124, HEK293-YFP-RasGEF1B cells, and light amino acids (Lys0, Arg0) 
labeled HEK-EV cells. In reverse experiments, cells were labeled oppositely. Then, 
the cells were lysed, immunoprecipitated using flag antibody-bound beads, and 
mixed in a 1:1 ratio. Subsequently, proteins were subjected to trypsin digestions, and 
analyzed by LC-MS/MS. The heavy amino acids labeled peptides are not chemically 
different from the light amino acids labeled peptides, but their masses change in 
relation with the type of amino acids (heavy or light) used in SILAC treatments. A 
higher peak intensity coming from heavy amino acids labeled cells indicates that 
protein was more abundant than light amino acids labeled proteins. In this way, we 
calculated ratio of interacting proteins abundance by comparisons of forward and 
reverse experiments, and we quantified those data by using MaxQuant software 
package (Appendix I). Figure 3.29-A shows putative sub-cellular localizations of 
Ccdc124 interacting partners, and similarly Figure 3.29-B shows putative sub-
cellular localizations of detected RasGEF1B interacting partners. Nearly half of the 
proteins that were found to interact with target factors (Ccdc124 or RasGEF1B) were 
either heat shock proteins or ribosome components that tend to bind to massively 
over-expressed proteins in mass-spectrometry analysis (Appendix II). 
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Figure 3.29 Putative Localizations of Mass-Spectrometry Identified Ccdc124 and 
RasGEF1B Interaction Partners. (A) Sub-cellular distribution of putative Ccdc124 
interaction partners. (B) Sub-cellular distribution of putative RasGEF1B interaction 
partner. 
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This analysis indicated a common set of 11 different proteins interacting both with 
Ccdc124 and RasGEF1B (Fig. 3.30 and Table 3.2). This list includes proteins with 
very interesting possible molecular functions, such as multidrug resistance, cellular 
proliferation, nucleosome assembly, or mRNA poly-A site binding (Table 3.2). 
Among those, GNB2L1 which is also known as RACK1 particularly stands out as it 
is shown in multiple studies that (similar to RasGEF1B and Ccdc124) this protein 
localizes to the centrosomes, kinetochores, the midbody, and nuclear envelopes 
during the cell cycle in Caenorhabditis elegans, and its knockdown caused 
cytokinesis failures in the early C. elegans embryo  [33, 85].  
 
 
 
 
 
 
 
 
 
Figure 3.30 Numbers of proteins interacting with Ccdc124 and RasGEF1B 
 
Table 3.2 Common set of interaction partners of Ccdc124 and RasGEF1B as 
detected by LC-MS/MS analysis. 
 
Therefore, as a priority we decided to focus on interactions with 
RasGEF1B/Ccdc124 and RACK1 in validating our MS data. 
In this analysis, we first performed expression analysis for RACK1 in different cell 
lines by using immunoblotting methods. This analysis has revealed that RACK1 is 
ubiquitously expressed in all cell lines that we had in our collection in the laboratory. 
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Figure 3.31 Representative Western blotting results of endogenous RACK1 protein 
expression in various selected human cell lines. 40 µg protein was loaded on the SDS 
gel. Calnexin was used as a loading control. 
 
Subsequently, we decided to monitor the subcellular localization of RACK1, in order 
to assess whether it could have also a common subcellular localization with 
RasGEF1B and Ccdc124. When asynchronous HeLa cells were co-stained with anti-
!-tubulin and anti-RACK1 antibodies, the metaphase centrosome and midbody 
associations of RACK1 were clearly observed (Fig. 3.32). 
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Figure 3.32 The subcellular localization of endogenous RACK1. HeLa cells were 
immunostained using anti-RACK1 antibody (Green) and centrosome-midbody 
marker anti-!-tubulin (Red) antibody (A) RACK1 localizes to centrosome together 
with anti-!-tubulin during metaphase and (B) to the midbody during late-
telophase/cytokinetic abscission. 
 
 
This result indicate that RACK1 and Ccdc124/RasGEF1B share common subcellular 
localizations, which suggests that MS detected interacting partners could be specific 
partners of these proteins, and they could be involved in similar cellular activities. 
 
3.10 Phosphorylation based post-translational regulation of Ccdc124 
There were several evidences indicating that Ccdc124 could be a phospho-protein. 
First, in our MS analysis (see above) the Ser-141 residue of Ccdc124 was found to be 
a phosphosite (see Appendix III). Second, bioinformatic analysis of Ccdc124 using 
ELM tools (http://elm.eu.org/) indicates Ser-92 and Thr-103 residues phosphorylated 
according to UniProtKB/Swiss Prot entry database, based on the experimental 
evidence provided by the study “Global proteomic profiling of phosphopeptides 
using electron transfer dissociation tandem mass spectrometry” (Serap Erkek M.Sc. 
thesis, Bilkent University 2009), [86]. Furthermore, phosphorylation sites were 
 99 
predicted via NetPhos  [87] which suggested 5 serines, 7 threonines, and one tyrosine 
residue in Ccdc124 protein to constitute target sequnces of various kinases, such as 
Casein Kinase-I (CK-I), Casein Kinase-II (CK-II), and Plk-I. Several components of 
MTOC were previously shown to translocate to midbody (or shuffle between 
midbody and centrosomes) by phosphorylation depending modifications of those 
proteins. Among those, CLIP-170 was shown to be sequentially phosphorylated first 
by CK-II and then by Plk-1, which targets the protein to kinetochores  [88]. Also, the 
midbody forming centrosomal factor Cep55 were shown to be a protein 
phosphorylated by Plk-1, and dephosphorylation of Cep55 was essential for its 
translocation to the midbody  [39].  
We therefore decided to assess whether Ccdc124 is a phospho-protein, and which 
sites in Ccdc124 could be functional phospho-sites. For this, we initially mutated all 
possible CK-I, CK-II, and Plk-1 sites in Ccdc124 either to phospho-inactivating 
residue Ala or to phospho-mimicking residues, Asp (D) and Glu (E). We then studied 
stabilities of these mutant proteins by Western blot analysis (Fig. 3.33-A).  
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Figure 3.33 Mutating the putative consensus CK2 phosphorylation site Ser122 
residue of Ccdc124 to Ala leads to a compromised stability. (A-B) HEK293 cells 
were transfected either with HA-tagged wild-type Ccdc124 expression vector, or 
with similar vectors carrying indicated mutations on Figures, and stabilities of 
mutants proteins were monitored by immunoblots using anti-Ccdc124 antibodies 
recognizing the N-terminus of the protein. Only one CK2 phosphorylation consensus 
site (Ser122) turned out to be essential for the stability of Ccdc124 protein as S122A 
mutants were cleaved at their C-terminus, whereas phospho-mimicking mutations 
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S121D, and S121E were normal in terms of Ccdc124 stability (B). Calnexin 
expressions were monitored as loading control. 
 
This analysis indicated that most putative phosphosites are dispensible for the 
stability of Ccdc124. However, conversion of the residue Ser-122 to Ala (S122A) 
leads to a destabilized Ccdc124, which is observed as degraded peptides on blots 
(Fig. 3.33-A). Both of the phospho-mimicking S122D or S122E mutations 
reconstituted stable Ccdc124 proteins (Fig. 3.33-B), indicating that it is not the loss 
of Ala-122 that leads to stability problems, but very likely, it is the lack of S122 
phosphorylation that leads to a compromised stability in Ccdc124 (Fig. 3.33 A-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34 CKII kinase phosphorylates specifically Ccdc124 in vitro. In vitro 
kinase assay of recombinant Ccdc124 by CKII kinase. The kinase assay was 
performed for 30 min. at 30°C using in the presence of equal amounts of Ccdc124 
(1.5µg) protein and CKII (10 units) kinase. CKII kinase assay was performed in the 
presence of ATP-!-S (100µM), PNMB (lane 2), in the presence of normal ATP 
(100µM), PNMB (line 1) and in the presence of ATP-!-S (100µM), PNMB, CKII 
(10 µM) inhibitor TBBt (line 3). Samples were then run on an SDS-gel. Lanes 1 and 
2 represent control experiments where proteins incubated normal ATP and PNBM 
(alkylate only ATP-!-S) or ATP-!-S, PNMB and CKII inhibitor. Lane 2 shows 
phosphorylation experiments of Ccdc124 by CKII. 
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Bioinformatics analysis of Ccdc124 protein indicated that Ser-122 residue is found in  
a possible CK-II target peptide consensus sequence (119-KAKSHLE-125). 
Therefore, in an in vitro experimental methodology, we studied phosphorylation of 
Ccdc124 by the CK-II enzyme. In this assay, we incubated bacteria purified full size 
Ccdc124 protein with pure CK-II enzyme in the presence of either ATP or ATP-!-S, 
with or without a CK-II inhibitor, TBBt. CKII thiophosphorylated Ccdc124 by using 
ATP-!-S. Then thiophosphorylated site of Ccdc124 was alkylated with PNBM and 
tagged Ccdc124 was detected by Thiophosphate Ester specific antibody (Fig. 3.34). 
This preliminary in vitro analysis indicated that Ccdc124 could be one of the targets 
of CK-II. Biological implications of a possible interaction between Ccdc124 and CK-
II remains to be established in future studies. 
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CHAPTER 4. DISCUSSION 
We were initially interested in finding the cellular function of Ccdc124, as the gene 
that encodes this protein was conserved from yeast-to-man (Fig. 3.1). Previous 
studies in our laboratory have indicate that Ccdc124 was an expressed gene in human 
cells in culture, and also in zebra fish vertebrate model, as well as in a lower 
eukaryote fungus, Aspergillus nidulans (Pelin Telkoparan, Hani Alotaibi, Elif 
Yaman, and Uygar H. Tazebay, unpublished results). We hypothesized that the 
conservation of an expressed gene in all eukaryotes might indicate a basic and 
essential function in eukaryote cell biology. We have started our studies by the 
molecular characterization of Ccdc124 at the protein level. In respect to this, we 
ordered polyclonal antibodies against the N-terminal 24 amino acids peptide of 
Ccdc124, and also we commercially obtained anti-Ccdc124 antibodies recognizing 
the mid- and C-terminal regions of Ccdc124 (see Material and Methods). By using 
these reagents, we first established that Ccdc124 encodes a protein of ~32 kDa (Fig. 
3.5). We also generated flag-epitope tagged forms of Ccdc124 with the purpose of 
using it in cell biology analysis, by inserting the epitope both at the N- and at the C-
termini of the protein. As a result, we have observed that insertion of the flag-epitope 
to the C-terminus of the protein leads to an N-terminus cleavage in Ccdc124 (Fig. 
3.7). We have further analyzed these two flag-epitope tagged versions of Ccdc124 by 
mass-spectrometry (LC-MS/MS) analysis in collaboration with Prof. Dr. Johannes L. 
Bos group at the Utrecht University Medical Center, the Netherlands. These analyses 
have further proven that the flag-tag at the C-terminus affects the stability of 
Ccdc124 (Fig. 3.9). Even though we have not analyzed the stability pattern of 
endogenous Ccdc124, it is likely that the protein could be subjected to a post-
translational regulation involving proteolytic cleavage(s). 
Subsequently, we have used anti-Ccdc124 or anti-flag antibodies in order to assess 
the sub-cellular localization of the Ccdc124 protein. In these cell immunofluoresce 
assays, we have established that this coiled-coil domain (CCD) protein is localized at 
single or double dot-like (puncta) structures in asynchronous growing cells (Fig. 
3.11). In the literature, previous biochemical studies and mass-spectrometry analyses 
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on purified centrosomes have shown that proteins with CCD motifs are abundant in 
PCM [30], [70]. More than 150 different proteins were identified in the PCM at 
different cellular stages, and about 60% of these were shown to contain predicted 
CCD type oligomerization motifs [8]. With the hypothesis that Ccdc124 could be a 
novel PCM/centrosome factor, we asked whether this protein colocalizes with PCM 
markers such as centrin (results not shown) or !-tubulin (Fig. 3.12). Thus, by using 
molecular and cell biology methods, we identified Ccdc124 as a novel component of 
the centrosome, as in synchronized cells at interphase and in mitotic cells up to the 
late-anaphase/telophase stage it clearly colocalized with two different centrosome 
markers, such as !-tubulin and centrin (Fig. 3.12, and results not presented). Despite 
multiple high throughput proteomics analyses targeting centrosome composition in 
the past, Ccdc124 was not in the list of PCM proteins prior to our work, indicating 
that combined genetic, cell biology and biochemical approaches are still necessary to 
identify all the components of PCM which has a remarkably dynamic composition 
[19], [89].  
Conservation of Ccdc124 in lower eukaryotic species without centrosomes, such as 
A. nidulans, or S. pombe was not surprising, as also some major centrosome proteins 
(for instance, !-tubulin) were common between this organelle and fungal spindle pole 
bodies [32].  
Our further studies presented in this work indicate that in synchronized cells at late-
anaphase/telophase stages of the cell cycle, Ccdc124 changes its subcellular 
localization: it dissociates from centrosomes, and first relocalizes to the midzone at 
late-anaphase, and then it accumulates at the midbody puncta at telophase and during 
cytokinetic abscission (Fig. 3.13). At the present, we do not know what stimulates 
the displacement of Ccdc124 from the centrosome, or its association to the 
midzone/midbody. In fact, Cep55, a relatively well studied CCD containing 
centrosome protein that relocates to the midbody and controls cytokinetic abscission, 
was shown to be a substrate of Plk1 [39]. Phosphorylation of Cep55 by Plk1 on its 
Ser436 residue is required for its interaction with centralspindlin and ESCRT 
complex proteins, leading to the recruitment of CHMP4B to the midbody [39], [34]. 
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CHMP4B then organizes series of ring-like structures at the abscission site, and 
brings the two membranes of the intercellular bridge into close proximity for the 
final cutting event [90], [42]. Even though in the current thesis work we have not 
fully addressed post-translational modifications of Ccdc124, we have carried-out a 
number of preliminary studies, and there are several reasons why we think that its 
functions/stability could be regulated by phosphorylation dependent mechanisms. 
First, Ccdc124 is identified as a phosphoprotein in our phosphopeptide analysis by 
mass-spectrometry methods, and Ser141 residue of Ccdc124 (which is a consensus 
Plk1 phosphorylation site) was detected as a phosphorylated residue (Pelin 
Telkoparan, Lars A.T. Meijer, and Uygar H. Tazebay, unpublished results). Second, 
as shown in Fig. 3.33, when we mutated predicted Ser, Thr, or Tyr phosphorylation 
sites to Ala residues in Ccdc124 by in vitro mutagenesis, the Ser121 residue 
conforming to a Casein Kinase-II phosphorylation consensus site turned out to be 
essential for the stability of Ccdc124 protein, even though phospho-mimicking 
mutations S121D, and S121E were normal in terms of protein stability (Fig. 3.33), 
indicative of possible phosphorylation dependent regulatory mechanisms operating 
on Ccdc124. Furthermore, a preliminary in vitro kinase assay indicate that Ccdc124 
could potentially be a substrate of CK-II, as an inhibitor of CK-II (TBBt, see 
Material and Methods) inhibits phosphorylation of Ccdc124 under these conditions 
(Fig. 3.34).  
By RNAi techniques, we have depleted Ccdc124 in a variety of human cells in 
culture, and assessed its results on cell biology. We found that Ccdc124 knocked-
down cells can still make intact centrosomes, but they undergo severe cytokinesis 
failure inducing aneuploidy and generating genomic instability in cultured human 
cells (Fig. 3.15). Also in the zebrafish vertebrate model, when Ccdc124 was 
knocked-down by specific morpholino oligonucleotides in early stages of 
embryogenesis, we observed very similar genomic unstabilities resulting in 
multinuclear cellular patterns, indicative of a blockage in cytokinetic abscission (Fig. 
3.16). According to current models of abscission, resolution of the membrane 
connection between two prospective daughter cells requires a concerted action of 
ESCRT proteins together with the targeting of three main types of recycling 
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endosomes to midbody for an appropriate regulation of cytokinetic abscission [18], 
[90]. In an early work, Gromley et al, proposed a role for secretory vesicle fusion in 
the final stages of cytokinetic abscission, as they have shown that the coiled-coil 
protein centriolin relocates to midbody where, preceding abscission, it interacts with 
components of vesicle-targeting exocyst complexes and membrane-fusion inducing 
SNARE components [40]. However, subsequent studies indicated that even though 
the secretary pathway could contribute to formation of the intracellular bridge 
membrane, it is rather recycling endosome-dependent mechanisms that make major 
contributions to spatiotemporal regulation of cytokinetic abscission [91]. 
Furthermore, other than Ral family G proteins RalA and RalB, endosome enriched 
complexes such as Rab35/OCRL and FYVE-CENT/TTC19 that were found on 
different types of endosomes, were previously shown to enable the completion of the 
final stages of abscission [92]-[94]. Our data suggested the following possible links 
between Ccdc124 and recycling endosomes: first, we identified an endosome 
localized nucleotide exchange factor RasGEF1B [77] as an interaction partner of the 
coiled-coil protein Ccdc124 (Fig. 3.21). Second, RasGEF1B activated small G 
protein Rap2 that we detected at the midzone/midbody, was previously reported to 
colocalize with Rab11-positive endosomes in Xenopus early embryos [95]. 
Importantly, Rab11-positive recycling endosomes containing the effector protein 
FIP3 (Rap11 Family of Interacting Protein 3) were previously shown to control the 
reorganization of the cortical actomyosin network during cytokinetic abscission, as 
they accumulate at the intercellular space between dividing cells and regulate local 
actin depolymerization by recruiting p50RhoGAP, and thus contributing to further 
thinning of the bridge [96].   
In this thesis work, we focused on the biological significance of the interaction 
between Ccdc124 and RasGEF1B, rather than studying mechanistic aspects of it. 
Yet, previous studies from our laboratory on the effect of bacteria purified Ccdc124 
on the rate of nucleotide exchange by RasGEF1B on RAP2A in in vitro reconstituted 
assay systems suggested that Ccdc124 does not functionally interfere with 
RasGEF1B activity (Elif Yaman, Alfred Wittinghofer, Uygar H. Tazebay, 
unpublished observations). We hypothesized that rather than affecting its GEF 
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activity, Ccdc124 could recruit RasGEF1B to midzone/midbody where the exchange 
factor activate its substrate G protein(s). A similar spatiotemporal regulation of Rap1 
signaling localized at the plasma membrane by recruitement and translocation of its 
cAMP responsive GEF, Epac1, through activation of Ezrin-Radixin-Moesin (ERM) 
complex proteins was previously described [97]. In follow-up studies regarding 
interaction partners of RasGEF1B and Ccdc124, we have purified complexes 
involving these two proteins, and analyzed their compositions by LC-MS/MS mass-
spectrometry analysis methods (Table 3.1 and Figs. 3.29 and 3.30). These assays 
have revealed that there are 11 possible common interacting proteins between 
Ccdc124 and RasGEF1B (Fig. 3.30). Among those factors, we are giving priority in 
studying possible interactions between RasGEF1B/Ccdc124 and RACK1, as this 
kinase was previously shown to be involved in cytokinesis in C. Elegans [33, 84], 
and it has a similar sub-cellular localization pattern as Ccdc124 and RasGEF1B (Fig. 
3.32). 
We have shown that both the activator RasGEF1B and its partner G protein Rap2 
have identical spatiotemporal subcellular distributions (Fig. 3.24). This indicated that 
RasGEF1B could potentially activate GDP/GTP exchange of Rap2 at midbody 
during late-telophase stage of cell cycle and at cytokinesis. Importantly, we observed 
the RasGEF1B substrate Rap2, but not its close homologue Rap1, accumulated in 
vesicular structures proximal to the midzone and at the midbody (Fig. 3.24, see 
panels metaphase to cytokinesis). Detection of active Rap2 (Rap2.GTP) binding 
reporter protein GFP-RBD(RalGDS) in midbody further proved local activation of 
Rap2 at midbody puncta during cytokinesis (Fig. 3.25). This midbody localization of 
GFP-RBD(RalGDS), was only observed in cells having Rap2-WT, but not its 
dominant negative form, Rap2-S17N, indicating that midbody localization of Rap2 
effectors requires activation of this small G protein (Fig. 3.26).  
A schematic representation of sub-cellular localizations of Ccdc124, RasGEF1B, and 
Rap2 at different stages of cell cycle is shown in Fig. 3.35. 
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Figure 3.35 A schematic representation of subcellular localizations of Ccdc124, 
RasGEF1B, and Rap2 at various stages of the cell cycle. 
Recently, it has been shown that Rap2 and its effector TNIK are components of the 
Lbk1 signaling pathway that control cellular polarity, and when induced by Lkb1, 
Rap2/TNIK control formation of brush borders by specification of the apical 
membranes of intestinal epithelial cells [66]. When in our study, HeLa cells were 
transfected with vectors carrying a YFP-linked version of TNIK, we also observed 
this effector protein of Rap2 at the midbody during cytokinetic abscission (Fig. 3.27), 
and interestingly approximately 41.6% of cells transfected with YFP-TNIK remained 
unseparated in culture conditions at time points corresponding to early post-
cytokinetic stages (i.e., 150 mins. After G2/M blocking MT polymerization inhibitor 
nocodazole was washed-off, Fig. 3.27). Moreover, YFP-TNIK was found to 
accumulate it these cells all along the membrane separating two postmitotic 
daughters (Fig. 3.27). This suggested that over-expression and accumulation of the 
effector YFP-TNIK at the intermembrane between the daughter cells alone could 
lead to joining of post-mitotic cells, independent of Rap2 signaling. These 
observations support the notion that localization of Rap2 at the midbody may serve 
to functionalize local membrane environment for molecular events following 
cytokinetic abscission, such as establishment of cell-cell junctions, cell-extracellular 
matrix adhesions, or polarizations of cells after division of daughter cells fully 
accomplished. Interestingly, neither cellular depletion of endogenous Rap2 by 
specific shRNA transfections, nor over-expression of the dominant negative form of 
Rap2 (S17N) has led to cytokinesis defects, as assessed by normal levels of bi- and 
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multinucleated cells in corresponding cellular assays (Fig. 3.26). Therefore, it seems 
that rather than playing a direct role in cytokinesis, localization of Rap2 at the 
midbody might serve to modulate and/or functionalize local membrane environment 
for molecular events following cytokinetic abscission, such as establishment of cell-
cell junctions, cell-extracellular matrix adhesions, or polarizations of cells after 
division of daughter cells fully accomplished. When we consider results obtained in 
this thesis altogether, we propose Ccdc124 as a novel factor that links cytokinesis to 
Rap signaling dependent junction/adhesion or cellular polarization promoting 
molecular mechanisms, thus bonding different cellular events that must closely 
follow each other in tissues of live organisms.  
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CHAPTER 5. FUTURE PERSPECTIVES 
 
Ccdc124 is conserved in all eukaryotes including lower yeast and fungal species. 
Also, RasGEF1B and Rap2 orthologues exist in lower eukaryotes [50]. Therefore, 
functional and mechanistic studies on Ccdc124 could effectively be carried-out in 
these simple model organisms, which also bring advantages of classical genetics. In 
simple yeast models (for instance Schizosaccharomyces pombe) where genetic 
crosses could be performed, not only mutants of Ccdc124, RasGEF1B, and Rap2 
could be obtained and analyzed, but also revertant strains (or second site repressors) 
can be selected, and double mutants are easily constructed. 
When we analyzed Ccdc124 proteins expressed from the mammalian expression 
vectors by immunoblots, we observed two bands of ~32kDa and ~26 kDa when we 
used antibodies recognizing middle or c-terminus epitopes in Ccdc124. The ~26 kDa 
band was not detectable in blots incubated with an N-ter specific anti-Ccdc124 
antibody, indicating that the small form was missing the N-terminus part (Fig. 3.5). 
In bioinformatics analysis, we found a second methionine residue (Met-47), which 
could have formed an alternative ATG start codon. We tested this hypothesis by 
inserting a M47L mutation in CMV-Ccdc124-HA vector construct, and then 
repeating a similar Western blot analysis (Fig. 3.6). As a result, the ~26 kDa band 
have disappeared, indicating that the second ATG (codon 47) was an alternative start 
site for Ccdc124 gene translation. In support of our result, Lee et al. [72] have 
recently found that in the endogenous gene, Met-47 codon provides an alternative 
Kozak sequence forming an alternative ribosome-binding site. In future work, we 
aim to analyze possible alternative cellular functions of these two different forms 
(short and long forms) of Ccdc124. 
By using a mass-spectrometry based proteomics system, we initiated studies for 
identification of complexes in which Ccdc124 and RasGEF1B proteins are involved. 
In this study we identified about 11 possible common interaction partners including 
some (for example, RACK1) that have a role in cytokinesis. However, as we were 
not aware of the localization of Ccdc124 when these mass-spectrometry analyses 
were done, immunoprecipitated complexes analyzed in this study were not coming 
from synchronized cells. We now anticipate that in future mass-spectrometry 
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analysis, Ccdc124 and RasGEF1B immunoprecipitations could be done on 
synchronized cells at different phases of the cells cycle, including the cytokinesis 
phase (post-anaphase/telophase). In other words, a better profile of possible 
interactions could be obtained, if similar analyses were done on purified centrosomes 
or midbody at appropriate stages of the cell cycle. This will be addressed in future 
studies. 
Mass-spectrometry studies revealed that Ccdc124 is in fact a phosphoprotein, as Ser-
141 appeared to be phosphorylated in phospho-peptide analysis. This residue (Ser-
141) is localized in a consensus Plk-1 modification site. We mutated this Ser-141 
residue to phospho-mimicking Asp, or Glu, or to phospho-mutant Ala residue. These 
mutations did not cause any stability problems in Ccdc124. On the other hand, by 
these experiments we could not conclude on the effect of Plk-1 to post-translational 
modifications of Ccdc124. Follow-up studies should address whether or not Ccdc124 
is a substrate of the Plk-1. For this, chemical genetics approaches with engineered 
cells having analogue sensitive Plk-1 forms (Plk1-AS), as well as typical in vitro 
kinase assays could be done.  
Bioinformatics analyses also identified CK-I and CK-II as putative kinases that could 
post-translationally modify Ccdc124. When possible CK-I and CK-II substrate 
residues are mutated to phospho-mimicking and phospho-mutant residues, we 
observed that a particular CK-II substrate residue is important for the stability of 
Ccdc124 (Fig. 3.33). We further extended these analyses to in vitro kinase assays, 
and found that under these conditions CK-II specifically phosphorylates Ccdc124 
(Fig. 3.34). It remains to be established whether or not Ccdc124 is a CK-II substrate 
under in vivo conditions. 
We have constructed GFP-tagged versions of Ccdc124, with GFP localized at 
different domains of Ccdc124 (results not shown). By using these vector constructs, 
we prepared stable cell lines (U2OS) expressing GFP-tagged versions of Ccdc124. 
These cell lines will be used in live imaging confocal microscopy for the analysis of 
subcellular localization dynamics of Ccdc124. These constructs will also be used for 
interaction mapping between Ccdc124 and its interaction partners (for instance 
RasGEF1B) in Co-IP experiments. 
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Zebrafish embryo model is a useful in vivo system for functional analysis of Ccdc124 
and its interaction partners. In our preliminary knockdown studies by using specific 
morpholino oligonucleotides, we observed cytokinesis defects with pronounced 
genomic unstabilities in early embryonic tissues, followed by an important 
embryonic lethality rate in these Ccdc124 depleted early embryos (Fig. 3.16). 
Furthermore, in later embryonic stages, Ccdc124 depleted individuals have shown 
major developmental defects characterized by shortened body forms and spinal cord 
malformations (Fig. 3.16). In future work, these results should be developed with 
rigorous molecular analysis including several other experimental controls. For 
example, phenotype rescue experiments where morpholino and wt-RNA injections 
are done simultaneously should be included to experimental designs. In order to 
establish functions of RasGEF1B and Rap2 in Zebrafish embryo development, the 
same experiments should also be done for these two genes, RasGEF1B and Rap2. 
Mouse knock-out projects will also be carried out to define the function of Ccdc124 
and RasGEF1B in development of mammalian models. For this purpose, we have 
already purchased from the University of California at Davis-KOMP facility the 
suitable mouse embryonic stem cells where Ccdc124 was unconditionally deleted. 
These ES cells will be implemented to mice in collaboration with the Animal 
Genetics facility located at the BIOGEM-Institute of Salvatore Gaitano, Ariano 
Irpino, Italy.  
Even though we have established the function of Ccdc124 in cytokinesis in 
mammalian cells, we have not addressed possible roles of Ccdc124 mutations in 
human diseases. For example, mutations of Cep152 that is another coiled-coil 
domain containing centrosomal protein, was shown to result in genomic instability, 
and a rare developmental disorder called Seckel syndrome in humans [98]. Depletion 
of Ccdc124 also causes genomic instability both in cell line models, and in the in 
vivo Zebrafish model. It is possible that mutations in Ccdc124 could be associated 
with similar developmental disorders in human. Genomic instability due to 
cytokinetic defects was also associated with human cancers in past studies [99-100]. 
Therefore, in future work, human cancer samples should be screened for mutations in 
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Ccdc124, in order to establish possible correlations between oncogenesis and 
Ccdc124. Possible epigenetic factors resulting in Ccdc124 expression modifications 
in human cancers should also be assessed in future studies. 
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Abstract 
Cytokinetic abscission is the cellular process leading to physical separation of two 
postmitotic sister cells by severing the intercellular bridge. The most noticeable 
structural component of the intercellular bridge is a transient organelle termed as 
midbody, localized at a central region marking the site of abscission. Despite its major 
role in completion of cytokinesis, our understanding of spatiotemporal regulation of 
midbody assembly is limited. Here, we report the first characterization of coiled-coil 
domain-containing protein-124 (Ccdc124), a eukaryotic protein conserved from fungi-
to-man, which we identified as a novel centrosomal and midbody protein. Knockdown 
of Ccdc124 in human HeLa cells leads to accumulation of enlarged and multinucleated 
cells; however, centrosome maturation was not affected. We found that Ccdc124 
interacts with the Ras-guanine nucleotide exchange factor 1B (RasGEF1B), establishing 
a functional link between cytokinesis and activation of localized Rap2 signaling at the 
midbody. Our data indicate that Ccdc124 is a novel factor operating both for proper 
progression of late cytokinetic stages in eukaryotes, and for establishment of Rap2 
signaling dependent cellular functions proximal to the abscission site. 
 
Keywords: Ccdc124 / Centrosome / Midbody / Cytokinesis / RasGEF1B / Rap2 
signaling 
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Introduction 
Centrosomes are microtubule-organizing centers (MTOCs) that play a key role in 
determining the geometry of microtubule arrays in animal cells. They control and 
influence cell shape, polarity, motility, spindle formation, as well as chromosome 
segregation and cell division [1]. Each centrosome comprises a pair of centrioles that are 
surrounded by an amorphous and dynamic proteinaceous matrix referred to as the 
pericentriolar material (PCM), which is considered to be the site where microtubule 
nucleation initiates [2]. Associated with the multifunctional role of this primary MTOC 
in the cell, the total amount of PCM organized around centrioles (corresponding to 
centrosome size) and the composition of PCM vary considerably throughout the cell 
cycle [2]-[4]. 
Microtubule-nucleating capacities of centrosomes are increased by recruitment of key 
PCM proteins such as !-tubulin and gamma-tubulin complex proteins (GCP) forming the 
!-tubulin ring complexes (!-tuRC), which orchestrate cell division-related MTOC 
activities leading to the formation of spindle asters and correct positioning of the two 
spindle poles. These cellular activities are required for genetically stable cells as it 
facilitates proper segregation of the duplicated chromosomes, ultimately resulting in 
diploid daughter cells [4]-[7]. 
Recently, a number of efforts aimed to establish both the precise composition of PCM at 
different stages of cell cycle, and the nature of dynamic networks of molecular 
interactions that lead to spatiotemporal regulation of PCM assembly. Jakobsen et al. [8] 
have obtained an extensive coverage of human centrosome proteome by using a mass 
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spectrometry-based proteomics approach combined with an antibody based subcellular 
screen of candidate proteins [8]. In this study, the authors identified 126 known and 40 
novel candidate centrosome proteins, of which 22 were validated as novel centrosome 
components, and 5 turned out to associate preferentially either with mother or daughter 
centrioles. These analyses also indicated that the majority (60%) of centrosomal proteins 
contain coiled-coil domain (CCD) type oligomerization motifs [8], [9], as their 
predominant structural features, which seem to be important for proper centrosome 
assembly.  
Previous studies have indicated the presence of microtubule nucleation-related proteins 
that are shared between the centrosome and the midbody, which is the central region of 
the intercellular bridge that is rich in anti-parallel microtubule bundles emanating from 
the central spindle [10]. These include for instance !-tubulin, as the midbody is also a 
secondary MTOC associated with the contractile ring forming at the site of cleavage 
furrow ingression [1], [11]. Again, another protein with a CCD motif, Cep55, is 
centrosomal in interphase cells but dissociates from the centrosome during entry into 
mitosis [12]-[14]. Precisely at cytokinetic abscission Cep55 is localized to the midbody 
where it plays an essential role in recruitment of the endosomal sorting complex required 
for transport (ESCRT) components such as Alix and tumor susceptibility gene 101 
(tsg101, an ESCRT-I member), as well as endobrevin (v-SNARE) [15]-[17]. This is then 
followed by the recruitment of ESCRT-III components via interactions with Alix and 
Tsg101, resulting in the translocation of CHMP4B to the midbody [18]. According to 
current models, polymerization of CHMP4B subunits forms series of cortical rings 
extending away from the midbody, either as continuous helical contractile filaments 
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[18], [19] or to give rise to a second immediately distal CHMP4B pool [20]. This then 
deforms the intercellular bridge membrane neck into a narrow constriction, and 
subsequently induces the abscission event.  
Recent studies have also identified a number of factors other than Cep55 that similarly 
localize to centrosomes early in mitosis but then move to the midbody at cytokinesis 
where they execute essential functions in fission of the daughter cells [10], [16]. Among 
those proteins, Polo-like-kinase-1 (Plk1) plays critical roles in centrosome maturation 
and microtubule organization [7], [21], [22]. At the midzone Plk1 also phosphorylates 
Cep55 on Ser-436, thereby modulating its interaction with Mklp1, a kinesin-like 
component of centralspindlin. This provides a temporal control of abscission, by 
inhibiting functions of Cep55 in the midbody at stages earlier than late-anaphase [23].   
During our earlier studies on specificities of Ras-guanine nucleotide exchange factor-1 
(RasGEF1) family members [24], we obtained preliminary evidences regarding possible 
interactions between RasGEF1B and a previously uncharacterized protein known as the 
coiled-coil domain-containing protein 124 (Ccdc124). Here, we report the first 
characterization of this conserved human protein, Ccdc124, and show that it is a novel 
component of the centrosome during interphase and at the G2/M transition. During cell 
division, Ccdc124 relocates to the midbody at telophase and acts as an essential 
molecular component in cytokinesis. Ccdc124 interacts with RasGEF1B at the midbody 
where this GEF could activate the small G protein Rap2 [24] at pre-abscission stages. 
Our data propose a mechanistic link between cytokinesis and Rap signaling that is 
mainly linked to the formation of cell-cell junctions, regulation of cell-extracellular 
matrix adhesion, and establishment of cell polarity [25], i.e., molecular processes that 
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must follow cell division while tissues are formed. 
Results  
Molecular characterization of Ccdc124  
The coiled-coil domain (CCD) is a motif that is found in most centrosome proteins [8]. 
Intrigued by its strict conservation in all eukaryotic genomes from fungi-to-man, we 
hypothesized that CCDC124, a human gene of unknown function encoding a putative 
CCD containing novel protein, could in fact be involved in centrosome biology. We 
carried-out a comparative sequence analysis on CCDC124 which encodes a cDNA that 
is transcribed from chromosome 19p13.11, consisting of five exons, of which exon 1 is 
non-coding. BLAST analysis indicated that the protein encoded from this genetic locus 
shares, for instance, 70% identity/89.1% similarity with its orthologue NP_956859 in the 
vertebrate model Danio rerio (zebrafish), or 50.4% identity/72.6% similarity with 
Y73E7A.1 in the invertebrate Caenorhabditis elegans. CCDC124 has also orthologues 
in lower eukaryotes such as the filamentous fungus Aspergillus nidulans (AN0879.2; 
35.1% identity/58.2% similarity), or the fission yeast Schizosaccharomyces pombe 
(SPBC29A10.12; 33% identity/57.8% similarity), while it is not found in the budding 
yeast Saccharomyces cerevisiae.  
Northern blot analysis have revealed that CCDC124 is ubiquitously expressed in all 
tested human tissues, and relatively high levels of expression were detected in the brain, 
placenta, liver, spleen, and prostate (Fig. 1A). In these analyses, a transcript of ~1061 
nucleotides was detectable in tested organs, in agreement with the predicted size of 
CCDC124 mRNA in the NCBI databases (http://genome.ucsc.edu), except in the 
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placenta where we observed a second shorter mRNA species indicative of a transcript 
variant (Fig. 1A). CCDC124 cDNA would encode a protein of 223 amino acids with two 
putative coiled-coil domains between residues 18-82 in the N-terminal half of the protein 
as detected by the ELM (http://elm.eu.org) and COILS 
(www.ch.embnet.org/software/COILS_form.html) bioinformatics analysis platforms 
(Fig. S1). No significant homology to other proteins or domains were found.  
We generated a rabbit polyclonal antibody recognizing the peptide corresponding to the 
N-terminal 24 amino acids of Ccdc124 and characterized its specificity towards Ccdc124 
in immunoblots including peptide competition assays (Fig. 1B). We identified Ccdc124 
as a ~32 kDa protein in immunoblots using different protein lysates obtained from 
Ccdc124 expression vector (CMV-Ccdc124) transfected or untransfected human HEK-
293 cells (Figs. 1B-C). Furthermore, when the Ccdc124 ORF was tagged with an N-
terminal flag-epitope in plasmid vectors, the antibody also detected the flag-Ccdc124 at 
the expected size (~35 kDa; Fig. 1C). When these bands were gel extracted and 
subjected to peptide analyses by mass-spectrometry, the band of ~35 kDa were identified 
as the full-size flag-Ccdc124, suggesting that without the flag epitope CCDC124 would 
encode a protein of ~32 kDa (Pelin Telkoparan, Lars A.T. Meijer, and Uygar H. 
Tazebay, unpublished results). Surprisingly, anti-flag antibodies failed to detect a similar 
robust band of ~35 kDa when the epitope was inserted at the C-terminus, but instead 
they revealed a band of ~32 kDa in lysates of cells transfected with vectors expressing 
Ccdc124-flag (Fig. 1C). This indicated possible proteolytic cleavage of the protein at its 
N-terminus when flag-epitope is inserted to the C-terminus of Ccdc124. We have not 
further characterized the proteolytic cleavage of this protein at the molecular level, and 
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we used the more stable N-terminus flag-tagged Ccdc124 expressing vector (flag-
Ccdc124) in the rest of our studies. 
Ccdc124 is a novel centrosome protein relocated to midbody at telophase  
In order to obtain insight into the biological function of Ccdc124, we assessed the 
subcellular localization of endogenous Ccdc124 by using generated or commercial anti-
Ccdc124 antibodies in cellular immunofluorescence assays. When asynchronusly 
growing HeLa cells were subjected to a preliminary immunofluorescence analysis by 
using an anti-mid-Ccdc124 antibody recognizing the central part of the protein (between 
residues 100-150), subcellular dot-like structures reminiscent of centrosomal staining 
patterns were detected (results not shown, but please see Fig. 2, below). We then 
synchronized the cells at G2/M stage of the cell cycle by the MT polymerization 
inhibitor nocodazole following double-thymidine treatments (Fig. S2, see Methods), and 
followed cell cycle stage-dependent subcellular localization of endogenous Ccdc124 by 
immunofluorescence assays using Ccdc124 N-terminal epitope (residues 1 to 24), mid-
region, or C-terminal epitope (residues 173 to 223)-specific antibodies. Independent of 
the Ccdc124 antibody used, these studies further indicated centrosome colocalization of 
Ccdc124 with !-tubulin at interphase, prophase, metaphase, and anaphase stages, albeit it 
was relatively diffused to the pericentrosomal region at anaphase (Fig. 2A). Similar 
results were obtained when subcellular localization of an N-terminus flag-tagged version 
of Ccdc124 was monitored by immunofluorescence stainings using anti-flag antibodies 
on cells transfected with the corresponding vector construct (Fig. 2B). Moreover, 
endogenous centrosome immunostainings with anti-Ccdc124 Abs were very 
significantly reduced in response to Ccdc124 depletion by esiRNAs targeting its 
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expression (see below, Fig. 4B), further supporting the notion that Ccdc124 is a novel 
centrosome protein. Centrosome localization of endogenous Ccdc124 was also observed 
in Retinal Pigment Epithelial cells (RPE1) containing another centrosomal marker, GFP-
Centrin [26] (results not shown). Interestingly, at telophase and in cytokinesis Ccdc124 
dissociates from centrosomes and relocalizes to the midzone, subsequently accumulating 
at the midbody at cytokinesis as assessed by its colocalization with the midzone-specific 
!-tubulin (Fig. 2A-B, and Fig. 3A, C), or by its positioning at the midbody marked by 
the empty mid-space in "-tubulin stainings (Fig. 3B). Immunofluorescence studies with 
peptide competition assays further indicated that the Ccdc124 signal detected at the 
midbody was specific, as anti-N-ter-Ccdc124 antibodies pre-treated with the epitope 
peptide failed to recognize Ccdc124 at the midbody (Fig. 3C). 
Knock-down of CCDC124 by siRNAs leads to defects in cytokinesis 
A number of midbody localized proteins were previously shown to be involved in 
cytokinetic abscission [13], [16], [27]. In order to test a possible role of Ccdc124 
during the separation of dividing sister cells, we initially knocked-down CCDC124 
in HeLa cells by separately transfecting them either with esiRNAs or with shRNA 
vectors specifically targeting this gene. We first monitored knock-down efficiencies 
by immunoblots that we carried-out using lysates obtained from Ccdc124-specific 
esiRNA or shRNA vector transfected cells as compared to scrambled 
esiRNA/shRNA vector transfected controls. We observed approximately 75-80% 
decrease in Ccdc124 levels in cells that received gene specific esiRNAs as compared 
to scrambled transfected controls (Fig. 4A). Again, depending on shRNA target 
sequence, close to 30-65% decrease were detected in Ccdc124 levels in cells 
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separately transfected with three different sequences of shRNAs (Sh1, Sh2, and Sh3), 
as compared to scrambled controls. In these assays, Ccdc-Sh1 was identified as the 
vector containing the most potent Ccdc124-targeting shRNA sequence (Fig. 4A) We 
then analyzed cellular morphologies, centrosome localizations, and midbody 
functions of asynchronous growing cells that received either Ccdc124 specific 
esiRNAs, or shRNA vectors targeting the same gene. In Ccdc124-depleted cells 
interphase centrosomes still formed, as assessed by immunostainings that mark !-
tubulin complexes (Fig. 4B). This indicated that the absence of Ccdc124 does not 
impair centrosome formation. However, in Ccdc124-depleted cells cytokinesis was 
remarkably blocked as assessed by the significantly increased percentage of bi- and 
multinucleated cells (Fig. 4C-D) from 2.5 ± 0.3 % in scrambled control esiRNA 
transfected cases to 14.6 ± 1.5 % in Ccdc124-specific esiRNA received 
asynchronous cultures (Fig. 4C). The percentage of multinucleated cells in Ccdc124-
depleted cultures were decreased significantly and nearly restored to normal levels 
(4.5 ± 0.8 %) when Ccdc124 was reintroduced in a strong expression vector (Fig. 
4A, C). This indicated that the cytokinesis defect observed with the esiRNA against 
Ccdc124 was specific. Further supporting this observation, the ratio of 
multinucleated cells also raised from 3.1 ± 0.2 % in scrambled shRNA vector 
received cells to 11.6 ± 2.7 % in cells transfected with Ccdc-Sh1 (Fig. 4B), 
indicating that defects in cytokinesis was specific to endogenous Ccdc124 depletion 
in HeLa cells rather than an off-target effect of RNAi. 
Identification and characterization of interaction partners of Ccdc124 
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In order to identify possible interaction partners of Ccdc124, a human liver cDNA 
library was screened in a yeast two-hybrid assay system as described in Materials 
and Methods. Colonies with interacting partners were selected, and the 
corresponding prey fragments were sequenced at their 5' and 3' junctions. All 15 
positive colonies contained overlapping cDNA sequences belonging to only one 
gene, RasGEF1B, suggesting that this guanine nucleotide exchange factor (GEF) is a 
strong candidate as an interaction partner of Ccdc124. RasGEF1B was first identified 
in zebrafish as a protein expressed in neural cells during late embryogenesis and 
early larval stages [28]. Furthermore, by using in vitro assay systems [24] we 
previously characterized RasGEF1B as an exchange factor exclusively activating the 
small G protein Rap2. RasGEF1B was also identified in murine macrophages as a 
toll-like receptor inducible protein with a subcellular localization in early endosomal 
vesicles [29]. 
Following the yeast two-hybrid assays, we were able to confirm the interaction 
between Ccdc124 and RasGEF1B, first by in vitro GST pull-down methods (Fig. 
5A), and then by analyzing their association in mammalian HEK-293 cells 
transfected with flag-Ccdc124 and GFP-RasGEF1B containing expression vectors 
(Fig. 5B). Coimmunoprecipitation of GFP-RasGEF1B and flag-Ccdc124 in 
transfected cells could indicate a functional interaction between these two proteins. 
In parallel to functional studies to establish cellular roles of Ccdc124 and 
RasGEF1B, we sought to determine whether the subcellular localizations of these 
two proteins were comparable throughout the cell cycle. In fact, in a previous study, 
RasGEF1B was shown to localize in endosomal vesicles when fluorescent protein-
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fused versions (YFP-RasGEF1B or mRFP-RasGEF1B) were ectopically expressed in 
asynchronous CHO cells [29]. However, the subcellular localization of RasGEF1B 
was not previously addressed in cell cycle-synchronized cells. Identification of an 
endosomal vesicle factor such as RasGEF1B as an interaction partner of centrosomal 
and/or midbody localized Ccdc124 is particularly interesting, as critical roles of 
endosomes in physical separation of cells during cytokinetic abscission are well 
established in recent studies (for a review, see [30]). Subsequently, we generated a 
rabbit polyclonal antibody recognizing the C-terminal 19 amino acids epitope of the 
Zebrafish orthologue of RasGEF1B, and by immunoblotting analysis we first 
established that it also recognizes the human RasGEF1B protein (Fig. S3). Then, by 
using this antibody, we observed that even though in HeLa cells at interphase and 
prophase it displays characteristics of previously suggested cytoplasmic/early 
endosome localization [29], in metaphase cells RasGEF1B was located at a 
pericentrosomal/centrosomal position, as assessed by its co-localization with !-
tubulin, a subcellular localization similar to that Ccdc124 at metaphase cells (Fig. 
6A, compare with Fig. 2).  
Again similar to Ccdc124, at telophase and during cytokinesis RasGEF1B was 
detected at the midzone and in the midbody, and the RasGEF1B immunostaining at 
the midzone/midbody was sensitive to shRNAs (Fig. S4) targeting the expression of 
this GEF (Fig. 6B-C), indicating that the immunofluorescence signal was specific to 
the midbody localized RasGEF1B. Furthermore, during late stages of cytokinesis 
GFP-tagged RasGEF1B localized to the midbody as described for the endogenous 
protein (Fig. 6D). Noticeably, in these cell assays GFP-RasGEF1B clearly 
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colocalized with Ccdc124 at the midbody puncta, suggesting that in late-cytokinesis 
the midbody forms a site of interaction for the two proteins. These results imply a 
possible role of Ccdc124 in linking cytokinesis to previously uncharacterized 
RasGEF1B dependent signaling at the midbody. As a note, we observed that bacteria 
purified Ccdc124 does not functionally interfere with the guanine nucleotide 
exchange activity of RasGEF1B in in vitro reconstituted assay systems (see below, 
Elif Yaman, Alfred Wittinghofer, and Uygar H. Tazebay, unpublished results), 
suggesting that Ccdc124 could affect spatial regulation of RasGEF1B, rather than 
modulating its GEF activity.  
RasGEF1B stimulates guanine nucleotide exchange of Rap2 in mammalian cells 
in culture 
Activation cycle of small G proteins is regulated by guanine nucleotide exchange 
factors (GEFs), which induce dissociation of bound GDP and its replacement by the 
more abundant GTP, and the resulting conformational change allows the binding of 
effector proteins and thereby stimulation of downstream signaling. Previous 
functional studies by Yaman et al. [24] indicated that under in vitro conditions 
RasGEF1B specifically activates Rap2 by stimulating guanine nucleotide exchange 
only of this small G protein, whereas it does not activate even its close family 
member, Rap1, or other members of Ras family. We decided to take these in vitro 
studies to one level up, and confirm the stimulatory effect of RasGEF1B on Rap2 
GDP/GTP nucleotide exchange by knocking-down this GEF in HEK-293 cells, 
followed by assessing GTP-bound active Rap2 (Rap2.GTP) status in these cells. For 
this, we used a Rap-activity assay method based on immunoprecipitation of active 
 152 
Rap proteins by the Rap-binding domain of RalGDS (RBD-RalGDS), as previously 
described [31]. When RasGEF1B is knocked-down to nearly 55% in HEK-293 cells 
by specific down-regulatory shRNA-containing vectors (Fig. S4), significantly less 
Rap2.GTP were present in cells, even though total Rap2 amounts were not affected 
(Fig. 7). This indicated a functional link between RasGEF1B and Rap2 GTP-binding 
protein activation in this cell system. These results were consistent with our previous 
in vitro studies that established Rap2 as the sole RasGEF1B activated Ras-family 
GTP-binding protein [24]. 
Active Rap2 GTP-binding protein is relocated to the midbody at cytokinesis 
We then decided to assess if RasGEF1B substrate G protein Rap2 was also located in 
centrosomes and midbody during different stages of cell cycle. Our data indicated 
that at the midbody the position of Rap2 overlapped both with RasGEF1B and with 
Ccdc124 in binary comparisons (Fig. 8A, B). Depletion of endogenous Rap2 in HeLa 
cells by transfecting them with Rap2-specific shRNA vectors have led to the loss of 
endogenous Rap2 at the midbody (Fig. 8C, D). However, depletion of Rap2 did not 
result in a significant increase in percentages of multinucleated cells above 
scrambled controls (Fig. 8C, D). This result could suggest that although Rap2 is 
located at the midbody, its molecular function(s) at this organelle is(are) not essential 
for proper completion of cytokinesis. Subsequent immunofluorescence assays using 
anti-Rap2 antibodies on dividing HeLa cells indicated that Rap2 migrates to the 
midzone during anaphase/telophase (Fig. 9A, B), which is in contrast to its 
homologue Rap1 that is non-responsive to RasGEF1B [24] (Fig. S5). We also 
observed that in synchronously dividing cells 90 mins after they were released from 
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nocodasole, at initial stages of cytokinesis Rap2 associates with microtubules 
originating at the midzone, and it migrates to the very center of intercellular bridge 
(boundaries marked with "-tubulin, Fig. 9B), relocating itself to midbody during 
cytokinetic abscission (Fig. 9A, B).  
We then inquired whether Rap2 located at the midbody was functionally active 
during cytokinetic abscission, by transfecting HeLa cells with a GFP-labeled 
recombinant version of the Rap Binding Domain (RBD) of RalGDS referred as GFP-
RBD(RalGDS). This GFP-labeled effector protein interacts with Rap2 specifically in 
the GTP-bound active state of the G protein, and thus serves as a subcellular Rap2 
activity reporter [32]. When the signal coming from the GFP-RBD(RalGDS) that 
interacts with Rap2.GTP was followed at the subcellular level, at the interphase both 
endogenous Rap2 and GFP-RBD(RalGDS) were detected to localize diffusely at the 
cytoplasm with only a partial overlap (Fig. 10A, interphase). However, during 
cytokinetic abscission, GFP-RBD(RalGDS) very clearly colocalized with Rap2 at the 
midbody, indicating that Rap2 protein identified at the spindle midzone/midbody is 
in its GTP-bound active form (Fig. 10A, cytokinesis), and that it may potentially act 
on its specific effectors at this location. Midbody localization of GFP-labeled 
RBD(RalGDS) strictly depended on the presence of an active Rap2, as in cells co-
transfected with dominant negative version of Rap2 (Rap2-S17N) the reporter 
protein GFP-RBD(RalGDS) did not relocate with the same efficiency to the midbody 
during cytokinesis as compared to cells transfected with wild-type Rap2 (Fig. 10B). 
The endogenous activation of local Rap2 signaling at midbody did not require 
pretreatment of cells with secondary messengers such as cAMP, diacylglycerol 
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(DAG), or calcium that were previously shown to stimulate Rap signaling through 
activation of various GEFs [33], [34]. This indicate that the recruitement of 
RasGEF1B to the midbody could be sufficient for regulation of Rap2 activity, as 
well as for translocation of Rap2 effectors to this subcellular location.  
Conclusion and Discussion 
Previous biochemical studies and mass-spectrometry analyses on purified 
centrosomes have shown that proteins with CCD (coiled-coil domain) motifs are 
abundant in PCM [8], [35]. Close to 150 different proteins were identified in the 
PCM at different cellular stages, about 60% of which contain predicted CCD type 
oligomerization motifs [8]. In this work, by using molecular and cell biology 
methods we identified Ccdc124 as a novel component of the centrosome, as in cells 
at interphase and in mitotic cells up to the late-anaphase/telophase stage it clearly 
colocalized with two different centrosome markers, such as !-tubulin and centrin 
(Fig. 2, and unpublished data). Despite multiple high throughput proteomics analyses 
targeting centrosome composition in the past, Ccdc124 was not in the list of PCM 
proteins prior to this study, indicating that combined genetic, cell biology and 
biochemical approaches are still necessary to identify all the components of PCM 
which has a remarkably dynamic composition [1], [36]. Conservation of Ccdc124 in 
lower eukaryotic species without centrosomes, such as A. nidulans, or S. pombe was 
not surprising, as also some major centrosome proteins (for instance, !-tubulin) were 
common between this organelle and fungal spindle pole bodies [37]. The absence of 
an orthologue of Ccdc protein in S. cerevisiae, however, might indicate that Ccdc124 
is not essential for fungi with budding-type of cell division. 
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Our data revealed that at late-anaphase/telophase stages of cell cycle Ccdc124 
changes its subcellular localization: it dissociates from centrosomes, and first 
relocalizes to the midzone at late-anaphase, and then it accumulates at the midbody 
puncta at telophase and during cytokinetic abscission (Fig. 2-4). Currently, we do not 
know what triggers the displacement of Ccdc124 from the centrosome, or its 
association to the midzone/midbody. In fact, Cep55, a relatively well studied coiled-
coil containing centrosome protein that relocates to the midbody and controls 
cytokinetic abscission, was shown to be a substrate of Plk1 [13]. Phosphorylation of 
Cep55 by Plk1 on its Ser436 residue is required for its interaction with 
centralspindlin and ESCRT complex proteins, leading to the recruitment of 
CHMP4B to the midbody [13], [16]. This is then followed by the assembly of this 
ESCRT-III component into a series of ring-like structures organizing the abscission 
site, mainly by bringing the two membranes of the intercellular bridge into close 
proximity for the scission [20], [38]. Even though in the current study we have not 
addressed post-translational modifications of Ccdc124, there are several reasons why 
we anticipate that its functions/stability could be regulated by phosphorylation 
dependent mechanisms. First, Ccdc124 is identified as a phosphoprotein in our 
preliminary phosphopeptide analysis by mass-spectrometry methods, and Ser141 
residue of Ccdc124 (which is a consensus Plk1 phosphorylation site) was detected as 
a phosphorylated residue (Pelin Telkoparan, Lars A.T. Meijer, and Uygar H. 
Tazebay, unpublished results). Second, when we mutated predicted Ser, Thr, or Tyr 
phosphorylation sites to Ala residues in Ccdc124 by in vitro mutagenesis, the Ser121 
residue conforming to a Casein Kinase-II phosphorylation consensus site turned out 
to be essential for the stability of Ccdc124 protein, even though phospho-mimicking 
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mutations S121D, and S121E were normal in terms of protein stability (Fig. S6A, B), 
indicative of possible phosphorylation dependent regulatory mechanisms operating 
on Ccdc124.  
We found that Ccdc124 depleted cells can still form MTOC, but they undergo 
cytokinesis failure inducing aneuploidy and generating genomic instability in 
cultured human cells (Fig. 4). According to current models of cytokinetic abscission, 
resolution of the membrane connection between two prospective daughter cells 
requires a concerted action of ESCRT proteins together with the targeting of three 
main types of recycling endosomes to midbody for an appropriate regulation of 
cytokinetic abscission (see below) [39], [40]. In an early work, Gromley et al, 
proposed a role for secretory vesicle fusion in the final stages of cytokinetic 
abscission, as they have shown that the coiled-coil protein centriolin relocates to 
midbody where, preceding abscission, it interacts with components of vesicle-
targeting exocyst complexes and membrane-fusion inducing SNARE components 
[11]. However, subsequent studies indicated that even though the secretary pathway 
could contribute to formation of the intracellular bridge membrane, it is rather 
recycling endosome-dependent mechanisms that make major contributions to 
spatiotemporal regulation of cytokinetic abscission [40]. Furthermore, other than two 
Ral family G proteins RalA and RalB, endosome enriched complexes such as 
Rab35/OCRL and FYVE-CENT/TTC19 that were found on different types of 
endosomes, were previously shown to enable the completion of the final stages of 
abscission [41]-[43]. Our data suggested possible links between Ccdc124 and 
recycling endosomes. First, we identified an endosome localized nucleotide 
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exchange factor RasGEF1B [29] as an interaction partner of the coiled-coil protein 
Ccdc124 (Fig. 5-6). Second, RasGEF1B activated small G protein Rap2 that we 
detected at the midzone/midbody, was previously reported to colocalize with Rab11-
positive endosomes in Xenopus early embryos [44]. Importantly, Rab11-positive 
recycling endosomes containing the effector protein FIP3 (Rap11 Family of 
Interacting Protein 3) were previously shown to control the reorganization of the 
cortical actomyosin network during cytokinetic abscission, as they accumulate at the 
intercellular space between dividing cells and regulate local actin depolymerization 
by recruiting p50RhoGAP, and thus contributing to further thinning of the bridge 
[45].   
In this study, we primarily focused on the biological significance of the interaction 
between Ccdc124 and RasGEF1B, rather than studying mechanistic aspects of it. 
Yet, our studies on the effect of bacteria purified Ccdc124 on the rate of nucleotide 
exchange by RasGEF1B on Rap2A in in vitro reconstituted assay systems suggested 
that Ccdc124 does not functionally interfere with RasGEF1B activity (Elif Yaman, 
Alfred Wittinghofer, Uygar H. Tazebay, unpublished observations). We could 
hypothesize that rather than modulating its GEF activity, Ccdc124 could recruit 
RasGEF1B to midzone/midbody where the exchange factor activate its substrate G 
protein(s). A similar spatiotemporal regulation of Rap1 signaling localized at the 
plasma membrane by recruitement and translocation of its cAMP responsive GEF, 
Epac1, through activation of Ezrin-Radixin-Moesin (ERM) complex proteins was 
previously described [46]. 
We have shown that both the activator RasGEF1B and its partner G protein Rap2 
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have identical spatiotemporal subcellular distributions (Fig. 8). This indicated that 
RasGEF1B could potentially activate GDP/GTP exchange of Rap2 at midbody 
during late-telophase stage of cell cycle and at cytokinesis. Importantly, we observed 
the RasGEF1B substrate Rap2, but not its close homologue Rap1, accumulated in 
vesicular structures proximal to the midzone and at the midbody (Fig. 9A, see panels 
metaphase to cytokinesis, and Fig. S5). Detection of active Rap2 (Rap2.GTP) 
binding reporter protein GFP-RBD(RalGDS) in midbody further proved local 
activation of Rap2 at midbody puncta during cytokinesis (Fig. 10). This midbody 
localization of GFP-RBD(RalGDS), was only observed in cells having Rap2-WT, 
but not its dominant negative form, Rap2-S17N, indicating that midbody localization 
of Rap2 effectors requires activation of this small G protein (Fig. 10B). Neither 
cellular depletion of endogenous Rap2 by specific shRNA transfections, nor over-
expression of the dominant negative form of Rap2 (S17N) has led to cytokinesis 
defects, as assessed by normal levels of bi- and multinucleated cells in corresponding 
cellular assays (Fig. 8, 10). Therefore, in our opinion rather than playing a direct role 
in cytokinesis, localization of Rap2 at the midbody might serve to modulate and/or 
functionalize local membrane environment for molecular events following 
cytokinetic abscission, such as establishment of cell-cell junctions, cell-extracellular 
matrix adhesions, or polarizations of cells after division of daughter cells fully 
accomplished. When we consider results obtained in this study altogether, we 
propose Ccdc124 as a novel factor that links cytokinesis to Rap signaling dependent 
junction/adhesion or cellular polarization promoting molecular mechanisms, thus 
bonding different cellular events that must closely follow each other in tissues of live 
organisms.  
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Methods 
Ethics Statement 
All cell lines of human origin used in this study were obtained legally either from 
commercial sources, or they were previously published. Material transfer agreements 
were duly signed between appropriate offices/persons-in-charge at donating and 
receiving institutions. 
Cell culture and reagents 
Hek-293 and HeLa cells were maintained in DMEM and Retinal Pigment Epithelial-
1 (RPE1) cells were grown in DMEM/F12 (1:1) supplemented with 10% FBS and 
kept at 37 °C in a humidified 5% CO2 atmosphere. Cell lines used in this work were 
either from commercial sources, or described in previous publications. RPE1 cells 
[26] were obtained from Nurhan Özlü (Koç University, Istanbul), and RPE1 lines 
stably expressing GFP-Centrin [26], and GFP-Plk1 [47] were gifts from Greenfield 
Sluder (U. Mass. Medical School, MA), and Prasad Jallepalli (Memorial Sloan-
Kettering, NY), respectively. 50 nM of Mission® esiRNA from Sigma-Aldrich (cat. 
EHU004061) was used for silencing Ccdc124 in HeLa cells by using Oligofectamine 
(Invitrogen) as transfection reagent. We have also targeted Ccdc124 expression by 
using the following three shRNA vector constructs prepared in pTRIPZ plasmids 
(Open Biosystems-Thermo) closely following the procedures described by Paddison 
et al. [48]. Ccdc124 specific shRNA sequences inserted in pTRIPZ vectors were as 
follows: shRNA #1: 5’-
TGCTGTTGACAGTGAGCGACTCGACCAGCTGGAACGTAA|GTAGTGAAGC
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CACAGATGTACTTACGTTCCAGCTGGTCGAGGTGCCTACTGCCTCGGA-3’; 
shRNA #2: 5’-
TGCTGTTGACAGTGAGCGACGAGACCATCAGCTCAGGGA|GTAGTGAAGC
CACAGATGTACTCCCTGAGCTGATGGTCTCGGTGCCTACTGCCTCGGA-3; 
shRNA #3: 5’-
TGCTGTTGACAGTGAGCGACCCAAGAAGTTCCAGGGTGA|GTAGTGAAGC
CACAGATGTACTCACCCTGGAACTTCTTGGGCTGCCTACTGCCTCGGA-3. 
pTRIPZ vector containing scrambled shRNA control were purchased (Open 
Biosystems-Thermo, cat. no. RHS4750). In experiments to rescue cellular effects of 
Ccdc124 knock-downs by specific esiRNAs, 40 ng of pCDN3.1-CMV-Ccdc124 
plasmids were cotransfected with the above indicated amounts of esiRNAs. In order 
to knock-down RasGEF1B expression, a set of five plasmids containing shRNA 
sequences specific for human RasGEF1B gene in pLKO1 vectors, and the 
corresponding scrambled shRNA control plasmid were purchased (Open 
Biosystems-Thermo) with the catalog number RHS4533 (TRC Lentiviral shRNAs) 
and following sequences: 1) Oligo ID: TRCN0000072963, 5’-
CCGGGCTGACAGATAGACTCAGATTCTCGAGAATCTGAGTCTATCTGTCA
GCTTTTTG-3’, renamed as sh-A; 2) Oligo ID:  TRCN0000072964, 5’-
CCGGCGGAAACATTTCCCTATGATTCTCGAGAATCATAGGGAAATGTTTC
CGTTTTTG-3’, renamed as sh-B; 3) Oligo ID:  TRCN0000072965, 5’-
CCGGCGGTTATTTATGCATCCGTATCTCGAGATACGGATGCATAAATAAC
CGTTTTTG-3’, renamed as sh-C; 4) Oligo ID:  TRCN0000072966, %’-
CCGGGCTCTCTACTTGGCTTCTTATCTCGAGATAAGAAGCCAAGTAGAGA
GCTTTTTG-3’, renamed as sh-D; 5) Oligo ID:  TRCN0000072967, 5’-
 161 
CCGGGAAGCACTCATCCAGCACTTACTCGAGTAAGTGCTGGATGAGTGCT
TCTTTTTG-3’, renamed as sh-E. Similarly, for decreasing Rap2 expression, a set of 
three plasmids containing shRNA sequences specific for human Rap2 gene in pGIPZ 
vectors, together with the corresponding scrambled shRNA control vector were 
purchased (Open Biosystems-Thermo) with the catalog number RHS4531 (TRC 
Lentiviral shRNAs) and following sequences: 1) Oligo ID: V2LHS_34663, 5’-
TGCTGTTGACAGTGAGCGCACTCAGAACAGGTTATGTAAATAGTGAAGC
CACAGATGTATTTACATAACCTGTTCTGAGTTTGCCTACTGCCTCGGA-3’, 
renamed as sh-1; 2) Oligo ID:  V2LHS_34666, 5’-
TGCTGTTGACAGTGAGCGAAGAGATATAGTTCACAGTTAATAGTGAAGC
CACAGATGTATTAACTGTGAACTATATCTCTGTGCCTACTGCCTCGGA-3’, 
renamed as sh-2; 3) Oligo ID:  V2LHS_34662, 5’-
TGCTGTTGACAGTGAGCGCTGACCTTGTGTCACTATTTATTAGTGAAGCC
ACAGATGTAATAAATAGTGACACAAGGTCAATGCCTACTGCCTCGGA-3’, 
renamed as sh-3. When indicated, cells were synchronized by a first thymidine block 
(2,5 mM) for 16 hours, released for 8 hours, and then blocked a second time with 
thymidine for 16 hours, followed by 200 nM nocodasole treatment/12 hours. Mitotic 
arrested cells were collected by “mitotic shake-off”, and either they were analyzed 
directly (0 min.), or recultured for 15, 30, 45, 60, 120, 150, and 180 mins. At the 
beginning of the experiments cell cycle status of samples were established by FACS 
analysis as described in Fabbro et al. [13] and at each time point cells were processed 
for immunofluorescence.  
Vector Constructions 
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pCDNA3.1 was used to generate CMV-promoter controlled Ccdc124 expression 
vector construct by using EcoRI/BamHI restriction sites and 5’-
AAGCTTGAATTCATGCCCAAGAAGTTCCAGGGTGAG-3’ (forward) and 5’-
GGTACCGGGATCCTCTTGGGGGCATTGAAGGGCAC-3’ (reverse) primers. 
Cloning of RasGEF1B into pEGFP-C1 (Clontech) was done by using 5’- 
GTCGACGAATTCTTAAACTCTGCCTAAGAGGCTCGACC-3’ (forward), and 
5’-GTCGACGAATTCTTAAACTCTGCCTAAGAGGCTCGACC-3’ (reverse) 
primers and XhoI/EcoRI sites. Flag-tagged Ccdc124 expressing vectors were 
constructed by sub-cloning the gene in p3X-Flag-CMV10 or p3X-Flag-CMV14 
vectors (Sigma) by using 5’-
CTTGAATTCATGCCCAAGAAGTTCCAGGGTGAG-3’ (forward) / 5’-
GACCGGGATCCTCTTGGGGGCATTGAAGGGCAC-3’ (reverse) and 5’-
CTTGAATTCATGCCCAAGAAGTTCCAGGGTGAG-3’ (forward) / 5’-
GGATCCTCTAGAGTCCTTGGGGGCATTGAAG-3’ (reverse) primers together 
with EcoRI/BamHI, and EcoRI/XbaI restriction enzyme sites, respectively. HA-
epitope linked versions of Rap2 in Rap2-WT-HA, Rap2-G12V-HA, and Rap2-S17N-
HA vectors were kind gifts of Daniel Pak (University of California, Berkeley). GFP-
RBD(RalGDS) expression vector was a gift from Johannes L. Bos (University 
Medical Center Utrecht, the Netherlands). 
Rap Activity Assays 
Rap activity assays were carried-out as described previously by van Triest and Bos 
[31]. Briefly, HEK-293 cells grown in 6-cm plates were lysed in buffer containing 
1% NP-40, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 10% glycerol, 2 mM MgCl2, 
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and protease and phosphatase inhibitors. Lysates were cleared by centrifugation, and 
active Rap was precipitated with a glutathione S-transferase fusion protein of the 
Rap-binding domain of RalGDS precoupled to glutathione-Sepharose beads. 
Immunoprecipitation, Immunoblotting and GST-Pull Down Assays 
Cells lysed in 50 !l lysis buffer consisting of 50mM Tris 8.0 Base, 250mM NaCl, 
proteinase inhibitor cocktail (Roche), and 1% NP40. Protein concentrations were 
determined by using Bradford assay. 40µg of whole cell extracts were denatured in 
gel loading buffer [50 mM Tris-HCl pH 6.8, 1% SDS, 0.02% bromophenol blue, 
10% Glycerol and 5% 2-mercaptoethanol] at 95°C for 5 min, resolved by SDS-
PAGE using a 12% gel, and electrotransferred onto PVDF membranes (Millipore). 
For RasGEF1B/Ccdc124 coimmunoprecipitation experiments, HEK-293 cells were 
transfected with flag-Ccdc124 and YFP-Rasgef1B vectors. 48 hours later, cells were 
lysed in NP-40 lysis buffer, flag-tagged agarose beads (A2220, Sigma-Aldrich) were 
used to precipitate proteins for two hours, followed by a centrifugation for 30 sec. at 
8800 rpm, then beads were washed three times with NP-40 lysis buffer. 50µl sample 
buffers were added to lysates and incubated at 95°C for 5 min, fractionated by SDS-
PAGE for immunoblot analysis and transferred onto PVDF membranes (Millipore). 
Anti-GFP (G1544, Sigma-Aldrich) and anti-Flag-HRP M2 (A8592, Sigma-Aldrich) 
were used in Western blot analysis. Blotted proteins were visualized using the ECL 
detection system (Amersham). For GST pull-down assays, 100!l 50% slurry (~50!l 
packed) GSH beads were washed 3 times with wash buffer (50mM Tris HCl pH 7.5, 
100mM NaCl, 3mM "-Mercaptoethanol). First two vials were immobilized with 
200!g purified GST-RasGEF1B protein, second vial was immobilized with 200!g 
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GST protein, whereas the fourth vial was incubated with buffer only and rotated at 
4#C for 1 hour. The first and the third vials incubated with wash buffer only, second 
and fourth vials incubated with 500!g bacteria purified His-Ccdc124 protein and 
incubated at 4#C for 1 hour by rotating. Beads were washed 10 times with wash 
buffer, and samples were eluted with 40!l 4xSDS loading buffer, boiled for 5 min 
and loaded on an SDS gel. For the control of protein sizes samples from a 10µg/µl 
stock of each protein were loaded to the same gel. The gel then stained with 
commassie blue and destained with water. 
Generation of polyclonal antibodies 
3 mg of N-terminus 24mer peptide MPKKFQGENTKSAAARARRAEAK-[C]-
amide of human Ccdc124, and [C]-NNMEKDR-W-KSLRSSLLNRT peptide 
corresponding to partly conserved C-terminus of the zebra fish homologue of 
RasGEF1B (Danio rerio RasGEF domain family member 1Ba, NCBI accession 
number: NM_199829) were coupled to KLH through their inserted cysteine residues 
via MBS, and Both peptides were used in rabbit immunizations at the Cambridge 
Research Biochemicals (Cambridge, United Kingdoms). 10 mg of each peptide 
affinity column purified (Glycine and TEA eluates) antibodies and pre-immune 
control sera were then received for use in molecular biology research. 
Immunofluorescence 
HeLa cells on cover slips were fixed by ice cold 100% Methanol for 10 min at -20°C, 
washed three times with PBS-T; blocked in 2% BSA for 1 hour and incubated 1 hour 
with primary antibodies, washed again three times with PBS-T and incubated for 1 
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hour with suitable secondary antibodies. Sources of antibodies: Plk1 a gift from 
Nurhan Özlü, Koç University, Istanbul; monoclonal (ab17057), or polyclonal 
(ab109777) Abs were purchased from Abcam; anti-RasGEF1B-C-ter epitope Ab and 
anti-Ccdc124-N-ter epitope Ab were custom produced by Cambridge Research 
Biochemicals-UK (see above), Ccdc124 middle-epitope specific (A-301-835A) or C-
ter epitope specific (A-301-834A) Abs were from BETHYL Laboratories; anti-!-
tubulin were either from Abcam (ab11316), or from BioLegend (rabbit polyclonal 
cat.620902); anti-"-tubulin were from Santa Cruz (SC-5286); rabbit anti-flag-Ab 
was from Sigma (F-7425); rabbit anti-Rap2 polyclonal was purchased from Genetex 
(GTX108831); mouse anti-Rap2 monoclonal was from BD Biosciences (610215), 
DNA dye (DAPI) was from Invitrogene (P36931); and Alexa Fluor 488, or 568 
labeled anti-rabbit, and anti-mouse secondary antibodies were purchased from 
Invitrogene. 
Fluorescent microscopy and imaging 
Fluorescent images were done by Zeiss Imager-A1 microscope with a Zeiss 
Acroplan 40X objective. Images were captured on the Zeiss Axia Cam MRc 5- CCD 
camera for fixed samples. Microscope control and image processing were done 
through Axiovision version 4.6 software program (Universal Imaging).  
Northern blot analysis 
Northern blotting was performed on commercially obtained "FirstChoice Northern 
Human Blot-1 and Blot-2 Membranes" (Ambion) which contained 2 !g poly(A)-
RNA from indicated human organs on each lane. Donor information is available at 
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the suppliers (Ambion) documents; human derived materials have been prepared in 
the mentioned company from tissues obtained with consent from a fully informed 
donor, or a member of the donor’s family, as certified by the company. DNA probes 
used in hybridizations were as follows: ApaI-XbaI DNA fragment (381 bp) of 
CCDC124 cut-out from Flag-Ccdc124 plasmid vector, GAPDH fragment (408 bp) 
obtained after PCR amplification of a HeLa cell cDNA library by using forward 
primer 5’-GGCTGAGAACGGGAAGCTTGTCAT-3’ and reverse primer 5’-
CAGCCTTCTCCATGGTGGTGAAGA-3’ as amplification primers, and "-actin 
fragment (539 bp) obtained after PCR amplification of the same cDNA library by 
using forward 5’- GATGACCCAGATCATGTTTG-3’ and reverse 5’- 
CATGGAGGAGCCGCCAGACAGC-3’ primers in PCR amplifications in the 
following conditions: 5 min initial denaturation at 95˚C, 35 cycles of 30 sec 
denaturation at 95˚C, 30 sec primer annealing at 60˚C and 30 sec extension at 72˚C, 
and a 5 min final extension at 72˚C. Then, DNA templates corresponding to expected 
band sizes were isolated from agarose gels, labeled by North-2-South Biotin random 
prime labeling kit (Pierce). Nucleic acids hybridization and detection were done by 
North-2-South Chemiluminescent hybridization and detection kit (Pierce). Resulting 
blots were exposed to autoradiography films (Kodak).  
Identification of CCDC124-interacting proteins by using the yeast two-hybrid 
(Y2H) screening method  
Bait cloning and Y2H screening were performed by Hybrigenics, S.A., Paris, 
France (http://www.hybrigenics.com). Human CCDC124 cDNA (encoding 223 
a.a protein) was PCR-amplified and cloned in a LexA C-terminal fusion vector. The 
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bait construct was checked by sequencing the entire insert, and was subsequently 
transformed in the L40 GAL4 yeast strain [49]. Then, a human liver cDNA library 
containing ten million independent fragments were transformed into the Y187 yeast 
strain, which was used for mating. The screen was performed in conditions ensuring 
a minimum of 50 million interactions tested, in order to cover five times the primary 
complexity of the yeast-transformed cDNA library. After selection on medium 
lacking leucine, tryptophane, and histidine, 15 positive clones were picked, and the 
corresponding prey fragments were sequenced at their 5' and 3' junctions. Sequences 
were contigued as described previously, and then they were compared to the latest 
release of the GenBank database using BLASTN [50]. A Predicted Biological Score 
(PBS) was attributed to assess the reliability of each interaction, as described 
previously [51]. 
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Figure Legends 
Figure 1. CCDC124 mRNA is ubiquitously expressed in human tissues, and it 
encodes a 32 kDa protein. (A) Hybridization of part of the coding region of 
CCDC124 to an adult human multiple tissue Northern blot containing 2µg of polyA-
mRNA each lane. A single transcript of !1061 nucleotides was detectable in all 
human tissues analyzed, except the placenta with a second smaller transcript variant. 
The same blot was rehybridized with probes corresponding to two differentially 
expressed genes, "-actin and GAPDH, to monitor blotting quality. (B) Specific 
detection of ectopically expressed Ccdc124 by anti-Ccdc124 antibodies. HEK-293 
cells, either non-transfected, or transfected with CMV-promoter controlled Ccdc124 
were lysed, protein lysates were separated by SDS-PAGE, and immunoblot was 
performed either with anti-Ccdc124 antibodies alone, or same antibodies pre-
incubated with 100 ng of competing peptide epitope corresponding to N-terminus 
24mer peptide of Ccdc124. (C) Expression of Flag-tagged Ccdc124 protein was 
specifically detected by the anti-Ccdc124 or with anti-Flag antibodies, as indicated. 
Asterisk (*) indicates C-terminus flag-tag insertion dependent N-terminus cleaved 
form of Ccdc124. The expression of calnexin was confirmed in all cell lysates as an 
equal loading control. 
Figure 2. Ccdc124 is present at the centrosome and it concentrates at the 
midbody in late stages of cytokinesis. (A) HeLa cells were arrested at G2/M phase 
by sequential double thymidine and nocodazole treatments, then the drug was 
washed-off, cells were analyzed by immunofluorescence at time points with intervals 
of 15 minutes, and they were classified according to phases of mitosis, and 
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cytokinesis. Samples of cells were then costained with anti-Ccdc124 and anti-!-
tubulin antibodies, and in interphase and prophase, Ccdc124 was observed as puncta 
in cells, and it is located in the MTOC area. In metaphase and anaphase cells, 
Ccdc124 appeared at the spindle poles. Ccdc124 was present at the midzone and at 
the spindle poles in late anaphase, and concentrated in the midbody during 
cytokinesis. (B) HeLa cells were transfected with the N-ter flag-Ccdc124 vector 
construct as in Fig. 1. 48 hours later samples of cells were subjected to 
immunofluorescence costainings using anti-flag and anti-!-tubulin Abs together. 
Representative micrographs of cells at different stages of cell cycle are given. Bars 
represent 10 µm. 
Figure 3. Ccdc124 accumulates at the midbody. HeLa cells were synchronized as 
described in the legend of Fig. 2, and samples of cells were then stained with anti-
Ccdc124 Ab together either with anti-!-tubulin or with anti-"-tubulin Abs to monitor 
subcellular positions of centrosomes and the midbody. (A-B) At telophase and 
cytokinesis Ccdc124 is observed as puncta typically associated with the midbody 
positioned at the middle of intercellular bridge separating daughter cells, as detected 
in costainings with anti-!-tubulin and anti-"-tubulin Abs, respectively. (C) Peptide 
competition assays were done by pre-incubating anti-N-ter-Ccdc124 antibody with 
the corresponding epitope peptide in 200-fold molar excess amounts. Signals 
generated by Ccdc124 localized at the midbody (shown with arrowhead) were lost in 
immunofluorescence assays where peptide pre-treated antibodies were used. Bars 
represent 10 µm. 
Figure 4. Depletion of Ccdc124 in HeLa cells by RNAi leads to cytokinesis 
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failure. (A) HeLa cells were transfected with either esiRNAs or shRNA vectors 
(Sh1, Sh2, Sh3) targeting Ccdc124, cell lysates were collected at 48 hrs post-
transfection, and immunoblotted with antisera to Ccdc124. Where indicated, 
Ccdc124 expression vector (CMV-Ccdc124) was cotransfected with gene-specific 
esiRNAs in order to rescue the cellular effect of Ccdc124 depletion. Scrambled 
control transfections were indicated (Scr). Calnexin expression was monitored as 
loading control. (B) Immunostainings of endogenous Ccdc124 in cells transfected 
with Ccdc124-specific esiRNA, or with scrambled control esiRNA were carried out 
with anti-Ccdc124 Ab.  Costainings with !-tubulin antisera have indicated 
subcellular positions of MTOCs (C) Cells described and analyzed in (A) were scored 
for bi- and multinucleation (n=5 ± SD). (D) Representative micrographs of Ccdc124 
depleted multinuclear or control esiRNA treated normal dividing cells described in 
(C). Bars represent 10 µm. 
Figure 5. RasGEF1B is an interaction partner of Ccdc124. (A) In vitro GST pull-
down assay indicating a possible interaction between RasGEF1B and Ccdc124. GST-
RasGEF1B protein were immobilized on GSH-beads, followed by incubation with 
empty PBS buffer control (lane 1), or with bacteria purified His-tagged Ccdc124 
(lane 2). As controls, GSH-beads w/o RasGEF1B protein incubated with His-
Ccdc124 to monitor the amount of His-Ccdc124 proteins binding to GSH-beads in 
the absence of a putative interaction partner (lane 3), or GSH-beads immobilized 
with GST protein and incubated with His-Ccdc124 to monitor interaction capacity of 
Ccdc124 with GST (lane 4). Lanes 5, 6, 7 are stainings of 100 ng bacteria purified 
GST-RasGEF1B, His-Ccdc124, and GST proteins, respectively, run in the same gel 
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to monitor their corresponding sizes. Bands corresponding to His-Ccdc124 were 
marked with asterisks (*). (B) HEK-293 cells were either transfected with Flag-
Ccdc124 or GFP-RasGEF1B expression vectors alone or with indicated control 
plasmids, or alternatively they were co-transfected with Flag-Ccdc124 and GFP-
RasGEF1B together, followed by immunoprecipitations (IP) on cell lysates using 
protein-G beads with anti-Flag antibodies. Subsequently, immunoblots were done on 
IP or cell lysate samples using anti-GFP (monitoring GFP-RasGEF1B) or anti-Flag-
HRP (to assess Flag-Ccdc124) antibodies.  
Figure 6. RasGEF1B and Ccdc124 colocalize at the midbody (A-B) Subcellular 
localizations of RasGEF1B proteins in synchronously dividing HeLa cells were 
detected with specific anti-RasGEF1B antibodies. Cell divisions were synchronized 
as described in the legend of Figure 2, above. Representative immunofluorescence 
microscopy images of HeLa cells costained with anti-RasGEF1B, and either anti-!-
tubulin (A) or "-tubulin (B) antibodies illustrating the position of MTOCs and the 
midbody at cytokinesis. Arrowheads show RasGEF1B detected at the midzone and 
the midbody. (C) Immunofluorescence signals observed at midbody were 
significantly decreased when endogenous RasGEF1B were depleted by transfections 
with specific shRNA vectors (Sh-C or Sh-D, Fig. S4) and representative micrographs 
were shown. (D) HeLa cells transiently transfected with GFP-RasGEF1B were fixed 
and stained using anti-Ccdc124 Abs. Arrowheads indicate midbody positions of 
GFP-RasGEF1B, Ccdc124, and their colocalizations at the midbody. Bars represent 
10 µm. 
Figure 7. The guanine nucleotide exchange factor RasGEF1B controls cellular 
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Rap2.GTP status. HEK-293 cells were transfected either with RasGEF1B specific 
shRNA expressing vector (Sh-D, Figure S4), scrambled shRNA expressing vector, or 
empty vector (negative control), 48 hrs later cells were lysed as described at 
Materials and Methods, they were cleared by centrifugation, and active Rap was 
precipitated with a glutathione S-transferase fusion protein of the Ras-binding 
domain of RalGDS precoupled to glutathione-Sepharose beads. Rap2 activation 
assay were carried-out by using anti-Rap2 monoclonal Abs. Results confirmed that 
shRNA mediated down-regulation of RasGEF1B expression effectively block 
generation of Rap2.GTP, although total cellular Rap2 was not affected. Calnexin 
expression was monitored as loading control.  
Figure 8. Rap2 colocalize with Ccdc124 and RasGEF1B at the subcellular level.  
Subcellular localizations of endogenous Rap2 and Ccdc124 or RasGEF1B proteins 
were studied in HeLa cells by immunofluorescence methods. (A) At anaphase, Rap2 
was clearly localized at the midzone, while Ccdc124 concentration at the same 
localization was less pronounced. However, at telophase, both proteins were 
concentrated at the puncta characterizing the midbody, Rap2 rather surrounding 
Ccdc124. During cytokinetic abscission, a clear colocalization of both Rap2 and 
Ccdc124 were observed at the midbody. (B) Similar to panel (A), Rap2 translocation 
to the midzone has started during anaphase. Two representative images of anaphase 
cells were shown in the corresponding panel. Both Rap2 and RasGEF1B proteins 
colocalized at the midbody during cytokinetic abscission. Arrowheads either indicate 
subcellular localization of Rap2 at anaphase and telophase, or they indicate the 
colocalization of Rap2 with RasGEF1B/Ccdc124 at the midbody during cytokinesis. 
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(C) HeLa cells were transfected with shRNA vectors (Sh1, Sh2, Sh3) targeting Rap2, 
then cell lysates were collected at 48 hrs post-transfection, and immunoblotted with 
anti-Rap2 Ab. Scrambled control transfection was indicated (Scr). Calnexin 
expression was monitored as loading control. In parallel experiments, similarly 
treated cells were immunostained with anti-Rap2 and anti-"-tubulin antibodies, 
followed by scorings for multinucleation (n=5 ± SD), as reported on the graph above 
the immunoblot. (D) Representative micrographs of midbody stage cells depleted in 
endogenous Rap2 (C). Bars represent 10 µm. 
Figure 9. Active endogenous Rap2 relocates to midzone at anaphase, and to 
midbody during cytokinetic abscission. (A) HeLa cells were arrested at G2/M 
phase by sequential double thymidine and nocodazole treatments as described in the 
legend of Figure 2, and they were classified according to phases of mitosis, and 
cytokinesis. Samples of cells were then stained with anti-Rap2 antibody, and with 
DAPI to visualize DNA. At anaphase Rap2 was detected at the midzone with 
staining characteristics reminiscent of endosomes, and at telophase/cytokinesis Rap2 
was observed as puncta at the middle of the intercellular bridge, a position typically 
occupied by midbody associated factors. (B) Following synchronization of cells as 
above, 80 mins. after nocodazole was washed-off samples were taken with four 
consecutive intervals of 10 minutes (I, II, III, and IV), the last one (IV) 
corresponding to ~120 minutes after the drug was removed, and dynamic positioning 
of Rap2 at the intercellular bridge in respect to "-tubulin was monitored. A time-
dependent relocalization of Rap2 from peripheral flanking regions to the midbody 
was detected. Intercellular bridge localizations of Rap2 were concluded with 
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observations from a sample of ~50 cells in which over 75% showed similar 
positioning patterns. Two sets of representative micrographs were displayed. Bars 
represent 10 µm. 
Figure 10. Rap2 effector proteins translocate to the midbody depending on the 
signal transduction activity of Rap2. (A) HeLa cells were transfected with the 
vector containing GFP-labeled Rap Binding Domain of RalGDS [GFP-
RBD(RalGDS)] which interacts only with the GTP-bound active form of Rap2, and 
cells were monitored at interphase and at cytokinetic abscission following 
immunostainings involving anti-Rap2 monoclonal Abs and Alexa568-red labeled 
anti-mouse secondary Abs.  Colocalization of GFP-RBD(RalGDS) with Rap2 
indicated that at the midbody Rap2 is in its active (Rap2.GTP) form.  (B) HeLa cells 
were cotransfected with GFP-RBD(RalGDS) either together with HA-Rap2-WT, or 
with HA-Rap2-S17N (inactive dominant negative form) and their localizations were 
monitored with anti-HA-epitope Abs. Positioning of GFP-RBD(RalGDS) were 
assessed by monitoring GFP-signal observed at the midbody. Localization of the 
GFP-RBD(RalGDS) depended on the presence of active Rap2 in cells. As in (A), at 
least 50 cells were monitored in each experiment, and representative pictures display 
Rap2 and GFP-RBD(RalGDS) localizations observed at least ~90% of cells 
cotransfected with indicated vectors. Bars represent 10 µm. 
Supporting Information Figures 
Figure S1. Ccdc124 contains two main coiled-coil domains at its N-terminal 
part. Schematic representation of the coiled-coil prediction of Ccdc124 is presented. 
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The graph was obtained by the COILS 
(www.ch.embnet.org/software/COILS_form.html) bioinformatics analysis platform.  
 
Figure S2. Double-thymidine and nocodazole treatments synchronized HeLa 
cells at G2/M phase of cell cycle. HeLa cells were treated with thymidine and MT 
polymerization inhibitor drug nocodazole as indicated in Methods. 1x106 
unsynchronized (A) or synchronized (B) cells were collected as samples, and 
resuspended in 0.3 ml of PBS buffer. Cells were fixed by addition of 0.7 ml cold 
ethanol (70%), left on ice for 1hr, and then washed and resuspended in 0.25 ml of 
PBS in which it is treated with 0.5mg/ml RNAse-A for 1 hr at 37°C. Cellular DNA is 
then stained with 10 µg/ml propidium iodide (PI) solution, and cytometric analysis 
was performed by FACS at 488 nm. Percentages of cells in each sample at various 
stages of the cell cycle are indicated below each panel (A-B). 
 
Figure S3. Polyclonal Anti-RasGEF1B antibody raised against zebrafish 
homologue of RasGEF1B cross-reacts strongly with human RasGEF1B. HEK-
293 cells were transfected with mCherry-labeled human RasGEF1B or YFP-labeled 
human RasGEF1B expression vectors (mCherry-RasGEF1B and YFP-RasGEF1B, 
respectively), after 48 hours cells were lysed, proteins were separated by SDS-
PAGE, and immunoblot was performed with anti-RasGEF1B antibody alone (1 µg at 
1:1000 dilution), and then the membrane was stripped and sequentially reprobed first 
with the same antibody pre-incubated with 100 ng of competing 20mer peptide 
epitope [C]-NNMEKDR-W-KSLRSSLLNRT corresponding to C-terminus of ZF-
RasGEF1B, and then with anti-GFP antibody recognizing YFP as its epitope in YFP-
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RasGEF1B. Calnexin expression was monitored as loading control.  
 
Figure S4. Screening of RasGEF1B specific shRNA plasmids to monitor their 
down-regulatory capacities. HEK-293 cells were transfected with RasGEF1B 
shRNA plasmids described in Supplementary Materials and Methods. 48 hours after 
transfections, cells were lysed and proteins were separated by SDS-PAGE. 
Immunoblot was performed with custom made anti-RasGEF1B antibody. Image-J 
software program were used to obtain densitometric readings of band intensities 
corrected by calnexin values, and these were indicated below each band. RasGEF1B 
specific shRNA expressing vector renamed as sh-D (see Supplementary Materials 
and Methods) was selected to carry-out experiments described in Results. Calnexin 
expression was monitored as loading control.  
 
Figure S5. Endogenous Rap1 does not relocate to the midzone/midbody during 
cytokinetic abscission. HeLa cells were arrested at G2/M phase by sequential 
double thymidine and nocodazole treatments as described in the legend of Figure 2, 
and they were classified according to phases of mitosis, and cytokinesis. Samples of 
cells were then costained with anti-Rap1 and anti-"-tubulin antibodies, which were 
used to monitor intercellular bridge and the space containing midbody complexes. 
DAPI staining was used to visualize DNA. Bars represent 10 µm. 
 
Figure S6. Mutating the consensus CK2 phosphorylation site Ser122 to Ala 
leads to compromised stability of Ccdc124. (A-B) HEK-293 cells were transfected 
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either with HA-tagged wild-type Ccdc124 expression vector, or with similar vectors 
carrying indicated mutations on Figures, and stabilities of mutants proteins were 
monitored by immunoblots using anti-Ccdc124 antibodies recognizing the N-
terminus of the protein. Only one CK2 phosphorylation consensus site (Ser122) 
turned out to be essential for the stability of Ccdc124 protein as S122A mutants were 
cleaved at their C-terminus, whereas phospho-mimicking mutations S121D, and 
S121E were normal in terms of Ccdc124 stability (B). Calnexin expressions were 
monitored as loading control.  
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ABSTRACT
Activity of the sodium/iodide symporter (NIS) in
lactating breast is essential for iodide (I–) accumula-
tion in milk. Significant NIS upregulation was also
reported in breast cancer, indicating a potential
use of radioiodide treatment. All-trans-retinoic acid
(tRA) is a potent ligand that enhances NIS expres-
sion in a subset of breast cancer cell lines and in
experimental breast cancer models. Indirect tRA
stimulation of NIS in breast cancer cells is very
well documented; however, direct upregulation
by tRA-activated nuclear receptors has not
been identified yet. Aiming to uncover cis-acting
elements directly regulating NIS expression, we
screened evolutionary-conserved non-coding
genomic sequences for responsiveness to tRA in
MCF-7. Here, we report that a potent enhancer in
the first intron of NIS mediates direct regulation by
tRA-stimulated nuclear receptors. In vitro as well as
in vivo DNA–protein interaction assays revealed
direct association between retinoic acid receptor-a
(RARa) and retinoid-X-receptor (RXR) with this
enhancer. Moreover, using chromatin immunopre-
cipitation (ChIP) we uncovered early events of NIS
transcription in response to tRA, which require the
interaction of several novel intronic tRA responsive
elements. These findings indicate a complex inter-
play between nuclear receptors, RNA Pol-II and
multiple intronic RAREs in NIS gene, and they estab-
lish a novel mechanistic model for tRA-induced
gene transcription.
INTRODUCTION
In alveolar cells of the lactating mammary gland, the
activity of Na+/I– symporter (NIS) is required for the
secretion of I– in mother’s milk (1,2). I– in milk is then
used by the newborn in thyroid hormone biosynthesis, and
therefore it has an essential role in postnatal development
of the baby (3). The timing of NIS expression in mammary
epithelia is precisely synchronized with the onset of gesta-
tion and with lactation, and it ends when newborns stop
suckling (2). NIS is not expressed in non-lactating
mammary gland tissue unless experimental animals were
treated with combinations of steroid and lactogenic
hormones (2,4,5). Yet, a functional overexpression of
NIS was detected in transgenic mice bearing experimental
mammary tumors induced by mouse mammary tumor
virus (MMTV) promoter-driven activated Ras and
Erb-B2/neu oncogenes, polyoma middle-T antigen
(PyMT), or cyclooxygenase-2 gene (2,6,7).
Relevant with the human breast cancer, increased NIS
expression was also detected in about 70–80% of ductal
carcinoma in situ and invasive breast cancer samples, as
compared to the absence of NIS expression in healthy
breast samples obtained in reductive mammoplasty oper-
ations (2,8). On the one hand, these results have raised the
possibility that radioiodide may be used for diagnosis and
treatment of breast cancer, as it is routinely used against
thyroid cancer and its metastasis (9). On the other hand,
only a small fraction of these NIS-positive tumors has the
capacity to accumulate radio-labeled substrates of the
symporter (2,4,8), suggesting that further enhancement
of NIS expression or post-translational activation of
NIS are required for an effective use of radio-labeled
substrates for imaging and/or treatment of malignant
breast disease.
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Related with this, a number of hormones or ligands,
such as retinoids (natural or synthetic analogs of vitamin
A), human chorionic gonadotropin (hCG), dexame-
thasone (Dex) and troglitazone (a PPAR-g ligand), were
identified as molecules having an upregulatory effect on
NIS expression and I– transport in the ERa-positive
(ERa+) breast cancer cell model, MCF-7 (6,10–12).
Retinoids have the most robust effect on NIS transcrip-
tion, and among this group of ligands, all-trans-retinoic
acid (tRA) is the most potent as it leads to an increase
up to 10-fold both at the transcriptional level, as well
as at the level of I! transport (10–12). Moreover, in
immunodeficient mice model with MCF-7 cell xenografts,
systemic tRA treatment stimulated NIS expression and
radioiodide uptake around 15-fold in the implemented
graft (7).
We have previously shown that, tRA induces NIS
expression only in ERa+ mammary cell line models,
and neither basal nor inducible NIS transcription is
observed in ERa-negative (ERa!) mammary cell lines
(13). ERa directly interacts with a responsive element in
NIS promoter, and independent from the presence of
estradiols the presence of ERa is important for maximal
tRA induced NIS transcription (13). tRA stimulates NIS
transcription also in human follicular thyroid carcinoma
cell lines FTC-133 and FTC-238, and in these cells the
effect of tRA is mediated by a RA response element
(RARE) that is located at position –1375 relative to
human NIS start codon (14). Dentice et al. (15) have
shown that the cardiac homeobox transcription factor
Nkx2.5 is induced by tRA, and this factor is involved in
the upregulation of NIS transcription by binding to two
cis-acting elements in NIS promoter.
Conserved transcriptional expression patterns of
orthologous and paralogous genes could reflect common
molecular regulatory mechanisms, as well as the presence
of conserved regulatory cis-acting elements. Results sup-
porting this view have previously been published for the
Drosophila homeotic (hox) gene complex (16), and similar
observations were reported for NIS (17). For instance,
when the entire 50-flanking sequences starting from NIS
coding region up to the upstream neighboring gene
(RPL18A) were compared, it was found that the similarity
between rat and human sequences is only 11.8%. Yet, the
similarity ratios of previously established cis-acting
elements that are located in the same sequence are remark-
ably high, for example, in the NIS upstream enhancer
(NUE), which is a strong thyroid-stimulating hormone
(TSH) responsive enhancer that is localized between
!9470 and !9046 on the human NIS and !2611 and
!2230 on the rat Nis is 70% similar (18,19). Again, as
expected, the basal promoter of the human NIS (–475 to
!393) has "72% similarity with the rat Nis promoter (17).
In this study, we initially undertook a comparative
genomics approach in order to identify evolutionary con-
served sequences that could play a role in tRA-dependent
NIS regulation. Subsequently, our experimental studies
resulted in the identification of a potent intronic
enhancer, which binds RARa and RXR, and upon stim-
ulation by tRA activates NIS promoter both in vitro and
in vivo. We also show that the initiation of transcription by
tRA involves interactions between several identical RARE
sequences found in multiple introns of the gene and RA
stimulated nuclear receptors in vivo. We present a novel as
well as a rather complex and dynamic interplay between
putative RA responsive cis-acting elements, RNA Pol-II
and RA-stimulated nuclear receptors during NIS
transcription.
MATERIALS AND METHODS
Sequence information and databases
Genomic DNA sequences to be analyzed for DNA con-
servation in non-coding sequences were obtained from the
Genome Browser database at the University of California
Santa Cruz (20). The analysis was performed on 90-kb
sequences from Homo sapiens (Release July 2003; Chr.
19: 17816282-17906905), Rattus norvegicus (release June
2003; Chr. 16: 19018698-19107000) and from Mus
musculus (Release October 2003; Chr. 8: 71152446-
71242000). Annotations for the human sequence were
obtained from the Genome Vista database, and sequences
were aligned with the mVista tool using the human
sequence at the x-axis and at 50% conservation level
and a window length of 75 bp.
Polymerase chain reaction amplification
of conserved regions
Conserved regions clustered within about 1 kb were
amplified by polymerase chain reaction (PCR) as one
larger fragment and subsequently cloned into the
reporter vector. PCR amplification was performed in
25-ml reaction volumes containing 0.8#PCR buffer,
3mM MgCl2, 200 mM dNTP, 10 pmol of each primer
(see Supplementary Table S1 for primer sequences), 5%
DMSO, 1U of Taq DNA polymerase (Roche) and 100 ng
of human genomic DNA. Thermal cycler conditions were
an initial denaturation step at 94$C for 4min; a loop cycle
of 94$C, 30 s/62$C, 30 s/72$C, 40 s; and a final extension
at 72$C for 7min.
Reporter vector constructs
The reporter pGL3-E1b is a modified version of the
original plasmid pGL3-Basic (Promega), which contains
the E1b TATA element (50-TCG AGT CTA GAG GGT
ATA TAA TGG ATC-30) between XhoI/BglII sites of
pGL3-Basic; destroying the BglII site while keeping the
XhoI site intact. PCR products containing conserved
regions were cloned into MluI/XhoI sites of pGL3-E1b
to produce the reporter plasmids named clusters (Cl) 1,
2, 3, 4, 5, 6 and 7.
Cluster 3 derivatives containing individual or combined
conserved regions were prepared by restriction endo-
nuclease digestion of internal sequences, or by PCR. The
plasmid Cl3-1 was prepared by removing EspI/XhoI
fragment from cluster 3, likewise plasmids Cl3-pm, Cl3
!3-4, Cl3-xp and Cl3-4 were prepared by removing the
PvuII/MluI, the PstI/SmaI, the XhoI/PvuII and the SacI
fragments, respectively. The plasmids Cl.3-2 and Cl3-3
were prepared by cloning PCR product containing each
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conserved region using the primers shown in
Supplementary Table S2. Subsequently, PCR products
were cloned into MluI/XhoI sites of pGL3-E1b.
The plasmid DR2-1del was created by introducing a
490-bp deletion in Cl4Wt, deletion was created using
restriction enzyme digestion with MluI and BalI. MluI
digested overhangs were filled by incubating the digestion
products with 5U of Klenow fragment of DNA
polymerase I (Fermentas) in the presence of 50 mM
dNTP at 37!C for 1 h prior to ligation.
The plasmid Cl4-R was prepared by cloning the insert
from Cl4Wt into BamHI and SalI sites downstream of the
luciferase reporter. Cl3-pm was created by removing the
sequence between PvuII and MluI from Cl3. The reporter
Cl4-pm was created by replacing the MluI/PvuII fragment
from Cl3 with KpnI/XhoI fragment containing Cl4 insert.
Finally, Cl34-pm was prepared by cloning the insert from
Cl4 into BamHI/SalI of Cl3-pm.
Site-directed mutagenesis
Site-directed mutagenesis was performed on constructs
harboring the retinoic acid response elements in clusters
3 and 4. Summary of the oligonucleotides used in this
procedure is presented in Supplementary Table S2.
PCR-based mutagenesis was performed in 50-ml reaction
volumes containing 40 ng of target plasmid DNA, 1" Pfu
buffer, 200 mM dNTP mix, 100 ng of each primer and
2.5U of Pfu-Turbo DNA polymerase (Stratagene).
Reaction conditions were an initial denaturation step at
95!C for 30 s followed by 15 cycles of 95!C for 30 s/55!C
for 1min/68!C for 6min and 20 s. Following the PCR
reaction the tubes were cooled to 37!C on ice and then
1 ml of DpnI (10U/ml; Fermentas) was added and
incubated at 37!C for 1 h. Following the DpnI digestion
of the parental (methylated) strand, 5 ml were used for
transformation of super-competent E. coli (DH5a) cells.
Plasmids were rescued from single colonies and checked
for the presence of the mutation by automated DNA
sequencing.
Luciferase reporter assay
MCF-7 cells were maintained in high glucose DMEM
(Gibco) supplemented with 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin (P/S) and 1%
L-glutamine (Biochrom), at 37!C in a 5% CO2 incubator.
Cells were transfected with plasmid DNAs using
FuGENE-6 reagent (Roche). FuGENE:DNA ratios
were determined experimentally to be 3:1. Cells were
seeded in 24-well plates in DMEM; so that they would
reach conFuence at the time of the assay. Two days
later, and 1 h prior to transfection, cells were washed
twice with phosphate-buffered saline (PBS), and the
medium was replaced with DMEM lacking antibiotics.
Transfection was carried out with 200 ng of reporter
vector plus 3 ng phRL-TK (Promega) to normalize for
transfection efficiency. Two days post-transfection,
medium was changed with fresh DMEM containing
1 mM tRA (Sigma) and continued incubation for 24 h,
dimethyl sulfoxide (DMSO) was used as vehicle control.
Then the cells were harvested and luciferase reporter
assays were performed using the Dual-Glo Luciferase
Assay system (Promega). Luciferase values for all
samples were normalized by first subtracting the back-
ground of untransfected control, and then dividing
firefly luciferase values over those of Renilla luciferase.
Fold induction is relative to the value of the empty
vector. Fold stimulation was calculated by dividing the
values of the tRA-stimulated sample by the DMSO
control sample and relative to the vector containing
promoter only control. Experiments were performed at
least three times in duplicates.
Electrophoretic mobility shift assay
Nuclear extracts were prepared using the NE-PER
solution (Nuclear and Cytoplasmic Extraction Reagents
– Pierce Biotechnology). Sub-confluent MCF-7 cells
grown in 150-mm plates were treated with 10-nM E2
(for maximal RARa expression) for 6 h and then har-
vested by trypsinization and collected by centrifugation
at 1200 r.p.m. Nuclear protein extraction was performed
using 50 ml packed cell volume samples according to the
manufacturer’s procedure. Oligonucleotide labeling was
performed using the Biotin 30 End Labeling Kit (Pierce
Biotechnology). The labeling reactions contained
1" TdT reaction buffer, 100 nM unlabeled oligo, 0.5mM
Biotin-11-UTP and 10U TdT in 50-ml reaction volumes.
Electrophoretic mobility shift assay (EMSA) experiments
were performed using the Lightshift Chemiluminescent
EMSA kit (Pierce Biotechnology) according to the proto-
cols provided. In brief, binding reactions included
1" binding buffer, 2.5% glycerol, 5mM MgCl2, 50 ng/ml
Poly (dI#dC), 0.05% NP-40, 4 pmol of unlabeled oligo,
5 ml nuclear extract and 20 fmol of biotin labeled oligo.
For the super shift reaction 1 mg of anti-RARa (C-20,
Santa Cruz) or anti-RXR (F-1, Santa Cruz) antibodies
were included to the reaction just before adding the
Biotin labeled oligos (Supplementary Table S2). Binding
reactions were incubated at room temperature for 40min
and then resolved on a 6% native polyacrylamide gel in
0.5" TBE in a minigel electrophoresis apparatus (dimen-
sions 8" 8" 0.1 cm). After electrophoresis, complexes
were electro-transferred to Hybond-N+ nylon mem-
branes (Amersham), and then cross-linked in the GS
Gene Linker (Bio-Rad) at an energy level of 150mJ.
Chemiluminescent detection of biotin-labeled DNA was
performed according to the supplier’s protocol (Pierce
Biotechnology).
Chromatin immunoprecipitation
MCF-7 cells (in 6-well plates) grown in steroid-free and
phenol-red-free DMEM (Gibco) were treated with 1 mM
tRA (Sigma) in the presence of 10 nM estradiol (Sigma).
Formaldehyde cross-linking [1% (w/v)] was performed for
10min at room temperature. Cross-linking was terminated
by the addition of glycine to a final concentration of
125mM. Cells were scraped in PBS, divided into two
tubes and lysed in 400 ml lysis buffer [1% SDS, 10mM
EDTA, 50mM Tris–HCl (pH 8.0) and 1" protease inhib-
itor cocktail]. Cell lysates were then sonicated twice in the
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ultrasonic processor VCX-500 (Sonics and Materials,
INC.), each for 15min at 4!C using a pulse of 30 s and
80% amplitude. Cell lysates were cleared by centrifugation
at 13 000 r.p.m. for 10min, diluted to 6.1ml in dilution
buffer [0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA,
16.7mM Tris–HCl (pH 8.0), 167mM NaCl and
1" protease inhibitor cocktail]. At this point, 100ml of
chromatin solution was removed and labeled as ‘Input’.
Chromatin solution was precleared by adding 50 ml of
protein A-Sepharose CL-4B (GE Healthcare) as 50%
slurry containing 0.5mg/ml BSA (Sigma), 200 mg/ml
sonicated salmon sperm DNA (Sigma) in TE (pH 8.0)
for 60min. at 4!C. Immunoprecipitation was performed
at 4!C for 16 h using chromatin immunoprecipitation
(ChIP)-grade antibodies against RARa (H1920, Abcam),
RXR (F-1, Santa Cruz), Pol-II (N-20, Santa Cruz) and
FGFR1 (C-15, Santa Cruz). Then, immunocomplexes
were incubated with 50 ml protein A-Sepharose (50%
slurry) for at least 16 h at 4!C. Afterwards, beads were
collected, washed four times in wash buffer I [0.1%
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris–HCl
(pH 8.0) and 150mM NaCl], and twice in wash buffer II
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris–
HCl (pH 8.0) and 500 mM NaCl]. Precipitated DNA (as
well as the inputs) was recovered using a solution of 10%
Chelex (Bio-Rad) and Proteinase K, and was used for
qPCR amplification. Primers used for qPCR amplification
are presented in the Supplementary Table S3. Quantitative
real-time PCR was performed using iQTM SYBR! Green
Supermix (BioRad) and amplification was performed in
the Mx3005P! QPCR System (Stratagene) using the fol-
lowing cycling parameters: 95!C for 10min, then 45 cycles
of 95!C for 15 s followed by 64!C for 15 s and 72!C for
20 s, and a melt curve starting at 55!C with 0.5!C incre-
ments for 80 cycles, except for intron 8 element, annealing
temperature was 58!C. Data was normalized to the back-
ground (No Ab) and calculated as fold enrichment over
the control IgG (FGFR1) applying the formula
[2#(normalized Ct sample - normalized Ct IgG)]. Parallel PCR reac-
tions were performed for agarose gel electrophoresis
analysis, PCR parameters were an initial denaturation at
95!C for 5min and 19 cycles of 15 s at 95!C, 15 s at 64!C
and 20 s at 72!C. PCR products were resolved on a 2%
agarose gel stained with ethidium bromide. At least three
qPCR reactions in triplicates were performed on two inde-
pendent ChIP experiments.
mRNA expression analysis
A small fraction of the cells used for ChIP analysis was
used for expression analysis. RNA was prepared using the
Nucleospin RNA II kit (Macherey-Nagel) as recom-
mended by the manufacturer. RNA quality was checked
spectrophotometrically and quantified using NanoDrop
2000 (Thermo Scientific). Two micrograms of total RNA
were used for cDNA synthesis using the Revert-Aid First
Strand cDNA Synthesis Kit (Fermentas). NIS and
GAPDH primers used for real-time PCR quantification
are presented in Supplementary Table S3. Quantitative
real-time PCR was performed as described above.
Cycling parameters were similar with annealing
temperature of 60!C. Quantification was performed
using the !!Ct method. Data represent three qPCR
experiments in triplicates from two independent samples.
Statistical analysis
Statistical significance was determined by performing the
Student’s t-test (Figures 4D, 6 and 7A) or paired Student’s
t-test (Figures 2, 3, 4C and 7C) using a 95% confidence
interval; P-values <0.05 were considered significant.
RESULTS
Comparative genomics identifies potential cis-acting
elements controlling NIS transcription
We analyzed the conservation of non-coding DNA
sequences of NIS by comparing genomic sequences in
three species, R. norvegicus, M. musculus and H. sapiens.
Conserved sequences at non-coding regions (defined as
windows of 75 bp with 50% nucleotide identity) were
identified in pair-wise alignments using the VISTA
program (21). Figure 1 shows the results of the VISTA
alignment in which the short conserved regions that are
localized in non-coding sequences and that meet the
selected criteria were highlighted in pink. Conserved
regions clustered within 1 kb were later studied as single
blocks and they were named as cluster 1, cluster 2, cluster
3 and so forth (Supplementary Table S1). This grouping of
conserved regions facilitated subsequent functional
analyses.
Conserved clusters 3 and 4 respond to tRA in
MCF-7 cells
Identified individual conserved regions that were located
in clusters varied between 13 (as in cluster 6) and 244 bp
(as in cluster 3) in length (Figure 1). We studied tRA
responsive transcriptional activation capacities of these
regions in MCF-7 cells in which, induction of NIS gene
by tRA was previously reported (7,10,13). We amplified
clusters of interest by PCR using human genomic DNA as
a template, and we cloned these fragments into the
luciferase reporter vector pGL3-E1b as described in
‘Materials and Methods’ section. Previously characterized
NIS upstream enhancer, which contributes to the regula-
tion of this gene in thyroid cells (18,19), was located in the
coding sequence of the neighboring upstream gene,
RPL18A. This region, named as ‘cluster 1’, was also
included in our analysis in order to assess a possible
function of this enhancer in a mammary cell system. All
vector constructs were transiently transfected into MCF-7
cells, which were subsequently treated with either DMSO
(as vehicle control) or 1 mM tRA for 24 h, and the regula-
tory potentials of these conserved clusters were assessed by
luciferase reporter assays. As a result, we found that only
clusters 3 and 4 significantly responded to the tRA
stimulus (Figure 2).
Cluster 3 is a 1.1-kb sequence upstream of the human
NIS, located from -1138 to -42 relative to the transcription
start site (22,23). In a previous study, the tRA
responsiveness of the human NIS promoter was attributed
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to a RARE which is located between bases 125 and 146 of
this cluster [at !1375 relative to the ATG, (14)]. In order
to assess the functionality of this RARE in MCF-7
cells, we created a mutant version of Cl3, in which we
introduced the same mutation (Figure 3A) that completely
abolished tRA response from this sequence in thyroid cell
lines (14). Interestingly, this mutation had a minor effect
on tRA stimulation of Cl3, reducing the tRA stimulation
by only 7% (Figure 3B), indicating that this RARE is
not the major RA responsive site in MCF-7. This result
suggests the presence of an alternative site for tRA
responsiveness in mammary cell systems. To this end, we
created deletion mutants of Cl3 in reporter plasmids,
which contained individual as well as combined conserved
regions (Figure 3C and results not shown). These con-
structs were then tested for tRA responsiveness using
luciferase reporter assays in MCF-7. Despite intensive
analysis on a relatively large number of overlapping
deletion mutants, a tRA responsive region other than
the previously identified RARE could not be found in
Cl3 (see Figure 3C for a summary of our results). On
the other hand, removal of conserved region 3–4
("100 bp) has significantly reduced the magnitude of
tRA response and the overall transcriptional potential
Figure 1. VISTA plot of sequence conservation in a 90-kb genomic DNA in human, mouse and rat. Percent nucleotide identities between human,
mouse and rat DNA sequences are plotted as a function of position along the human sequence. Peaks of evolutionary conservation in overlapping
exonic sequences are shaded blue. Aligned regions of >50% identity over 75 bases are shaded pink. Lines above each alignment indicate the position
of the conserved cluster selected for PCR amplification. Only 80 kb of the alignment is shown.
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of this construct (Figure 3C), indicating the presence of ele-
ments essential for maximum levels of transcription. These
results suggest that tRA responsiveness of Cl3 requires a
synergistic effect of multiple regulatory elements.
A functional RARE is present in the first intron of NIS
Cluster 4 is a 774-bp sequence located in the first intron
of the human NIS. This cluster is composed of
three conserved regions numbered from 4-1 to 4-3
(Figure 4A). A closer look at the sequence composition
of this cluster revealed the presence of three putative
RAREs. The first is a perfect DR2-type consensus
RARE sequence (24) (DR2-1: AGGTCAggAGTTCA)
located in the second conserved region (region 4-2) and
starting at +927 relative to the ATG. The second is a
DR10-type sequence [DR10: AGGTGG(n10)AGGTCA],
located just after the third conserved region (region 4-3)
and starting at +1206 relative to the ATG. The third is,
again, a DR2-type sequence identical to DR2-1 (DR2-2: A
GGTCAggAGTTCA) and is located at +1222 relative to
the start codon, overlapping with the DR10-type sequence
described above (Figure 4A). A series of pGL3-E1b-based
luciferase reporter constructs containing different frag-
ments of this intronic region, as well as in vitro
mutagenized versions of putative RARE sequences were
constructed. A summary of mutations created is presented
in Figure 4B. Functional activity of these RARE
sequences was assessed by transient transfections
followed by luciferase reporter assays in MCF-7 cells
treated either with DMSO (as vehicle control) or with
1 mM tRA for 24 h. In MCF-7 cells transfected with the
wild-type construct, tRA treatment results in an increase
of about 4-fold when compared to cells treated with
DMSO. This result confirmed once again that the
intronic region contains tRA responsive sequences
(Figure 4C; Cl4Wt), which have the capacity to activate
the transcription of the reporter gene. A very small
deletion (3 bp) that changed the second half-site of
DR2-2 but left the DR2-1 and DR10 sequences intact
abolished entirely the tRA responsive activity
(Figure 4C; DR2-2del), indicating that DR2-2 has a func-
tional role in ligand responsive activation of reporter
expression. Moreover, when single or double point muta-
tions were introduced by in vitro mutagenesis in each half
site of the DR2-2, the tRA response was completely lost
(Figure 4C; DR2-2mut1 and DR2-2mut2). However,
removal of the DR2-1 region from the construct by
introducing a 490-bp deletion did not make any effect at
all on tRA responsive activity of the reporter, showing
that DR2-1 is fully dispensable for tRA response
(Figure 4C; DR2-1del). Absence of the DR10 element
both in an otherwise wild-type intronic fragment
context, and in the context of a fragment missing the
DR2-1 element (DR2-1del) did not abolish tRA
responsiveness coming from this region (Figure 4C;
DR10mut and DR2-1del/DR10mut), but they had a
minor effect on the magnitude of the response (2- to
3-fold stimulation).
We also investigated the potential of this intronic
RARE to activate transcription through the native NIS
minimal promoter. For this purpose, we constructed
reporter plasmids containing the minimal NIS promoter
(218 bp of NIS upstream region between !260 bp and
!42 bp relative to transcription start site, and capable of
initiating transcription as assessed by functional reporter
assays, Figure 3C) controlled by Cl4 sequence either
upstream of the promoter element or downstream of the
reporter sequence (mimicking its location in the intron of
NIS). Similar constructs were also prepared using the viral
TATA element, E1b. As anticipated, Cl4 significantly
activated NIS promoter in response to tRA when posi-
tioned either at the 50 (P< 0.0001, n=8) or at 30 of the
reporter (P=0.005, n=8), in agreement with the
function of an enhancer (Figure 4D). On the other hand,
regarding E1b promoter activation, Cl4 responded to the
tRA stimulus only when positioned at the 50 of the
promoter element. Altogether these findings clearly
indicate that the DR2-2 sequence can act as a RA respon-
sive element, and it is the major RARE that is present in
the first intron of human NIS.
RARa and RXR physically interact with the intronic
response element DR2-2 both in vitro and in vivo
Retinoids exert their effects by binding to nuclear retinoic
acid receptors (RARs) and retinoid-X-receptors (RXRs),
which in turn interact with cis-acting regulatory elements,
or RAREs, and stimulate transcription of target genes.
Consistently, previous work of Kogai et al. (12) has
indicated that tRA stimulation of human NIS is
mediated by RAR and RXR. In the presence of tRA,
RAR could form homo- or hetero-dimers with RXR,
Figure 2. Conserved clusters 3 and 4 respond to tRA in MCF-7.
Conserved clusters were amplified by PCR and cloned into the
luciferase reporter plasmid pGL3-E1b. MCF-7 cells were transfected
with all conserved clusters and treated with tRA or DMSO for 24 h.
Of the seven clusters analyzed, only clusters 3 and 4 were significantly
responsive to tRA treatment. P-values for the tRA-induced samples
were calculated using paired Student’s t-test with 95% confidence
interval, values <0.05 were considered significant.
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and the dimer mediates ligand-dependent gene activation
by physically interacting with RAREs in RA responsive
genes. In order to establish whether RAR and/or RXR
have the potential to bind the DR2-2 element, we
designed oligonucleotide probes corresponding to the
wild-type DR2-2 sequence, or a variant of DR2-2 where
single-point mutations were introduced in each half-site
(Supplementary Table S2). We then studied in vitro
binding capacities of the two nuclear receptors (RARa
and RXR) to these probes by EMSA experiments
(Figure 5). Initially, we have prepared nuclear extracts
from 17-b-estradiol (E2)-treated MCF-7 cells, and we
determined the abundance of both RARa and RXR in
nuclear extracts by immunoblotting (data not shown).
Subsequently, we incubated nuclear extracts with
biotin-labeled probes containing either a consensus
RARE that was known to interact with RARa and
RXR, the wild-type DR2-2 sequences, or the mutant
form of DR2-2. As expected, we have clearly observed
retarded complexes when nuclear extracts were incubated
with probes carrying the consensus RARE, or the novel
element, DR2-2 (Figure 5, lanes 2 and 7). On the other
hand, the introduction of point mutations into DR2-2
half-sites abolished this shift (Figure 5, compare lanes 7
and 12), unequivocally proving that these band shifts were
observed as a result of direct interactions between the
nuclear factors and the DR2-2 element (Figure 5, shown
with bold arrows). A retarded band marked by an asterisk
has indicated a DR2-2 independent interaction between
nuclear proteins and the DNA probe. All bands were
appropriately competed or shifted, confirming the
specificity of the interactions (Figure 5, lanes 3, 8 and
13). In order to test whether the two nuclear transcription
factors of interest, RARa and RXR, interact with DR2-2,
we have added factor-specific monoclonal antibodies to
our binding reactions. Both RARa and RXR antibodies
caused a super shift in the consensus RARE and in DR2-2
probe (arrowheads), while they failed to do so when
probes carrying point mutations on DR2-2 were used
(Figure 5, for RARa compare lanes 4, 9 and 14; for
RXR see lanes 5, 10 and 15). These results clearly
indicate direct interactions between the nuclear
Figure 3. Stimulation of conserved cluster 3 is indirect and distinct from that in thyroid cells. (A) Map of Cl3, conserved regions are represented by
boxes labeled 3-1 to 3-4, the previously characterized RARE is indicated by the black box, the wild type and the mutant sequences are shown below
the map. (B) MCF-7 cells were transiently transfected with either the wild type or the mutant construct, cells were treated with tRA or DMSO and
luciferase assays were performed. (C) Several deletion mutants were prepared to study the transcriptional potential in response to tRA stimulation of
individual or combined conserved regions of Cl3. Plasmids were transfected to MCF-7 cells, followed by tRA (or the vehicle DMSO) treatment for
24 h, then luciferase assays were performed. The luciferase values were normalized to those of Renilla luciferase; fold induction was calculated relative
to the empty vector. *Numbers above bars indicate the overall fold stimulation by tRA. P-values for the tRA-induced samples were calculated using
paired Student’s t-test with 95% confidence interval, values <0.05 were considered significant.
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transcription factors RARa/RXR and the novel intronic
RARE, DR2-2.
Subsequently, in order to assess whether RARa and/or
RXR occupies the DR2-2 element in response to tRA
in vivo, we carried out a series of ChIP experiments
in MCF-7 cells. In the presence of RARa or RXR
antibodies, a DNA fragment containing the DR2-2
element was precipitated from formaldehyde cross-linked
total cell lysates (Figure 6). In contrast, the unrelated
control IgG against fibroblast growth factor receptor 1
(FGFR1) did not precipitate the DR2-2 element above
background levels (No Ab) of protein-A Sepharose
beads (Figure 6A). We also investigated the presence of
the two nuclear receptors on DR2-1 using the same
Figure 4. A Functional RARE (DR2-2) is present in the first intron of NIS. (A) Representation of conserved regions and putative RARE sequences
in cluster 4. The boxes labeled 4-1 to 4-3 represent the position of the three conserved regions; the positions of putative RARE sequences,
transcription start site and the ATG are indicated. Ex 1 and Ex 2 indicate positions of exons 1 and 2, respectively. (B) Sequence representation
of the Cl4 variants used, RARE half sites are capitalized and mutated nucleotides are underlined and bolded, deleted nucleotides are replaced with
dashes. (C) MCF-7 cells were transiently transfected with Cl4Wt or its mutant derivatives, cells were treated with tRA (or DMSO) for 24 h and
luciferase reporter assays were performed. Luciferase values were normalized to those of Renilla luciferase and the fold induction is represented
relative to the empty vector. Reporter constructs are presented in the drawing on the left; putative RAREs are indicated by vertical boxes, an X on a
box indicates the RARE being altered. P-values were calculated using paired Student’s t-test with 95% confidence interval, values <0.05 were
considered significant. (D) MCF-7 cells were transfected with Cl4 controlling either the viral E1b promoter or the native NIS promoter (fragment
NIS in Cl3-pm, see ‘Materials and Methods’ section). The sequence for Cl4 was located either 50 of the promoter, or 30 of the luciferase reporter.
Luciferase assays were performed as mentioned above. Fold stimulation by tRA was calculated relative to the vector containing only the pro-
moter element. P-values were calculated using Student’s t-test with 95% confidence interval, values <0.05 were considered significant. Drawings are
not to scale.
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immunoprecipitated samples. Despite being non-
responsive to tRA stimulation in reporter assays
(Figure 4C), we found that DR2-1 is actually occupied
by both nuclear receptors in MCF-7 cells (Figure 6B),
but with lower abundance when compared to DR2-2
(!50% less). These findings demonstrate that, endogenous
RARa and RXR bind to both DR2-1 and DR2-2 that are
present in the first intron of NIS in vivo, thereby strongly
suggesting that at least part of the regulatory effects of
the two nuclear receptors, RARa and RXR, on NIS
expression in MCF-7 cells were due to a direct interaction
between the receptors and the intronic RAREs (Figure 6).
Initiation of NIS transcription in response to tRA involves
dynamic interactions between multiple intronic elements,
nuclear receptors and the RNA Pol-II
Besides the intronic enhancer identified above (DR2-2
in intron 1), there exists several other putative intronic
RARE sequences within NIS gene (25). As we found a
functional RARE in intron 1, we were intrigued to study
a possible involvement of other intronic putative RARE
sequences in NIS gene transcription. As nuclear receptors
interact with cognate response elements in a dynamic
manner (26), we decided to study the dynamics of inter-
actions taking place between cis- and trans-acting factors.
To this end, we used ChIP assays to screen for the
involvement of intronic sequences in NIS transcription
in response to tRA treatment in MCF-7 cells (Figure 7).
MCF-7 cells were cultured in charcoal-treated
steroid-free medium lacking phenol-red, and they were
either treated with DMSO, or with tRA for 15, 30 or
60min, and interactions of RARa, RXR and/or RNA
Pol-II with sequences located in introns 1, 5, 7, 8, 12, 13
and 14 (Figure 7) were investigated. Prior to tRA stimu-
lation (time point 0) all intronic sequences, except the one
in intron 8, were engaged in an interaction with basal
transcriptional machinery (based on precipitation of
these sequences with RNA Pol-II, Figure 7A). By 15min
Figure 5. RARa and RXR interacts with the novel intronic RARE in gel retardation assays. Nuclear extracts from E2-treated MCF-7 cells were
incubated with biotin labeled oligonucleotide probes representing a consensus RARE, the wild-type DR2-2 or the mutant variant DR2-2mut
(DR2-2-Mut1-S in Supplementary Table S2). Samples were resolved on a 6% non-denaturing polyacrylamide gel in TBE, transferred to Hybond
N+ membranes and then incubated with streptavidin, and biotin-labeled DNA probes were detected by chemiluminescence. The name of the probe
used in each binding reaction is indicated on the top of each panel. All binding reactions were competed with 200-fold molar excess of the
corresponding unlabeled probe. Arrows point out the nuclear receptor–DNA complexes, while arrowheads point out the super shift. The asterisk
indicates a DR2-2 independent interaction with nuclear proteins. Labeled probes were incubated in the absence of nuclear extract (lanes 1, 6 and 11),
in the presence of nuclear extract alone (lanes 2, 7 and 12), nuclear extract together with an excess of competing unlabeled probe (lanes 3, 8 and 13),
in the presence of RARa antibodies (lanes 4, 9 and 14), or in the presence of RXR antibodies (lanes 5, 10 and 15). Experiments were repeated at least
three times and a representative result is shown.
Figure 6. RARa and RXR occupy the novel intronic element in vivo.
MCF-7 cells grown in DMEM were treated with 1 mM tRA and used
for ChIP analysis using RARa and RXR specific antibodies. (A) DNA
isolated from immunocomplexes was used as a template for PCR
amplification using primers specific for DR2-2. PCR products were
resolved on a 2% agarose gel (containing Ethidium bromide) and
visualized on a UV transilluminator, RARa; anti-RAR-a Ab
precipitated DNA, RXR; anti-RXR Ab precipitated DNA, FGFR1;
anti-FGFR1 Ab precipitated DNA, No Ab; bead-only control, and
-PCR is a negative control with H2O as a template. (B) Quantitative
PCR was performed using immunoprecipitated DNA using DR2-1 and
DR2-2 specific primers. Ct values were normalized to background levels
of bead-only controls (No Ab) using 2(dCt). Data are represented as fold
enrichment compared to IgG control. *P-values were calculated using
Student’s t-test (average of three experiments) with 95% confidence
interval, values <0.05 were considered significant.
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Figure 7. Nuclear receptors and RNA Pol-II interact with NIS intronic elements in a dynamic manner during the initiation of transcription. MCF-7
cells grown in steroid-free and phenol-red-free DMEM were treated either with DMSO (time 0) or with 1 mM tRA for 15, 30 and 60min and used for
ChIP analysis using RARa and RXR and RNA Pol-II specific antibodies. (A) DNA isolated from immunocomplexes was used for quantitative PCR
using primers described in Supplementary Table S3. Ct values were normalized to background levels of bead-only controls. Data are represented as
fold enrichment compared to IgG control. (B) mRNA was isolated from a fraction of the cells used for ChIP analysis above. Two micrograms
of total RNA was converted to cDNA and used for quantitative real-time PCR. Expression was normalized to the levels of GAPDH using the !!Ct
method and presented as relative fold induction compared to DMSO-treated samples. (C) Schematic representation of ChIP data depicting the
events of transcription initiation of NIS in response to tRA stimulation. Arrow heads indicate the position of the intronic element investigated,
vertical small lines represent NIS exons, numbers below indicate introns studied, asterisks above numbers indicate identical sequences. Parallelograms
with question mark represent unidentified interacting proteins. DR, direct repeat; ER, everted repeat. Statistical significance was determined by
performing the Student’s t-test (Figure 7A) or paired Student’s t-test (Figure 7C) using a 95% confidence interval; P-values <0.05 were considered
significant.
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of stimulation, interactions were limited to RXR but then
they were replaced by RARa (30min), with strong appear-
ance together with RNA Pol-II on the element from intron
7 (Figure 7A). This presence of RARa persists at 60min
post-stimulation in the absence of RXR, accompanied by
an acute increase in mRNA levels (Figure 7B). It appears
that interactions with transcription machinery are sus-
tained by sequences in intron 7 (30 and 60min.) and in
intron 14 (60min.). Figure 7C recapitulates the dynamic
events taking place during initiation of transcription in
response to tRA stimulation.
DISCUSSION
The identification of elements that control NIS regulation
in mammary gland cells is of particular importance in the
context that mammary-tumor-specific stimulation of NIS
activity followed by radioiodide substrate (131I, 123I or
99mTcO4) administration could have an important poten-
tial as a novel alternative in the diagnosis and treatment
of breast tumors (2,7,8,17,27). Yet, in a recent publication
(28), it was reported that NIS-related intracellular staining
in immunohistochemistry experiments on thyroid cancers
was due to non-specific binding of the antibodies. These
authors also conclude that the intracellular signal in breast
tumors might not always be specific. Therefore, in our
opinion, establishing clinical methods of increasing
expression levels of NIS would be essential if the activity
of this symporter is to be used for a radio-labeled
substrate-based diagnosis and therapy of a large set of
breast tumors (29,30). In a series of publications, Kogai
et al. (7,17,25,31) has demonstrated that tRA stimulates
NIS expression and the selective cytotoxic effect of
radioiodide both in MCF-7 cells as well as in
MCF-7-derived xenografts in nude mice. Yet, the molec-
ular mechanisms of tRA effect on NIS in mammary gland
cells are not completely revealed. Although tRA
upregulates both rodent and human NIS expression at
the transcriptional level in a variety of thyroid and
mammary gland cell lines, molecular mechanisms and
elements that were reported to mediate tRA responsive
NIS regulation varied depending on the organism and
the cell origin. A better understanding of molecular deter-
minants, mechanisms and ligands that have a role in NIS
regulation would be essential for successful implementa-
tion of possible NIS-activity-based novel methods for the
management of malignant breast diseases. In this respect,
our description regarding the molecular interplay between
retinoid receptors, intronic cis-acting elements and RNA
Pol-II brings important clarifications about precise molec-
ular mechanisms and interactions controlling tRA-
dependent NIS gene upregulation (see below).
In an initial effort to identify mammary-gland-specific
enhancers of NIS, we adopted a comparative genomics
approach followed by functional assays of conserved
DNA sequences in different cell types (data not shown).
As widely appreciated, interspecies genome comparisons
were in general very useful for a rather accurate prediction
of protein encoding genes in different organisms (32).
On the other hand, prediction of gene regulatory regions
by genome comparisons tends to be relatively more diffi-
cult as they tolerate much more sequence divergence than
coding sequences while retaining their original function.
Yet, several reports have indicated that interspecies
genome comparisons of close relatives could lead to
correct predictions of regulatory sequences (33–35). A
similar comparative analysis of a 90-kb region, including
and flanking NIS loci in mice, rat and human genomes,
followed by functional tests in MCF-7 cells, has led us to
identify a novel tRA responsive region in the first intron of
the human NIS.
A conserved 50 upstream region of the human NIS
(referred to as cluster 3 in this work) contains a tRA
responsive element that was previously identified as a
RARE in human follicular thyroid carcinoma cell lines,
FTC-133 and FTC-238 (14). As expected, we have
observed that this region has a remarkable tRA responsive
regulatory capacity (Figure 2) in MCF-7 cells.
Surprisingly, point mutations that were shown to abolish
tRA responsiveness of this element in thyroid cells (14)
had no significant suppressive effect on tRA stimulation
in MCF-7 cells (Figure 3B). Our intensive search both by
bioinformatics and by experimental methods, as well as
studies carried out by other groups (25), did not reveal
another RARE in this region. This could imply that
first, the mechanism of RA stimulation of human NIS
expression in mammary cell models is distinct from that
of thyroid cells; and, second, the stimulatory effect of RA
on this sequence is actually an indirect one. Moreover,
analysis of overlapping deletion mutations in Cl3 did
not reveal any RA responsive sequence (Figure 3C), sug-
gesting that RA stimulation of the human NIS gene
requires the synergistic effect of multiple factors.
Indirect stimulation of NIS by tRA was previously
reported; tRA was shown to upregulate the rat Nis
promoter in MCF-7 cells by activating the homeobox-
containing transcription factor, Nkx2.5 (15). In this cell
line, tRA treatment stimulates the expression of this
NK2-type transcription factor, which in turn, activates
Nis promoter by binding to two cis-acting elements
located at !446 and !154 relative to ATG (15). Despite
extensive search for similar binding sites in the human NIS
locus, Nkx2.5 responsive cis-acting sequences were not
found (data not shown). In a more recent study, Kogai
et al. (25) described an indirect effect of RA on NIS
expression that is mediated by IGF-1/PI3K signaling
pathways in MCF-7 but not in the rat normal thyroid
cell line FRTL-5. In MCF-7 cells, RA exerts its effect by
activating PI3K signaling pathways, which result in the
activation of an unknown transcription factor, leading
to an enhanced NIS expression (36). It would be interest-
ing to find out whether the binding site of this
yet-uncharacterized factor maps in Cl3 or not.
Intronic sequences could contain motifs and cis-acting
elements with varying functions, such as exon/intron rec-
ognition, regulation of alternative splicing events, activa-
tion of transcription, stimulation of polyadenylation and,
surprisingly enough, in certain cases elements regulating
the stability of encoded proteins (37–42). In this report,
we describe a novel enhancer that is located in intron 1,
and that mediates retinoic acid responsive NIS gene
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expression. We have initially shown evidences for a direct
interaction between RARa/RXR and a novel RARE
within the first intron of the human NIS in MCF-7 cells
(Figures 5–7). This DR-2 type RARE (DR2-2) was func-
tional in reporter assays and had the capacity to activate
both the native NIS promoter (regardless of position or
orientation) as well as the viral E1b TATA element
(Figure 4D). Recently, Kogai et al. (25) reported
putative RARE sequences present within several introns
of the human NIS, including elements found in the first
intron, but they could not attribute a functional role to
these elements (25). Thus, it seems that other than its
native promoter, NIS intronic enhancer could activate
only a subset of heterologous promoters. Interestingly,
another DR-2-type element (DR2-1) of identical
sequence in the same intron was occupied by tRA
stimulated nuclear receptors in vivo despite being
non-responsive to tRA in reporter assays. The difference
in the regulatory potential of these sequence-wise identical
elements in intron 1 could be related to initial (time 0) and
persistent (60min) interactions with RARa that we
observe in DR2-2 but not DR2-1 (Figure 7A). This
temporal regulation of RARa interaction with its
cognate response elements could well be governed by
epigenetic factors modifying local chromatin structure of
this region. Related to this, we have clearly observed
tri-methylation of H3K4 residues both on DR2-1,
DR2-2 as well as on other intronic RAREs (see below,
and also Supplementary Figure S1), a characteristic
histone H3 modification found at enhancer regions of
transcriptionally active genes (43). We have previously
shown that tRA-upregulated NIS expression is restricted
to ERa-positive mammary gland cell lines. In the absence
of ERa, neither NIS promoter, nor the luciferase reporter
gene under control of cluster 3 were stimulated in response
to tRA stimulation, even though tRA signaling was
operative in these cells (13, and Supplementary Figure
S2). Re-introduction of ERa in previously ERa (!) cells
was required for the recovery of NIS expression (13). It is
therefore plausible to anticipate that intronic elements
that were described in this work could only stimulate ini-
tiation of NIS gene transcription only in the presence of
active ERa.
Our ChIP assays have revealed that at the onset of NIS
gene transcription, sequences located in introns 1, 5, 7, 8,
12, 13 and 14 (Figure 7) interact temporally with nuclear
receptors and with RNA Pol-II. Interestingly, all intronic
elements (except the one in intron 8) were found to
interact intensively with RNA Pol-II in the absence of
ligand, tRA (Figure 7A and C), which might keep the
polymerase ready for the initiation. With the tRA-
dependent onset of transcription, interactions between
cis-acting sequences and RNA Pol-II become undetectable
in our assay system, and in the first 15min of tRA induc-
tion RXR solely occupies all intronic positions
(Figure 7C), indicating the early role of this trans-acting
factor in tRA dependent transcription. At later time
points (30 and 60min) while mRNA levels increase in a
steady manner (Figure 7B), interactions between
sequences in intron 7 and RNA Pol-II (and later in
intron 14 and RNA Pol-II) becomes detectable once
again, suggesting frequent interactions between general
transcription apparatus and elements in intron 7 and 14
during maximal levels of transcription (Figure 7A–C).
At the same time points, RARa replaces RXR and
dominates interactions in intronic sites, which implies
the principal role of RARa at relatively late stages of
tRA-dependent transcription initiation. Positions of
intronic sequences found to interact with the RNA
Pol-II and tRA-stimulated nuclear receptors matches
exactly with locations where H3K4 tri-methylations were
observed (Supplementary Figure S1). In fact, in most
cases, persistent RARa interactions at later stages
(30–60min) with intronic elements coincide with increased
H3K4 tri-methylation (Figures 7 and S1). Nuclear recep-
tors, including RARa and RXR, are well known to recruit
histone-modifying co-regulators facilitating conversion
of chromatin regions to transcriptionally permissive
states (44). For instance, MLL5, which is a histone
lysine methyltransferase, was recently described to be
one of the H3K4 modifying enzymes enhancing RARa-
dependent gene transcription (45); one of the epigenetic
mechanisms that could also operate during NIS
expression.
Earlier work and results presented in this manuscript
clearly indicate that molecular mechanisms presiding
NIS expression involve a number of classical and
intronic elements that regulate temporal and spatial
expression, and they are likely to be more complex than
previously anticipated. Future experiments will show
whether the activities of intronic enhancers lead also to
a tissue- or cell-type-specific regulation of NIS. A better
understanding of this mechanism of regulation, as well as
the ability to selectively enhance NIS expression in tumor
cells will, eventually, be of great importance for potential
future applications in breast cancer diagnosis and
treatment.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Prof. Mehmet O¨ztu¨rk and Dr. Khemais Benhaj
for valuable discussions.
FUNDING
The EU 7th Framework Program Project UNAM-
REGPOT Grant no: 203953 and by an EMBO Short
Term Fellowship (to H.A.); Associazione Italiana per
la Ricerca sul Cancro (to R.D.L. and D.S.); Turkish
Scientific and Technical Research Council (104-T-231 to
U.H.T); the Turkish Academy of Sciences-Young Scientist
Award (GEBIP/2001-2-18 to U.H.T); Bilkent University
Research Funds; DPT-KANILTEK Project Funds;
Feyzi Akkaya Research Fund for Scientific Activities
(FABED; to U.H.T.). Funding for open access charge:
partially waived by Oxford University Press.
Nucleic Acids Research, 2010, Vol. 38, No. 10 3183
 at Bilkent University Library (BILK) on July 2, 2013
http://nar.oxfordjournals.org/
Downloaded from 
Conflict of interest statement. None declared.
REFERENCES
1. Spitzweg,C., Joba,W., Eisenmenger,W. and Heufelder,A.E. (1998)
Analysis of human sodium iodide symporter gene expression in
extrathyroidal tissues and cloning of its complementary
deoxyribonucleic acids from salivary gland, mammary gland, and
gastric mucosa. J. Clin. Endocrinol. Metab., 83, 1746–1751.
2. Tazebay,U.H., Wapnir,I.L., Levy,O., Dohan,O., Zuckier,L.S.,
Zhao,Q.H., Deng,H.F., Amenta,P.S., Fineberg,S., Pestell,R.G.
et al. (2000) The mammary gland iodide transporter is expressed
during lactation and in breast cancer. Nat. Med., 6, 871–878.
3. Stubbe,P., Schulte,F.J. and Heidemann,P. (1986) Iodine deficiency
and brain development. Bibl. Nutr. Dieta., 206–208.
4. Cho,J.Y., Leveille,R., Kao,R., Rousset,B., Parlow,A.F.,
Burak,W.E. Jr, Mazzaferri,E.L. and Jhiang,S.M. (2000) Hormonal
regulation of radioiodide uptake activity and Na+/I- symporter
expression in mammary glands. J. Clin. Endocrinol. Metab., 85,
2936–2943.
5. Perron,B., Rodriguez,A.M., Leblanc,G. and Pourcher,T. (2001)
Cloning of the mouse sodium iodide symporter and its expression
in the mammary gland and other tissues. J. Endocrinol., 170,
185–196.
6. Knostman,K.A., Cho,J.Y., Ryu,K.Y., Lin,X., McCubrey,J.A.,
Hla,T., Liu,C.H., Di Carlo,E., Keri,R., Zhang,M. et al. (2004)
Signaling through 30,50-cyclic adenosine monophosphate and
phosphoinositide-3 kinase induces sodium/iodide symporter
expression in breast cancer. J. Clin. Endocrinol. Metab., 89,
5196–5203.
7. Kogai,T., Kanamoto,Y., Che,L.H., Taki,K., Moatamed,F.,
Schultz,J.J. and Brent,G.A. (2004) Systemic retinoic acid
treatment induces sodium/iodide symporter expression and
radioiodide uptake in mouse breast cancer models. Cancer Res.,
64, 415–422.
8. Wapnir,I.L., van de Rijn,M., Nowels,K., Amenta,P.S., Walton,K.,
Montgomery,K., Greco,R.S., Dohan,O. and Carrasco,N. (2003)
Immunohistochemical profile of the sodium/iodide symporter in
thyroid, breast, and other carcinomas using high density tissue
microarrays and conventional sections. J. Clin. Endocrinol.
Metab., 88, 1880–1888.
9. Mazzaferri,E.L. (1999) An overview of the management of
papillary and follicular thyroid carcinoma. Thyroid, 9, 421–427.
10. Kogai,T., Curcio,F., Hyman,S., Cornford,E.M., Brent,G.A. and
Hershman,J.M. (2000) Induction of follicle formation in
long-term cultured normal human thyroid cells treated with
thyrotropin stimulates iodide uptake but not sodium/iodide
symporter messenger RNA and protein expression. J. Endocrinol.,
167, 125–135.
11. Tanosaki,S., Ikezoe,T., Heaney,A., Said,J.W., Dan,K., Akashi,M.
and Koeﬄer,H.P. (2003) Effect of ligands of nuclear hormone
receptors on sodium/iodide symporter expression and activity in
breast cancer cells. Breast Cancer Res. Treat., 79, 335–345.
12. Kogai,T., Kanamoto,Y., Li,A.I., Che,L.H., Ohashi,E., Taki,K.,
Chandraratna,R.A., Saito,T. and Brent,G.A. (2005) Differential
regulation of sodium/iodide symporter gene expression by nuclear
receptor ligands in MCF-7 breast cancer cells. Endocrinology, 146,
3059–3069.
13. Alotaibi,H., Yaman,E.C., Demirpenc¸e,E. and Tazebay,U.H.
(2006) Unliganded estrogen receptor-alpha activates transcription
of the mammary gland Na+/I- symporter gene. Biochem.
Biophys. Res. Commun., 345, 1487–1496.
14. Schmutzler,C., Schmitt,T.L., Glaser,F., Loos,U. and Ko¨hrle,J.
(2002) The promoter of the human sodium/iodide-symporter gene
responds to retinoic acid. Mol. Cell. Endocrinol., 189, 145–155.
15. Dentice,M., Luongo,C., Elefante,A., Romino,R., Ambrosio,R.,
Vitale,M., Rossi,G., Fenzi,G. and Salvatore,D. (2004)
Transcription factor Nkx-2.5 induces sodium/iodide symporter
gene expression and participates in retinoic acid- and
lactation-induced transcription in mammary cells. Mol. Cell. Biol.,
24, 7863–7877.
16. Negre,B., Casillas,S., Suzanne,M., Sa´nchez-Herrero,E., Akam,M.,
Nefedov,M., Barbadilla,A., de Jong,P. and Ruiz,A. (2005)
Conservation of regulatory sequences and gene expression
patterns in the disintegrating Drosophila Hox gene complex.
Genome Res., 15, 692–700.
17. Kogai,T., Taki,K. and Brent,G.A. (2006) Enhancement of
sodium/iodide symporter expression in thyroid and breast cancer.
Endocr. Relat. Cancer, 13, 797–826.
18. Ohno,M., Zannini,M., Levy,O., Carrasco,N. and di Lauro,R.
(1999) The paired-domain transcription factor Pax8 binds to the
upstream enhancer of the rat sodium/iodide symporter gene and
participates in both thyroid-specific and cyclic-AMP-dependent
transcription. Mol. Cell. Biol., 19, 2051–2060.
19. Taki,K., Kogai,T., Kanamoto,Y., Hershman,J.M. and Brent,G.A.
(2002) A thyroid-specific far-upstream enhancer in the human
sodium/iodide symporter gene requires Pax-8 binding and cyclic
adenosine 30,50-monophosphate response element-like sequence
binding proteins for full activity and is differentially regulated in
normal and thyroid cancer cells. Mol. Endocrinol., 16, 2266–2282.
20. Kent,W.J., Sugnet,C.W., Furey,T.S., Roskin,K.M., Pringle,T.H.,
Zahler,A.M. and Haussler,D. (2002) The human genome browser
at UCSC. Genome Res., 12, 996–1006.
21. Mayor,C., Brudno,M., Schwartz,J.R., Poliakov,A., Rubin,E.M.,
Frazer,K.A., Pachter,L.S. and Dubchak,I. (2000) VISTA:
visualizing global DNA sequence alignments of arbitrary length.
Bioinformatics, 16, 1046–1047.
22. Behr,M., Schmitt,T.L., Espinoza,C.R. and Loos,U. (1998)
Cloning of a functional promoter of the human sodium/
iodide-symporter gene. Biochem. J., 331(Pt 2), 359–63.
23. Endo,T., Kaneshige,M., Nakazato,M., Ohmori,M., Harii,N. and
Onaya,T. (1997) Thyroid transcription factor-1 activates the
promoter activity of rat thyroid Na+/I- symporter gene.
Mol. Endocrinol., 11, 1747–1755.
24. Gigue`re,V. (1994) Retinoic acid receptors and cellular retinoid
binding proteins: complex interplay in retinoid signaling. Endocr.
Rev., 15, 61–79.
25. Kogai,T., Ohashi,E., Jacobs,M.S., Sajid-Crockett,S., Fisher,M.L.,
Kanamoto,Y. and Brent,G.A. (2008) Retinoic acid stimulation of
the sodium/iodide symporter in MCF-7 breast cancer cells is
mediated by the insulin growth factor-I/phosphatidylinositol
3-kinase and p38 mitogen-activated protein kinase signaling
pathways. J. Clin. Endocrinol. Metab., 93, 1884–1892.
26. Metivier,R., Penot,G., Hubner,M.R., Reid,G., Brand,H., Kos,M.
and Gannon,F. (2003) Estrogen receptor-alpha directs ordered,
cyclical, and combinatorial recruitment of cofactors on a natural
target promoter. Cell, 115, 751–763.
27. Wapnir,I.L., Goris,M., Yudd,A., Dohan,O., Adelman,D.,
Nowels,K. and Carrasco,N. (2004) The Na+/I- symporter
mediates iodide uptake in breast cancer metastases and can be
selectively down-regulated in the thyroid. Clin. Cancer Res., 10,
4294–4302.
28. Peyrottes,I., Navarro,V., Ondo-Mendez,A., Marcellin,D.,
Bellanger,L., Marsault,R., Lindenthal,S., Ettore,F., Darcourt,J.
and Pourcher,T. (2009) Immunoanalysis indicates that the sodium
iodide symporter is not overexpressed in intracellular
compartments in thyroid and breast cancers. Eur. J. Endocrinol.,
160, 215–225.
29. Daniels,G.H. and Haber,D.A. (2000) Will radioiodine be useful in
treatment of breast cancer? Nat. Med., 6, 859–860.
30. Welcsh,P.L. and Mankoff,D.A. (2000) Taking up iodide in breast
tissue. Nature, 406, 688–689.
31. Kogai,T., Schultz,J.J., Johnson,L.S., Huang,M. and Brent,G.A.
(2000) Retinoic acid induces sodium/iodide symporter gene
expression and radioiodide uptake in the MCF-7 breast cancer
cell line. Proc. Natl Acad. Sci. USA, 97, 8519–8524.
32. Dolinski,K. and Botstein,D. (2007) Orthology and functional
conservation in eukaryotes. Annu. Rev. Genet., 41, 465–507.
33. Dubchak,I., Brudno,M., Loots,G.G., Pachter,L., Mayor,C.,
Rubin,E.M. and Frazer,K.A. (2000) Active conservation of
noncoding sequences revealed by three-way species comparisons.
Genome Res., 10, 1304–1306.
34. Boffelli,D., McAuliffe,J., Ovcharenko,D., Lewis,K.D.,
Ovcharenko,I., Pachter,L. and Rubin,E.M. (2003) Phylogenetic
shadowing of primate sequences to find functional regions of the
human genome. Science, 299, 1391–1394.
3184 Nucleic Acids Research, 2010, Vol. 38, No. 10
 at Bilkent University Library (BILK) on July 2, 2013
http://nar.oxfordjournals.org/
Downloaded from 
35. Haubold,B. and Wiehe,T. (2004) Comparative genomics: methods
and applications. Naturwissenschaften, 91, 405–421.
36. Ohashi,E., Kogai,T., Kagechika,H. and Brent,G.A. (2009)
Activation of the PI3 kinase pathway by retinoic acid
mediates sodium/iodide symporter induction and iodide
transport in MCF-7 breast cancer cells. Cancer Res., 69,
3443–3450.
37. Lou,H., Gagel,R.F. and Berget,S.M. (1996) An intron enhancer
recognized by splicing factors activates polyadenylation.
Genes Dev., 10, 208–219.
38. Mu¨ller,F., Chang,B., Albert,S., Fischer,N., Tora,L. and Stra¨hle,U.
(1999) Intronic enhancers control expression of zebrafish sonic
hedgehog in floor plate and notochord. Development, 126,
2103–2116.
39. Noe´,V., MacKenzie,S. and Ciudad,C.J. (2003) An intron is
required for dihydrofolate reductase protein stability. J. Biol.
Chem., 278, 38292–38300.
40. Khandekar,M., Brandt,W., Zhou,Y., Dagenais,S., Glover,T.W.,
Suzuki,N., Shimizu,R., Yamamoto,M., Lim,K.C. and Engel,J.D.
(2007) A Gata2 intronic enhancer confers its
pan-endothelia-specific regulation. Development, 134, 1703–1712.
41. Feng,W., Huang,J., Zhang,J. and Williams,T. (2008) Identification
and analysis of a conserved Tcfap2a intronic enhancer element
required for expression in facial and limb bud mesenchyme.
Mol. Cell. Biol., 28, 315–325.
42. Hertel,K.J. (2008) Combinatorial control of exon recognition.
J. Biol. Chem., 283, 1211–1215.
43. Barski,A., Cuddapah,S., Cui,K., Roh,T.Y., Schones,D.E.,
Wang,Z., Wei,G., Chepelev,I. and Zhao,K. (2007) High-resolution
profiling of histone methylations in the human genome. Cell, 129,
823–837.
44. McEwan,I.J. (2000) Gene regulation through chromatin
remodelling by members of the nuclear receptor superfamily.
Biochem. Soc. Trans., 28, 369–373.
45. Fujiki,R., Chikanishi,T., Hashiba,W., Ito,H., Takada,I.,
Roeder,R.G., Kitagawa,H. and Kato,S. (2009) GlcNAcylation
of a histone methyltransferase in retinoic-acid-induced
granulopoiesis. Nature, 459, 455–459.
Nucleic Acids Research, 2010, Vol. 38, No. 10 3185
 at Bilkent University Library (BILK) on July 2, 2013
http://nar.oxfordjournals.org/
Downloaded from 
The Ability to Generate Senescent Progeny as a
Mechanism Underlying Breast Cancer Cell Heterogeneity
Mine Mumcuoglu1, Sevgi Bagislar1,2, Haluk Yuzugullu1,2, Hani Alotaibi1, Serif Senturk1, Pelin
Telkoparan1, Bala Gur-Dedeoglu1, Burcu Cingoz1, Betul Bozkurt3, Uygar H. Tazebay1, Isik G. Yulug1,
K. Can Akcali1, Mehmet Ozturk1,2*
1 BilGen Genetics and Biotechnology Center, Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey, 2 INSERM - Universite´ Joseph Fourrier, CRI
U823, Grenoble, France, 3Department of Surgery, Ankara Numune Research and Teaching Hospital, Ankara, Turkey
Abstract
Background: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, ‘‘normal-like’’, and ERBB2+ subgroups
were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly
understood. In our study, we explored the role of cellular differentiation and senescence as a potential cause of heterogeneity.
Methodology/Principal Findings: A panel of breast cancer cell lines, isogenic clones, and breast tumors were used. Based on
their ability to generate senescent progeny under low-density clonogenic conditions, we classified breast cancer cell lines as
senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes. All SCP cell lines expressed estrogen receptor (ER).
Loss of ER expression combined with the accumulation of p21Cip1 correlated with senescence in these cell lines. p21Cip1
knockdown, estrogen-mediated ER activation or ectopic ER overexpression protected cells against senescence. In contrast,
tamoxifen triggered a robust senescence response. As ER expression has been linked to luminal differentiation, we compared
the differentiation status of SCP and ICP cell lines using stem/progenitor, luminal, and myoepithelial markers. The SCP cells
produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-like cells.
In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. Some ICP cell lines generated only CD44+/
CD24-/ER-/ASMA- progenitor/stem-like cells, and others also produced CD24+/ER- luminal-like, but not ASMA+myoepithelial-
like cells. Furthermore, gene expression profiles clustered SCP cell lines with luminal A and ‘‘normal-like’’ tumors, and ICP cell
lines with luminal B and basal-like tumors. The ICP cells displayed higher tumorigenicity in immunodeficient mice.
Conclusions/Significance: Luminal A and ‘‘normal-like’’ breast cancer cell lines were able to generate luminal-like and
myoepithelial-like progeny undergoing senescence arrest. In contrast, luminal B/basal-like cell lines acted as stem/
progenitor cells with defective differentiation capacities. Our findings suggest that the malignancy of breast tumors is
directly correlated with stem/progenitor phenotypes and poor differentiation potential.
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Introduction
Human breast tumors are heterogeneous, both in their
pathology and in their molecular profiles. Gene expression
analyses classify breast tumors into distinct subtypes, such as
luminal A, luminal B, ERBB2-positive (ERBB2+) and basal-like
[1,2,3]. The prognosis and therapeutic response of each subtype is
different. Luminal A cancers are mostly estrogen receptor-a-
positive (ER+) and sensitive to anti-estrogen therapy, with the best
metastasis-free and overall survival rates. Luminal B tumors have
an incomplete anti-estrogen response and lower survival rates.
Basal-like and ERBB2+ tumors are ER- and display the worst
survival rates [2,3]. The patterns of genetic changes such as
chromosomal aberrations and gene mutations observed in breast
tumors indicate that breast tumorigenesis does not follow a
stepwise linear progression from well-differentiated to poorly
differentiated tumors with cumulative genetic aberrations [4]. This
suggests that different breast tumor subtypes do not represent
different stages of tumor progression, but rather represent the cells
from which they initiate [4]. The mammary gland is composed of
differentiated luminal and myoepithelial cells that are generated
from multi-lineage, luminal-restricted, and myoepithelial-restrict-
ed progenitors originating from a hypothetical breast epithelial
stem cell. Thus, different types of breast cancers might originate
from such stem or progenitor cells at a given stage of commitment
and differentiation, as observed in hematological malignancies
[4,5]. Without compromising the author’s hypothesis, it is also
possible that the molecular heterogeneity of breast cancer is due to
subtle differences in the ability of tumor-initiating cells to generate
differentiated progeny.
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Epithelial cells isolated from mammary gland cells undergo two
successive senescence states in cell culture, termed ‘‘stasis’’ and
‘‘agonescence’’ [6,7]. In contrast to normal mammary epithelial
cells, established breast cancer cells are immortal by definition.
They may owe this phenotype of immortalization to genetic and
epigenetic inactivation of senescence checkpoints and reactivation
of telomerase reverse transcriptase expression [7]. Either in
relation to these changes or independently, breast cancer cells
may also present a stem/progenitor phenotype that is less
subjected or resistant to senescence barriers. However, the
abundance of non-tumorigenic and differentiated cells both in
breast tumors and cell lines strongly suggests that replicative
immortality cannot be assigned to all cells within a tumor or a
cancer cell line, and that spontaneous senescence after a limited
number of population doublings (PD) is likely to occur. If this
hypothesis is correct, then the rate of generation of senescent
progeny may reflect the potential of a cancer stem/progenitor cell
to produce terminally differentiated progeny. We tested this
hypothesis using a panel of luminal and basal-like breast cancer
cell lines (Table S1). Although a single cell line is not representative
of breast tumor heterogeneity, a panel of cell lines might
reproduce the heterogeneity that is observed in primary breast
tumors, albeit with some limitations [5,8]. Therefore, we hoped
that in vitro studies with a panel of cell lines might help to better
understand breast tumor heterogeneity.
Our senescence tests allowed us to classify breast cancer cell
lines as senescent cell progenitor (SCP) and immortal cell
progenitor (ICP) subtypes. We also show that senescent progeny
are observed exclusively in ER-positive cells, as a result of ER
inactivation, partly mediated with p21Cip1 protein. The ability to
produce senescent progeny was associated with the ability to
produce luminal-like and myoepithelial-like progeny from stem/
progenitor-like cells. In contrast, most of the cell lines lacking
senescent progeny were also unable to generate differentiated
progeny. Finally, we show that SCP-subtype cells cluster with
luminal A and ‘‘normal-like’’ breast tumor types and are less
tumorigenic, whereas ICP-subtype cell lines cluster with luminal B
and basal-like tumor types and are more tumorigenic.
Materials and Methods
Ethics Statement
We used archival tumor samples remaining from a previous
study by BB and IGY described in Gur-Dedeoglu et al. [9], for
which the use of the tissue material was approved by the Research
Ethics Committee of Ankara Numune Research and Teaching
Hospital (decision date: 04/07/2007). The tumor samples in this
study were used anonymously. All animals received care according
to the Guide for the Care and Use of Laboratory Animals. All
animal experiments have been pre-approved by the Bilkent
University Animal Ethics Committee (Decision No: 2006/1;
Decision date: 10/5/2006).
Clinical samples and cell lines
Freshly frozen tumor specimens were collected at Ankara
Numune Hospital. Breast cancer cell lines used in this study were
obtained from ATCC (http://www.atcc.org) and listed in Table
S1. Cell line authenticity was verified by short tandem repeat
profiling, as recommended by ATCC (Dataset S1). Isogenic clones
from the T47D (n= 20) cell line were obtained from single cell-
derived colonies. Briefly, cells were plated in 96-well plates to
obtain single colonies in fewer than 70% of the wells. Isolated
colonies were then transferred to progressively larger wells, and to
T25 flasks. Clones were subcultivated weekly at 1:4 dilution ratios,
and maintained in culture for 25–30 passages to reach .60 PD
before testing.
Primary antibodies
The following antibodies were used: anti-CD44 (559046; BD
Pharmingen), anti-CD24 (sc53660; Santa Cruz,), anti-ASMA
(ab7817; Abcam), anti-CK19 (sc6278; Santa Cruz,), anti-p21Cip1
(OP64; Calbiochem), anti-p16Ink4a (NA29, Calbiochem), anti-ERa
(sc8002; Santa Cruz).
Low-density clonogenic assays
Cells were seeded as low-density on coverslips in six-well plates
(500–2000 cells, according to plating efficiency) and allowed to
grow in DMEM supplemented with 10% fetal calf serum (FCS),
with medium change every three days, until they formed colonies
of a few hundred cells. Depending on the cell line, this took one to
two weeks. For bromodeoxyuridine (BrdU) incorporation assays,
cells were labeled for 24 h prior to immunocytochemistry, as
described previously [10].
Immunocytochemistry
For simple immunoperoxidase assays, cells were fixed with cold
methanol for five minutes, then blocked with 10% FCS in
phosphate-buffered saline (PBS) for 1 hour. This was followed by
incubation with a primary antibody for 1 h. Cells were then washed
with PBS three times and subjected to immunostaining using the
Dako-Envision-dual-link system and the liquid diaminobenzidine
(DAB) substrate chromogen system (Dako, CA, USA), according to
the manufacturer’s instructions. Hematoxylin was used as a
counter-stain when the visualization of cells was necessary. For
SABG-immunoperoxidase co-staining studies, unfixed cells were
first subjected to SABG assay, and then fixed prior to immuno-
staining assays. Hematoxylin counter-staining was omitted for co-
staining experiments, unless cells were negative for SABG staining.
Immunoblot analyses
Cell pellets were incubated in an NP-40 lysis buffer containing
50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 0.1% Nonidet P-40,
and a protease inhibitor cocktail (Roche) for 30 minutes in a cold
room. Cell lysates were then cleared by centrifugation, and a
Bradford assay was performed to quantify their protein concen-
tration. 30 mg of protein was denatured and resolved by SDS-
PAGE using 10% or 12% gels. The proteins were then transferred
to the PVDF or nitrocellulose membranes. Membranes were
treated for 1 h with a blocking solution of TRIS-buffered saline
containing 0.1% Tween-20 and 5% non-fat milk powder (TBS-T)
and probed with a primary antibody for 1 h. Next, membranes
were washed three times with TBS-T and incubated with an HRP-
conjugated secondary antibody for 1 h. Immunocomplexes were
then detected by an ECL-plus (Amersham) kit on the membrane.
a-tubulin was used as an internal control.
SABG assay and BrdU/SABG co-staining
SABG activity was detected as described [11], except that cells
were counterstained with eosin or nuclear fast red following SABG
staining. For BrdU/SABG co-staining, cells were first labeled with
BrdU (10 mg/ml) for 24 h in a freshly added culture medium as
described [10]. Next, cells were subjected to a SABG assay, fixed
in 70% methanol, and subjected to BrdU immunostaining.
Estrogen and tamoxifen treatment
Cells were seeded under low-density clonogenic conditions onto
coverslips in six-well plates, and cultivated in a standard culture
Senescence in Breast Cancer
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medium for seven to eight days. Then, cells were fed with phenol
red-free DMEM (Gibco) supplemented with 5% charcoal-stripped
FCS for 48 h, followed by two successive 48 h treatments with
1029 M estrogen (E2; 17b-estradiol; Sigma), 1026 to 1029 M 4-
hydroxytamoxifen (4OHT; Sigma) or an ethanol vehicle, under
the same conditions. Colonies were then subjected to a SABG
assay. Each experimental condition was conducted in triplicate
and experiments were repeated three times.
Generation of estrogen receptor-overexpressing clones
T47D-iso23 cells were transfected with the expression vector
pCMV- ERa [12] or an empty vector, using FuGENE-6 (Roche).
ER overexpressing and control clones were selected with 500 mg/
ml G418 for three weeks. Isolated single cell-derived colonies were
picked and expanded in the presence of G418.
Lentiviral infection and generation of p21Cip1 knockdown
clones
We used mission shRNA plasmid pLKO.1,-puro-p21
(NM_000389.2-640s1c1, Sigma) for p21cip1 knockdown experi-
ments. The Control vector shRNA-pGIPz-SCR-puro and a helper
packaging mix (Invitrogen) were also used. HEK293T was co-
transfected with the appropriate vector and packaging mix, using
the CalPhos Mammalian Transfection Kit (Clontech) and
following the manufacturer’s instructions. After 48 h of culture,
virus-containing culture media were collected, filtered, and used to
infect T47D-iso23 cells. After 4 h of infection, stable cells were
selected with 1 mg/ml puromycin for seven days.
Nude mice tumorigenicity and in vivo senescence assays
T47D and MDA-MB-231 cells (56106) were injected subcuta-
neously into CD-1 nude mice (Charles River). Females (n = 5 for
each cell line) and males (n = 4 for each cell line) were used.
Tumor sizes were measured up to 47 days post-injection. In
addition, four tumors from each cell line were analyzed for the
presence of senescent cells by SABG staining, as described
previously [10].
Cluster analysis
The two-channel microarray data containing 8102 cDNA
genes/clones generated by Sorlie et al. [2] were downloaded from
the Stanford Microarray Database (SMD) (http://genome-www.
stanford.edu/MicroArray/). In the downloading process, the ‘‘log
(base 2) of R/G Normalized Ratio (median)’’ parameter was used
for data filtering. We have median-centered expression values for
each array. We selected arrays and genes with greater than 75%
good data (representing the amount of data passing the spot
criteria). Sixty-eight tissue samples were obtained according to this
criterion and annotated with the subtypes described by the
authors, found in the ‘‘Supplementary Information’’ of the data set
in SMD. The expression values of ‘‘500 gene signature,’’ defined
by the authors, were extracted from the data. Gene expression
profiles of 31 breast cancer cell lines performed by Charafe-
Jauffret et al. [13], using the whole-genome cDNA microarray
Affymetrix HGU-133 plus 2, was obtained from the ‘‘Supplemen-
tary Table’’ of the article. The authors filtered genes with low and
poorly measured expression, and with low expression variation,
retaining 15, 293 genes. After log transformation of the data, we
median normalized the data arrays in R language, using the
Bioconductor biostatistical package (www.r-project.org/ and
www.bioconductor.org/). The ‘‘500 gene signature’’ tumor data
[2] and the normalized breast-cancer cell line data [13] were
combined with respect to probe IDs using a set of customized perl
routines (source codes are available upon request). A set of 175
genes was common. ‘‘Median center’’ normalization of genes was
done for the merged data set for the total samples. We performed
unsupervised hierarchical clustering with the 99 samples (the 31
breast cell line [13] and 68 breast tumor [2] samples) by the pair-
wise complete-linkage hierarchical clustering parameter, using the
Gene-Pattern program. The Pearson correlation method was used
for distance measurements. Clustering was visualized by java
treeview, again using Gene-Pattern (http://www.broad.mit.edu/
cancer/software/genepattern/).
Statistical analyses
Significant differences were evaluated using unpaired Student’s
t test for compared samples sizes of 10 or higher. Otherwise, one-
tailed Fisher’s exact test was used with 262 tables; P,0.05 was
considered statistically significant. On the graphical representation
of the data, y-axis error bars indicate the standard deviation for
each point on the graph.
Results
Classification of breast cancer cell lines as senescent-cell
progenitor and immortal-cell progenitor subtypes
Clonogenic assays have been successfully used to test the
generation and self-renewal abilities of phenotypically distinct
progeny of mammary stem/progenitor cells [14]. We previously
applied this technique to test the ability of cancer cells to produce
progeny with replication-dependent senescence arrest [10]. Cells
were plated under low-density clonogenic conditions and cultivat-
ed for one to two weeks until individual cells performed eight to
ten PDs and generated isolated colonies composed of several
hundred cells. This method permits tracing progeny generated by
a few hundred cells under the same experimental conditions. We
explored a panel of 12 breast cancer cell lines, composed of
luminal (n = 7) and basal (n = 5) subtypes (Table S1). Cell lines
formed two groups, according to the presence of senescent cells in
isolated colonies. One group of cell lines generated colonies with
high rates of senescence, while others did not produce appreciable
amounts of senescent cells. Representative pictures of colonies
subjected to the SABG assay are shown in Fig. 1A. The percent of
SABG+ progeny was calculated by manual counting of at least 10
different colonies for each cell line. Colonies derived from five cell
lines generated SABG+ cells at high rates (means: 5-40%)
Senescence rates were negligible (means ,5%) in the progeny of
the remaining seven cell lines. The first group, the senescent cell
progenitor subtype, included T47D, BT-474, ZR-75-1, MCF-7,
and CAMA-1 cell lines. The second group, the immortal cell
progenitor subtype, included MDA-MB-453, BT-20, SK-BR-3,
MDA-MB-468, HCC1937, MDA-MB-231 and MDA-MB-157
(Fig. 1B).
In order to verify whether the occurrence of senescent cells in the
SCP group was intrinsic to each cell line or due to the presence of a
side population, we generated clones from the T47D (n=20) cell
line, and subjected them to the SABG assay at different intervals. All
clones acted similarly to the parental T47D cell line with similar rates
of SABG+ progeny. No clone gained the ICP phenotype. More
importantly, none of the clones tested over a long period of time
(.60 PDs) entered full senescence (data not shown), unlike normal
mammary epithelial cells that undergo two stages of senescence
arrest over a period of ,20 PDs [7]. The SABG assay can provide
false-positive responses, especially when cells remain under conflu-
ence for a long period [15]. Although all our tests used low-density
clonogenic conditions, we wanted to confirm the senescence arrest
by a long-term (24 h) BrdU labeling assay under mitogenic
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conditions, as senescent cells in permanent cell cycle arrest cannot
incorporate BrdU under these conditions [16]. Co-staining of cells
for SABG and BrdU from CAMA-1, T47D, and T47D-iso23
colonies provided clear indication that the great majority of SABG+
senescent cells were BrdU-, whereas non-senescent BrdU+ cells were
usually SABG- (Fig. 1C). These findings indicated that SABG+
senescent cells were at the terminal differentiation stage with an
irreversible loss of DNA synthesis ability. Our observations also
indicated that SABG and BrdU tests could be used alternatively to
identify senescent (SABG+/BrdU-) and immortal (SABG-/BrdU+)
cells under our experimental conditions.
Senescent cell progenitor phenotype association with
p21Cip1 expression
p16Ink4a and p21Cip1 (in a p53-dependent manner or indepen-
dently) have been shown to be mediators of senescence arrest in
different cells, including mammary epithelial cells [6,15,17,18,19].
We therefore analyzed the expression of p16Ink4a and p21Cip1 in
the cell line panel. Heterogeneously positive nuclear p21Cip1
immunoreactivity was observed in four of the five SCP cell lines,
but not in any of the seven ICP cell lines (Fig. 2A). The association
of p21Cip1 expression with the SCP subtype was statistically
significant (P=0.01). We also compared the expression of p16Ink4a.
Three of five SCP cell lines displayed heterogeneously positive
immunostaining, whereas three of seven ICP cell lines displayed
homogenously positive staining (Fig. S1). The difference of
p16Ink4a expression between the two groups was not significant
(P=1). These observations indicated that the SCP phenotype was
associated with p21Cip expression in breast cancer cell lines.
To test whether p21Cip1 was directly involved in the senescence
observed in SCP cells, we first performed p21Cip1/SABG staining
in T47D-iso23 cells (hereafter termed T47D). p21Cip1, but not
p16Ink4a staining, was associated with SABG staining (Fig. S2).
Next, we generated two derivative cell lines following infection of
T47D with lentiviral vectors encoding p21Cip1 shRNA (T47D-
p21sh) or a scrambled control (T47D-scr). Following the
Figure 1. Classification of breast cancer cell lines as senescent cell progenitor and immortal cell progenitor subtypes. (A) Examples of
SABG staining for senescence of breast cancer cell line colonies obtained after plating at low-density clonogenic conditions. Breast cancer cell lines
(Table S1) were plated to obtain a few hundred colonies with 1–2 weeks of cell culturing and were subjected to SABG assay, followed by
counterstaining with nuclear fast red. T47D, ZR-75-1, MCF-7, CAMA-1 and BT-474 generated heterogeneous colonies composed of with SABG+ and
SABG- cells (shown here), but also fully negative and/or fully positive colonies. All other cell lines produced only SABG- colonies (,5% SABG+ cells).
Scale bar: 50 mm. (B) Classification of breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes by
quantification of the ability to generate senescent progeny. Cell lines with a mean of SABG+ cells higher than 5% were termed SCP, and the other cell
lines as ICP. Colonies that were generated and stained as described in (A) were counted manually to calculate % SABG+ cells. At least 10 colonies
were counted for each cell line. Error bars represent mean 6 SD. (C) SABG+ senescent cells displayed terminal growth arrest. CAMA-1, T47D and
T47D-iso23 colonies were generated as described in (A), labeled with BrdU for 24 h in the presence of freshly added culture medium, and subjected
to SABG/BrdU double-staining. SABG+ cells are BrdU-, and vice versa. T47D-iso23 is a clone derived from T47D. Note that parental T47D and T47D-
iso23 clones displayed similar staining features.
doi:10.1371/journal.pone.0011288.g001
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demonstration of p21Cip1 knockdown in T47D-p21sh cells by
western blot assay (Fig. 2B), both cell lines were plated under low-
density plating conditions, colonies were grown for 10 days, and
subjected to SABG and BrdU staining. It was not possible to
quantify SABG+ cells in T47D-p21sh cells because they formed
tight clusters in culture (data not shown). We therefore used BrdU
staining as an alternative method for senescent cell quantification
(Fig. 2C). Randomly selected colonies were counted for the
number of BrdU+ and BrdU- cells (Fig. 2D). The T47D-scr cell
line generated BrdU+ progeny at a rate of 48620% per colony
(n = 18). Under the same conditions, T47D-p21sh cells displayed
BrdU+ progeny at a rate of 65612% per colony (n= 18), with a
significant (P= 0.0043) increase in the number of cells escaping
terminal arrest (Fig. 2E). These results indicated that p21Cip1 was
responsible, at least partly, for inducing the senescence observed in
the progeny of T47D cells.
The control of senescent cell progeny generation by an
estrogen receptor
As stated above, p21Cip1 is a downstream target of p53 for
senescence, but T47D cells do not express wild-type p53 (Table S1).
Estrogen inhibits p21Cip1 expression [20] by c-Myc-mediated
repression [21], MYC gene being a direct target of ER complex
[22]. We therefore tested whether ER could be involved in the
senescence observed in T47D cells. The data shown in Fig. 3A
indicates that T47D cells displayed nuclear ER immunoreactivity in
their great majority, but some progeny was ER-. More interestingly,
these ER- cells tended to be SABG+, suggesting that senescence
occurred in T47D cells as a result of ER loss. Next, we tested
whether experimentally modifying ER activity in T47D cells had
any effect on senescence response. After plating at low-density
clonogenic conditions, cells were grown in a regular cell culture
medium that contained weakly estrogenic phenol red [23] for seven
days in order to obtain visible colonies. The culture medium was
then changed with phenol-free DMEM complemented with
charcoal-treated FCS, grown for two more days, and then cultivated
for four more days in the presence of E2 (1029 M), OHT (1029 M
to 1026 M), or an ethanol vehicle as control. Colonies were
subjected to SABG staining (Fig. 3B). Total and SABG+ cells were
counted from 20 randomly selected colonies for each treatment
(Fig. 3C). Colonies grown in a phenol-free charcoal-treated control
medium complemented with an ethanol vehicle only displayed
31613% SABG+ cells. Complementing this medium with 1029 M
Figure 2. Growth arrest observed in senescent cell progenitors was inhibited by p21Cip1 silencing. (A) Four of five senescent SCP cell
lines (top four from left) generated colonies with heterogeneous expression of p21Cip1; in contrast none of seven ICP cell lines generated p21Cip1 cells.
Colonies were immunostained for p21Cip1, with hematoxylin used as counterstain. Scale bar: 50 mm. (B–E) p21Cip1 silencing inhibited the production
of the terminally arrested progeny of SCP cells. (B) shRNA-mediated inhibition of p21Cip1 expression. T47D cells were infected with lentiviral vectors
encoding p21Cip1 shRNA or scrambled shRNA to generate T47D-p21sh and T47D-scr stable cell lines, and tested for p21Cip1 knockdown by western
blotting. (C–E) The ability to generate growth-arrested cells was inhibited by p21Cip1 knockdown. Colonies were generated from respective cell lines,
labeled with BrdU for 24 h, immunostained for BrdU, and slightly counterstained with hematoxylin to visualize BrdU+ and negative cells. Scale bar:
50 mm. (C). Individual colonies were manually counted for quantification of % BrdU cells. Each bar represents one colony (D). The silencing of p21Cip1
caused a significant increase (P = 0.0043) in % ratios of BrdU+ cells (E). Mean % BrdU+ cells (6 SD) values were calculated from data presented in (D).
Error bars represent mean 6 SD. Tub.; a-tubulin.
doi:10.1371/journal.pone.0011288.g002
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E2 generated colonies with 17618% SABG+ cells. Senescence
inhibition by E2 was nearly 50% and statistically significant when
compared to the ethanol-complemented control cells (P= 0.0093).
In contrast to E2, OHT provoked a dose-dependent increase in the
proportion of SABG+ cells. At the maximum dose used (1026 M
OHT), 90613% of colony-forming cells displayed a SABG+ signal
(Fig. 3D), indicating that tamoxifen-mediated inactivation of ER
can induce almost a complete senescence response in these cells
(P,0.0001). The increase in senescence rate was also significant
with 1027 M OHT (P= 0.0002).
Our findings strongly suggested that the senescence observed in
the SCP T47D cell line was due to a loss of expression and/or
function of ER in a subpopulation of the progeny of these cells.
For confirmation, we constructed ER-overexpressing stable clones
from T47D cells. The thhree clones with the highest ER
expression were selected. In addition, three clones with endoge-
nous expressions of ER were selected from stable clones obtained
with an empty vector (Fig. 4A). Progeny obtained from these six
clones were tested by BrdU assay (Fig. S3). Randomly selected
colonies (n = 10) from each clone were evaluated for total and
BrdU+ number of cells (Fig. 4B). Consistently higher levels of
BrdU+ cells were observed with clones ectopically expressing the
ER protein (Fig. 4C). Overexpression of ER resulted in a
significant increase in the BrdU+ progeny (P= 0.034). The
protective effect of ER overexpression was not as important as
the senescence-promoting effects of ER inhibition. This was not
unexpected, since the parental cells used for the ER overexpres-
sion studies were already expressing high levels of endogenous ER
(Fig. 4A), displaying a baseline anti-senescence activity due to the
serum estrogen and phenol red found in the cell culture medium.
The close relationship between ER and senescence in the ER+
T47D cell line, and the highly effective treatment of ER+ breast
tumors with tamoxifen, which induced senescence in our
experimental model, suggested that senescence induction might
be a relevant mechanism involved in anti-estrogen treatments. As
fresh tumor tissues cannot be obtained from tamoxifen-treated
patients for obvious ethical reasons, we analyzed untreated ER+
breast tumor samples for evidence of spontaneously occurring in
vivo senescence. We screened a panel of 12 snap-frozen ER+
breast tumor tissues from 11 patients for senescence by an SABG
Figure 3. Generation of senescent cell progeny was controlled by the estrogen receptor-a. (A) SCP cells (T47D) expressed nuclear ER.
Colonies were co-stained for senescence by SABG and for ER expression by immunoperoxidase. The MDA-MB-231 cell line was used as a negative
control. (B–D) The production of senescent progeny in SCP cells was inhibited by estrogen (E2), but enhanced by tamoxifen (4OHT) treatment. After
plating in low-density clonogenic conditions, T47D cells were grown in standard cell culture medium for seven days, followed by phenol-free DMEM
complemented with charcoal-treated fetal calf serum for two days, and then cultivated for four days in the presence of E2, OHT, or an ethanol vehicle
(control). Colonies were subjected to SABG staining (B). Total and SABG+ and SABG- cells were counted from 20 randomly selected colonies (C), and
mean % SABG+ cells (6 SD) values were calculated (D). Error bars represent mean6 SD. The inhibition of senescence by E2 and its activation by OHT
was statistically significant when compared to ethanol-complemented control cells (P values 0.0093, 0.0002 and,0.0001 for 1029 M E2, 1027 M OHT
and 1026 M OHT, respectively).
doi:10.1371/journal.pone.0011288.g003
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assay. The mean age of the patients was 58612 yrs, with a mixed
menopause status (Table S2). Two tumors (17%) displayed
SABG+ cells that were scattered within the tumor area (Fig. S4).
Thus, ER+ breast tumors also produced senescent progeny in vivo,
but at a lower rate.
Senescent cell progenitor and immortal cell progenitor
subtypes’ abilities to differentiate into luminal and
myoepithelial cell types
The cellular specificity of ER expression in the mammary
epithelial cell hierarchy is poorly understood. Previous data
suggests that normal ER+ cells may represent either relatively
differentiated luminal cells with limited progenitor capacity or
primitive progenitors with stem cell properties in the luminal cell
compartment [4,24,25]. Based on the close association between
senescence (which can be considered a manifestation of terminal
differentiation) and loss of ER positivity, we hypothesized that
ER+ SCP cells may differ from ER- ICP cells by their
differentiation potential. We surveyed a few hundred single-cell-
derived colonies from each of the 12 cell lines for production of
stem/progenitor-like, luminal-like, and myoepithelial-like cells.
We used CD44 as a positive stem/progenitor cell marker [26,27],
CD24, ER, and CK19 as luminal lineage markers [27,28,29], and
ASMA as a myoepithelial lineage marker [29].
Representative examples of marker studies by immunoperox-
idase staining in SCP and ICP cell lines are shown in Fig. 5. All
five SCP cell lines displayed a heterogeneous pattern of positivity
for CD44; some colonies were fully positive, some fully negative,
and others were composed of both positive and negative cells.
CD44/CD24 double immunofluorescence studies with the T47D
cell line indicated that SCP cells produce also CD44+/CD24-
stem/progenitor cells, as expected (data not shown). In sharp
contrast, five of the seven ICP cell lines generated only fully
positive CD44 colonies, indicating they do not produce CD44-
cells. One cell line was totally CD44-. Only one cell line displayed
Figure 4. Overexpression of estrogen receptor-a inhibited the production of terminally arrested progeny. (A) ER-overexpressing (ER-5,
ER-7, ER-26) and control (C-8, C-10, C-11) clones were established from T47D cells and tested for ER expression by western blotting using decreasing
amounts of total proteins. Calnexin was used as loading control. (B–C). Colonies were generated, labeled with BrdU for 24 h and immunostained for
BrdU (shown in Fig. S3). Individual colonies were manually counted for quantification of % BrdU cells (B), and mean % BrdU+ cells values were
calculated (C). Error bars represent mean6 SD. ER overexpression caused a significant increase in % ratio of BrdU+ cells (*three ER clones versus three
controls; P = 0.034).
doi:10.1371/journal.pone.0011288.g004
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a pattern similar to that of SCP cell lines. A comparison of the two
subtypes indicated that the ability to generate both CD44+ and
CD44- progeny was significantly associated with the SCP
phenotype (P= 0.0046). All five SCP cell lines displayed
heterogeneous, but mostly positive ER immunostaining, whereas
all seven ICP cell lines never generated ER+ cells. The expression
of ER was also significantly associated with the SCP subtype
(P= 0.0012), as well as the ability to produce ASMA+ progeny
(P= 0.0046). The ICP cell lines did not generate ASMA+ cells,
while four out of five SCP cell lines generated rare ASMA+ cells
under low-density clonogenic conditions. Interestingly, the abun-
dance of ASMA+ cells was much higher in the two SCP cell lines
that were tested at high cell density (Fig. S5). This suggests that
either the production of ASMA+ cells is enhanced at high cell
density, or these myoepithelial-like cells display limited survival
under long-term culture conditions. We did not find a strong
association between the expression of CD24 and CK19 markers
and cell subtype. All five SCP cell lines and three ICP cell lines
Figure 5. Senescent cell progenitor and immortal cell progenitor subtypes greatly differed in their ability to differentiate into
luminal and myoepithelial lineage cells. Senescent cell progenitor and immortal cell progenitor subtype cell lines were studied by
immunoperoxidase staining using CD44 and markers for luminal epithelial (CD24, CK19, ER) and myoepithelial (ASMA) lineages. Insets: magnified
views of positive cells. Both subtypes have CD44+ cells. Senescent cell progenitor cell lines produced both progenitor-like (CD44+; CD242), as well as
ER+ luminal-like and ASMA+ myoepithelial-like cells (except ZR-75-1 for myoepithelial-like cells). Immortal cell progenitor cell lines were defective for
generation of ER+ luminal-like or ASMA+ myoepithelial-like cells. Moreover, five of seven cell lines could not generate CD44- cells. The expression of
CD24 and CK19 markers did not differ significantly between the two subgroups, except that some immortal cell progenitor subtype cell lines did not
express CD24 or CK19.
doi:10.1371/journal.pone.0011288.g005
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generated heterogeneously staining colonies for CD24 expression.
Similarly, all five SCP cell lines, as well as three ICP cell lines,
expressed CK19, but homogenously.
Typical features of senescent progenitor and immortal
progenitor breast cancer cell lines
As summarized in Fig. 6, SCP and ICP subtype cell lines
displayed several subtype-specific features. All SCP cell lines
produced differentiated and senescent cells, in addition to putative
CD44+/CD242 stem/progenitor cells. Indeed, all of them
produced ER+ and CD24+ luminal-like cells and most of them
(n = 4/5) also produced ASMA+ myoepithelial-like cells. In
contrast, five of the seven ICP cell lines never produced CD44-
cells, suggesting they cannot generate differentiated progeny under
the experimental conditions tested. In confirmation of this
hypothesis, four ICP cell lines only produced CD44+/CD242/
ER-/CK19-/ASMA- stem/progenitor-like, but never differentiat-
ed cells. Furthermore, all seven ICP cell lines were unable to
produce ASMA+ myoepithelial-like, ER+ luminal-like or SABG+
senescent cells. CD24 and CD19 luminal lineage markers were
expressed in three cell lines, one of which was fully positive for the
CD44 stem/progenitor marker.
SCP and ICP subtype cell lines correlate with distinct
breast tumor subtypes
Distinct cell-type features associated with SCP and ICP subtypes
suggest that they may be phenocopies of molecularly defined
breast tumor subtypes [1,2,3,30]. As the prognosis and therapeutic
response of each subtype is different [2,3], we questioned whether
we could assign SCP and ICP cell lines to known molecular
subtypes of breast tumors. Using cell line and primary tumor gene
expression datasets, we conducted a hierarchical clustering
analysis. The ‘‘intrinsic gene set’’ data generated by Sorlie et al.
[2] to classify breast tumors into five molecular subtypes was used
to filter cell line data generated by Charafe-Jauffret et al. [13]. A
set of 175 genes was common between the two data sets. Sixty-
eight tumors and 31 cell lines were subjected to pair-wise
complete-linkage hierarchical clustering and distance measure-
ments. This tumor–cell line combined analysis produced two
major clusters. One cluster was composed of basal and luminal B
subtype tumors and five of six ICP cell lines. The other cluster
included luminal A, ERBB2+, and ‘‘normal-like’’ subtype tumors
and all five SCP subtype cells. Four cell lines clustered with the
luminal A tumor subclass. Finally. one cell line clustered with the
‘‘normal-like’’ subclass (Fig. 7A). A full list of clustered tumors and
cell lines is provided in Fig. S6.
Luminal A tumors clustering with our SCP subtype cell lines
displayed the longest tumor-free, distant metastasis-free, and
overall survival rates. In contrast, basal and luminal B tumors
clustering with our ICP subtype cell lines had the worst prognosis,
with shorter tumor-free, distant metastasis-free, and overall
survival times [2]. Our cluster analysis suggested that the ability
to generate differentiated and senescent progeny characterized
breast cancers with poor tumorigenicity, and that resistance to
differentiation and senescence was indicative of more aggressive
tumorigenicity. We compared in vivo intrinsic tumorigenic
behaviors of the SCP cell line T47D and the ICP cell line
MDA-MB-231 in female (n = 5 for each cell line) and male (n = 4
for each cell line) CD1 nude mice Fig. 7B). MDA-MB-231 cells
displayed higher tumorigenicity than T47D cells. In total, we
observed progressively growing tumors in five of nine animals
injected with MDA-MB-231. In contrast, T47D formed smaller
and regressing tumors in nine of nine animals (P,0.03).
Interestingly, the difference in tumorigenicity between these two
cell lines was more pronounced in male animals (P,0.05 after 20
days post-injection). To test whether the difference in tumorige-
nicity between MDA-MB-231 and T47D cells was correlated with
spontaneous in vivo senescence, we analyzed four tumors from
each cell line. Two T47D tumors displayed positive SABG
staining, whereas no positive staining was observed with all four
MDA-MB-231 tumors (Fig. S7).
Discussion
In recent years, phenotypic heterogeneity of breast cancers has
been correlated with genetic and molecular heterogeneity [1,3].
Breast cancer subtypes may represent cancers originating from
different progenitor cells. Molecular and phenotypic heterogeneity
and associated clinical manifestations of breast tumor subtypes
have been related to the type of hypothetical tumor progenitor
cells originating from a hypothetical mammary epithelial stem cell
or from downstream progenitor cells [4,5]. This hypothesis has
not been fully validated, mainly because a hierarchical map of
cells involved in mammary epitheliogenesis has not yet been
established.
To better understand phenotypic differences between breast
cancer subtypes, we applied senescence as a surrogate marker for
the potential to generate terminally differentiated progeny. We
completed these studies with markers for breast stem/progenitor
and differentiated luminal and myoepithelial lineage cells. The use
of low-density clonogenic conditions allowed us to follow the fate
Figure 6. Typical features of senescent progenitor and
immortal progenitor breast cancer cell lines.
doi:10.1371/journal.pone.0011288.g006
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of a large number of progeny for each cell line studied. From these
approaches, we draw several important conclusions. First, breast
cancer cell lines form two distinct groups: SCP and ICP subtypes.
The SCP cell lines produce non-senescent and senescent progeny,
whereas the ICP cell lines produce only non-senescent progeny.
Second, SCP and ICP cell lines are exclusively ER+ and ER- cell
lines, respectively. Senescence occurs as a result of ER loss
associated with p21Cip1 induction in SCP cells. Inversely,
experimental activation of ER by E2 protects from senescence,
whereas its inactivation by tamoxifen aggravates it. Thus,
senescence in ER-dependent cells appears to result from the loss
of survival signals generated by transcriptional activity of ER. A
similar type of senescence has been reported for lymphoma,
osteosarcoma, and hepatocellular carcinoma tumors upon c-MYC
inactivation [31]. Third, SCP cells generate ER+, CD24+, or
CK19+ luminal-like, as well as ASMA+ myoepithelial-like
progeny. These findings strongly suggest that most, if not all,
SCP cells have the capacity to give rise to two major types of
differentiated cells that are found in normal mammary epithelium.
In sharp contrast, ICP cells never produce ER+ luminal-like or
Figure 7. Senescence cell progenitor and immortal cell progenitor subtype cell lines correlate with distinct breast tumor subtypes.
(A) Unsupervised hierarchical clustering of breast tumor and cell line gene expression data were obtained from Sorlie et al [2] and Charafe-Jauffret et
al [25]. Dendrogram displaying the relative organization of tumor and cell line data demonstrated that ICP cell lines cluster with basal and luminal A
tumors in the same branch, except for MDA-MB-453. In contrast, SCP cell lines clustered with luminal A (BT-474, CAMA-1, MCF-7, T47D) and ‘‘normal-
like’’ tumors (ZR-75-1). No data was available for MDA-MB-468. A dendrogram with sample IDs was provided in Fig. S6. The ‘‘intrinsic gene set’’ data
generated by Sorlie et al. [2] was used to filter cell line data generated by Charafe-Jauffret et al. [13]. A set of 175 genes was common between the
two data sets. Sixty-eight tumors and 31 cell lines were subjected to pair-wise complete-linkage hierarchical clustering and distance measurements.
(B) Immortal cell progenitor MDA-MB-231 was more tumorigenic than the SCP type T47D cell line. Female (n = 5 per cell line) and male (n = 4 per cell
line) CD1nudemice received 56106 cells by subcutaneous injection and observed up to 47 days for tumor formation. Chart displays mean tumor sizes
(6 S.D.) generated by MDA-MB-231 and T47D cell lines, respectively in female (top) and mala (bottom) mice. T47D cells formed smaller tumors that
regressed and completely resolved within 30 days. Tumors formed by MDA-MB-231 were larger in size and did not show total resolution. Note that
this cell line was more tumorigenic in male mice.
doi:10.1371/journal.pone.0011288.g007
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ASMA+ myoepithelial-like cells. Indeed, some ICP cells generate
only CD44+ stem/progenitor-like cells and never CD442,
CD24+, CK19+, ER+, or ASMA+ cells. These findings indicate
that ICP cells have limited differentiation ability, at least under in
vitro conditions. The differentiation ability of ICP cells appears to
be lost completely or partially, so that they do not differentiate
fully while they self-renew as stem/progenitor-like cells. Fourth,
SCP cell lines form the same molecular cluster with luminal A and
‘‘normal-like’’ breast tumors. This suggests that SCP cell lines are
phenocopies of these relatively benign and/or anti-estrogen-
responsive tumors. The poor tumorigenicity of SCP cells in nude
mice correlates with better tumor-free and metastasis-free survival
of patients with luminal A type tumors. In contrast, ICP cell lines
cluster with luminal B and basal-like breast tumor subtypes, and
they are more tumorigenic, as expected for luminal B and basal-
like tumor cells. It is presently unknown whether breast tumor
subtypes that cluster with SCP or ICP cell lines are also composed
of either differentiating or mostly self-renewing stem/progenitor
cells. Recent studies reported that breast tumors may contain only
CD44+, or only CD24+ cells, as well as mixed cell populations,
and that CD44+ tumor cells express many stem-cell markers
[27,32]. In addition, an association between basal-like breast
cancer and the presence of CD44+/CD242 cells has been
established [32].
The mechanisms of the differentiation block observed in ICP
cell lines are not known. One might argue that cell lines that
produce only CD44+, but never differentiation marker-positive
cells, cannot be defined as stem/progenitor cells. However, such
cell lines are not completely inert to differentiation stimuli, and
may undergo differentiation under special conditions. For
example, MDA-MB-231 and MDA-MB-468 cells (identified as
ICP cell lines here) can be induced to differentiate into ER+ cells
by Wnt5a treatment, and MDA-MB-231 cells then become
sensitive to tamoxifen [33].
Most of the findings reported here are derived from in vitro
studies performed with established cancer cell lines. Presently, it is
unknown to what extent these findings are also relevant for breast
tumors. We provide here some promising data that supports in
vivo relevance of our conclusions. First, our cluster analyses
associated SCP cell types with luminal A and ‘‘normal-like’’ breast
tumors, whereas ICP cell types shared similar gene expression
profiles with luminal B and basal-like breast tumors. Second, ICP-
type MDA-MB-231 cells were more tumorigenic than SCP-type
T47D cells. T47D cells formed smaller tumors in some animals,
and all tumors displayed regression between 10 and 15 days post-
injection. Accordingly, we observed positive SABG staining in two
out of four T47D tumors, but not in MDA-MB-231 tumors.
Obviously, ICP-like and SCP-like tumors in affected women may
or may not display similar tumorigenic potentials, depending on
the women’s hormonal status and treatment conditions. However,
as most SCP-like luminal A or ER+ tumors are successfully treated
with tamoxifen [34], their less aggressive behavior could be related
to their highly effective senescence response to tamoxifen
treatment, as shown here with T47D cells under in vitro
conditions (Fig. 3). It will be interesting to examine whether the
success of anti-estrogenic treatments is indeed associated with
senescence induction in breast tumors. If this is the case,
senescence-inducing treatments could be considered for breast
cancer.
In conclusion, our analyses reveal that the in vitro ability to
generate senescent progeny permits discrimination between cells
that share molecular and tumorigenic similarities with luminal A
subtype breast tumors from cells related to basal/luminal B
subtype tumors. We also provide in vitro evidence for classifying
breast cancers into two major groups based on the ability to
generate differentiated progeny. Less-tumorigenic SCP cell lines
generate both luminal- and myoepithelial-like cells. In contrast,
more-tumorigenic ICP cell lines are defective in their ability to
generate differentiated progeny. Our findings may have prognostic
relevance and serve as a basis for therapeutically inducing
differentiation and senescence in breast cancer.
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Figure S7 Tumors derived from T47D but not from MDA-MB-
231 display SABG (+) senescent cells. Two of four T47D tumors
Senescence in Breast Cancer
PLoS ONE | www.plosone.org 11 June 2010 | Volume 5 | Issue 6 | e11288
displayed SABG+ cells. All four MDA-MB-231 tumors lacked
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